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ABSTRACT 
Kinesins are motor proteins that have roles in cell division as well as the transport of 
various organelles and protein complex cargoes within cells. Kinesin-1 is considered 
the conventional motor protein and consists of three main isoforms, KIF5A, KIF5B and 
KIF5C. The family of Trafficking Kinesin proteins (TRAKs) bind to the cargo binding 
domain of kinesin-1 forming a link between the motor protein and their cargoes. The 
best characterised cargo transported by TRAKs is mitochondria. 
To understand further the mode of association between kinesin and TRAKs, the aim of 
this study was to determine the structure of the C-terminal cargo binding domain of 
kinesin-1. Due to the known binding of TRAK2 with the kinesin-1 family it was 
hypothesized that TRAKs may stabilize the KIF5A cargo binding domain. Hence, the 
cDNA encoding the KIF5A cargo binding domain, KIF5A800-1032, and the cDNA encoding 
the kinesin interacting domain of TRAK2, i.e. TRAK2100-380 were cloned into a bicistronic 
expression vector to result in epitope-tagged constructs. The expression of both 
proteins was characterized with respect to yield and solubilisation efficiency. TRAK2100-
380 was stabilized by KIF5A800-1032. Affinity chromatography of soluble extracts found 
that KIF5A800-1032 and TRAK2100-380 did co-purify indicating that they do associate. 
However, the yield was insufficient for further characterisation.  
To determine the structure of the cargo binding domain of KIF5A several C-terminal 
constructs which varied in size and epitope tag location were generated. Bacterial 
growth and solubilisation conditions were optimized to maximize the yield of the 
various KIF5A cargo domain recombinant proteins. Each was purified by an appropriate 
affinity chromatography resin. Conditions were established to optimize the purity, 
yield, stability and aggregation state. One construct, KIF5A800-951 was isolated to a 
sufficient yield and did not aggregate. Therefore, KIF5A800-951 is a good candidate for 
further structural analysis. 
To refine further the TRAK binding site within the cargo domain of kinesin-1 a series of 
rationally designed C-terminal truncations of KIF5A and KIF5C were generated and co-
expressed with either TRAK1 or TRAK2 in mammalian cells.  The binding of kinesin-1 
truncations to the TRAKs was determined by co-immunoprecipitation assays followed 
by quantitative immunoblotting. Deletion of the distal 71 amino acids of KIF5A resulted 
in an increased co-immunoprecipitation of KIF5A with TRAK2. Three possible TRAK2 
binding sites within the KIF5A and KIF5C cargo binding domains were found. 
Furthermore, differences were found between TRAK1 and TRAK2 in terms of their 
association sites with KIF5A. 
Overall these studies yield new insights into kinesin/kinesin adaptor interactions which 
may impact in the future on a better understanding of neurodegenerative diseases 
such as hereditary spastic paraplegia and Charcot–Marie–Tooth disease which have 
both been linked to deficiencies in neuronal transport mechanisms of mitochondria. 
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HEK 293 – Human embryonic kidney cells 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His - Histidine 
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HRP – Horseradish peroxidise 
HSP – Hereditary spastic paraplegia 
HUMMR - Hypoxia up-regulated mitochondrial movement regulator 
IPTG – Isoproylthio-β-D-galactosidase 
JIP - JNK interacting protein 
JNK - C-jun N-terminal kinase 
Kb – Kilobase 
KDa - Kilodalton 
KHC – Kinesin heavy chain 
Kidins 220 - Kinase-D-interacting substrate of 220 kDa 
KIF – Kinesin superfamily 
KIF5A – Kinesin-1 sub-type A 
KIF5B – Kinesin-1 sub-type B 
KIF5C - Kinesin-1 sub-type C 
KLC – Kinesin light chain 
LB – Lennox B broth 
MAP – Microtubule associated protein 
MCS – Multiple cloning site 
MgADP – Magnesium adenosine diphosphate 
Mr – Molecular weight 
mRNA – Messenger ribonucleic acid 
NMR – Nuclear magnetic resonance 
OD – Optical density 
O-GlyNAc - N-Acetylglucosamine 
OGT – β-O-linked N-Acetylglucosamine transferase  
OIP106 – O-linked N-acetylglucosamine transferase interacting protein 106 
Ori – Point of origin 
PBS – Phosphate buffered saline 
PC12 - Pheochromocytoma 12 cells 
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PCR – Polymerase chain reaction 
Pink1 - PTEN induced putative kinase 1 
SAP – Shrimp alkaline phosphatise 
SDS – Sodium dodecyl sulphate 
SDS-PAGE - Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
shRNAi – Short hairpin ribonucleic acid interference 
siRNA – Small interfering ribonucleic acid 
SNAP23 - Synaptosome-associated protein of 23 kDa 
SNAP25 - Synaptosome-associated protein of 25 kDa 
TBE – Tris-borate-EDTA buffer 
TE – Tris-EDTA 
TEMED – N,N,N’,N’-tetramethylethylene diamine 
TPR - Tetratricopeptide repeat 
TRAK1 - Trafficking protein, kinesin binding 1 
TRAK2 - Trafficking protein, kinesin binding 2 
Tris – Tris(hydroxymethyl)aminomethane 
Triton® X-100 – 4-(1,1,3,3-tetramethylbutyl) phenyl-polyethylene glycol 
Tween®-20 – Polyethylene glycol sorbitan monolaurate 
β-ME – β mercaptoethanol 
γTuRC - γ-Tubulin ring complex 
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1.0 INTRODUCTON  
In all eukaryotic cells there is a constant movement of molecules, vesicles, protein 
complexes and organelles throughout the cytoplasm. Small molecules can move 
relatively easily throughout a cell over a short distance using simple diffusion. This is 
more difficult for larger cellular components such as vesicles, protein complexes and 
organelles. This is partly due to their large and bulky structure but also because the cell 
is crowded not allowing much free space for easy movement. Thus, motor proteins are 
necessary to facilitate movement and to direct these larger cellular components to 
their desired location within the cellular system. For example, the movement of 
mitochondria  occurs due to the association of two proteins, the molecular motor 
kinesin-1 and the family of kinesin adaptor proteins - trafficking protein kinesin binding 
(TRAKs), along microtubules. It is the molecular mechanisms behind the interaction of 
kinesin-1 and TRAKs which will be addressed in this PhD thesis. 
 
1.1 Transport in the central nervous system 
Intracellular transport is essential for correct cellular function and morphology. Most 
newly synthesised proteins are transported to various locations throughout the cell via 
a form of motor protein. The central nervous system (CNS) of vertebrates consists of 
the brain and spinal cord which help to coordinate movement and transmit signals via 
a network of neuronal cells. Due to the physical structure of neuronal cells the need 
for an effective transport mechanism is even more pronounced. Neurons are 
asymmetric, highly polarised cells that transmit and process information by electrical 
and chemical signalling. Signalling occurs via synapses that connect to each other to 
form neuronal networks. A typical neuron possesses a cell body, dendrites and a 
single axon. Dendrites are structures that protrude from the main cell body often 
branching multiple times giving rise to a complex "dendritic tree". The axon is a special 
cellular extension that extends from the main cell body and travels for a long distance, 
which can be as far as 1 m in humans (Goldberg, 2003). Correct maintenance of 
neuronal function requires the presence of vesicles, mitochondria and protein 
complexes in the axon and dendritic terminals. As these are generally synthesised in 
the main cell body, motor proteins are known to be responsible for the trafficking of 
cargo along the long length of both the dendrites and axon to the terminals (Miki et 
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al., 2005; Hirokawa et al., 2009; Hirokawa, 2011). Neuronal transport can occur in 
either an anterograde direction i.e. away from the main cell body towards the 
dendritic and axonal terminals, or in a retrograde direction i.e. towards the cell body 
from the dentritic and axonal terminals (Hirokawa et al., 2009). The transport of 
vesicles, protein complexes and organelles is mediated via several motor proteins 
along the neuronal cytoskeleton. 
 
1.1.1 Neuronal cytoskeleton 
The neuronal cytoskeleton is a dynamic structure present in the cytoplasm. It helps to 
protect and maintain the shape of neuronal cells and consists of three different 
structural microfilament complexes that interact with one another. These are actin 
microfilaments, neurofilaments and microtubules. Actin microfilaments are formed 
from 43 kDa actin monomers that arrange into fibrils of around 4 – 6 nm in diameter 
(Theriot, 1994). Actin microfilaments are found mostly at the periphery of the cell and, 
in the case of neurons, at the axon terminals and dendritic spines. Neurofilaments are 
intermediate filaments in neurons composed of three subunits; neurofilament heavy, 
medium and light subunits. They are used to help maintain structure within the axon 
and provide support for normal axonal radial growth (Siegel et al., 1999). Microtubules 
consist of a core polymer structure made from 50 kDa tubulin subunits. The polymer is 
formed by heterodimers of α- and β-tubulin making 13 helical rings. These can also 
exist as 12 and 14 helical rings which together form the long microtubules. The 
preferred end for addition of tubulin dimers, also known as the ‘plus’ end, is where the 
β-tubulin subunit is exposed. The opposite ‘minus’ end grows at a slower rate. The 
minus ends of microtubules are stabilised and nucleated by the γ-tubulin ring complex 
(γTuRC) which effectively acts as a cap (Kollman et al., 2011).  Microtubules have many 
roles in neurons besides acting as the substrate for the transport of membrane-bound 
organelles. Microtubules are needed for the extension of neurites during development 
as well as their maintenance. Microtubules also help to retain the integrity and 
definition of intracellular compartments within the neuron (Siegel et al., 1999). 
Microtubules are very dynamic structures and have the ability to alternate between 
states of polymerisation and depolymerisation. β-tubulin subunits bind to guanosine 
triphosphate (GTP) and act as GTPases. The presence of GTP and Mg2+ causes the 
microtubule to extend from the plus end forming a GTP cap which is progressively 
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hydrolysed by tubulin in turn providing protection from depolymerisation. It is only 
GDP-bound tubulin molecules that are able to depolymerise and once the GTP is 
hydrolysed the microtubule begins to depolymerise and shrink rapidly (Garnham and 
Roll-Mecak, 2012). The formation of microtubules from tubulin subunits is shown in 
Figure 1.1. 
 
 
 
 
 
 
Figure 1.1 A structure of a thirteen filament microtubule.  
Heterodimers of α-tubulin and β-tubulin forming a microtubule structure. α-tubulin is exposed at the 
minus end and β-tubulin at the plus end.  
 
1.1.2 Motor proteins 
Motor proteins are a class of molecular motors that are known to use the chemical 
energy taken from adenosine triphosphate (ATP) breakdown to fuel the force and 
motion needed to create movement along actin filaments and microtubule protein 
polymers (Cooke, 2001). These motor proteins can be divided into three protein 
superfamilies; myosin, dynein and kinesin. The myosin superfamily is responsible for 
force generation along actin polymers to create muscle movement as well as 
involvement in cytokinesis and short-range membrane/vesicle transport within cells 
(Hartman and Spudich, 2012). The dynein superfamily is responsible for movement of 
multiprotein complexes and organelles towards the designated minus ends of 
microtubules (Bowman, 2001). Dyneins are large protein complexes formed of two 
identical heavy chains that generate force movement along microtubules, two 
intermediate chains needed for binding to cargo, four light intermediate chains also 
needed for binding to cargo and several light chains which are again also thought to be 
involved in cargo binding (Kamal and Goldstein, 2002). Dynein is known to interact 
with dynactin which acts as a linker to help tether organelles during transport (Schroer, 
2004). The kinesin superfamily is responsible for movement of multiprotein complexes 
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and organelles along microtubules (Bowman, 2001). The kinesin protein superfamily 
will be discussed in more detail in Section 1.2. An example schematic of both kinesin 
and dynein transport in a neuron is shown in Figure 1.2.   
 
 
 
 
 
 
 
Figure 1.2 A schematic of motor protein transport of cargo in a neuronal cell.  
Kinesin motor proteins are shown in green trafficking in an anterograde direction. The dynein motor 
protein is shown in blue trafficking cargo in a retrograde direction.   
 
1.2 The kinesin superfamily of motor proteins  
As mentioned in Section 1.1.2 kinesins are microtubule based molecular motors that 
transport cargoes such as organelles and protein complexes (Bowman, 2001; Hirokawa 
et al., 2009). Kinesins have fundamental roles in the function, plasticity, 
morphogenesis and the survival of cells by helping to transport cargoes throughout the 
cellular system (Hirokawa et al., 2010). Generally kinesins consist of a motor, neck 
linker, stalk and tail domain. The motor domain is known to utilise the energy from the 
binding and hydrolysis of ATP to create movement along microtubules. The stalk 
domain gives flexibility to the kinesin protein and the tail domain is known to 
recognise and bind to cargoes to be transported (Hirokawa et al., 2010). The 
mammalian kinesin superfamily (KIF) of motor proteins consists of 14 kinesins 
currently made up of 138 recognised mammalian family members (Miki et al., 2005). A 
summary of the major mammalian KIFs found in mouse is shown in Figure 1.3. Initially 
the naming of the kinesin proteins was based upon several differing criteria including 
the functional characteristic, the position of the motor domain or the evolutionary 
origin of the motor protein. To simplify the system, Lawrence et al. (2004) introduced 
the characterisation of 14 kinesin family members to ease the confusion brought about 
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by many years of inconsistent naming and organisation of the kinesin proteins. This 
new system groups kinesins according to their phylogenic analysis.  
KIFs generally comprise three major groups depending on the position of the motor 
domain. These include N-terminal motor domain kinesins (N-KIFs), middle motor 
domain kinesins (M-KIFs) and C-terminal motor domain kinesins (C-KIFs) (Hirokawa and 
Takemura, 2005). N-KIFs generally move towards the microtubule plus end in an 
anterograde direction while C-KIFs move towards the microtubule minus end in a 
retrograde direction. Both N-KIFs and C-KIFs are composed of a motor domain, a stalk 
domain and a tail region known as the cargo binding domain. Whereas M-KIFs possess 
a motor domain yet lack the long flexible stalk domain exhibited by both N-KIFs and C-
KIFs (Ovechkina and Wordeman, 2003). It is also unclear if M-KIFs possess a tail domain 
in a similar manner to both N-KIFs and C- KIFs. The amino acid sequence encoding the 
motor domain is highly conserved across the 14 types of KIFs (Hirokawa and Takemura, 
2005). Comparatively, the rest of the kinesin protein has evolved and adapted to target 
different cargoes for transport whilst conserving the basic means of propulsion along 
the microtubule (Vale and Fletterick, 1997). An example of kinesin binding to cargo 
includes the kinesin-3 family member KIF16B and its interaction with fibroblast growth 
factor receptor vesicles (Ueno et al., 2010). The binding of cargoes to the tail domain is 
not always direct and can be mediated by a variety of adaptor proteins over the 
entirety of the different N-KIFs and C-KIFs (Hirokawa et al., 2009a). For example, the 
kinesin-2 family member, KIF17, is capable of transporting the N-methyl-D-aspartate 
(NMDA) receptor subunit NR2B-containing receptor vesicles present in dendrites of 
neuronal cells via several adaptor proteins including Lin10, Lin2 and Lin7 (Setou et al., 
2000; Guillaud et al., 2003). The kinesin-3 family member KIF13A is known to bind 
vesicles containing the mannose-6-phosphate receptor (M6PR) via the adaptor protein 
AP-1 (Nakagawa et al., 2000). The variety of adaptor proteins known to bind to kinesin-
1 will be discussed in further detail in Section 1.2.2.  
Nearly all KIFs are responsible for transporting some form of cargo for example, 
proteins or organelles. However, there are other roles than can be played by some 
KIFs. These include the members of the kinesin-8, kinesin-13 and kinesin-14 families 
which can depolymerise microtubules in an ATP-dependent manner. The need for 
kinesin motor proteins to depolymerise microtubules is thought either to deconstruct 
25 
 
microtubules at certain cellular locations or to help enable the coupling of microtubule 
depolymerisation to the movement of the cellular cargo (Moores et al., 2006). Most 
kinesin molecules form a dimeric structure consisting of two kinesin proteins 
interacting together via the stalk domain. However, the kinesin-3 family member, 
KIF1A, is unique in that it is a monomeric motor (Okada et al., 1995). The kinesin-2 
family members KIF3A, KIF3B and kinesin associated protein 3 (KAP3) are known to 
together form a tetrameric kinesin protein (Mueller et al., 2005). Also two KIF heavy 
chains of the kinesin-1 family are known to form a heterodimer with two kinesin light 
chain (KLC) proteins (Gauger and Goldstein, 1993). The kinesin-5 family are tetrameric 
kinesins with two motor domains on each side of the tetramer. This in turn allows 
kinesin-5 to simultaneously bind and walk along two antiparallel microtubules assisting 
to slide the microtubules apart in centrosome separation during cell division 
(Tanenbaum and Medema, 2010).  A summary of the major mammalian KIFs found in 
mouse is shown in Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 A summary of the major mouse kinesins.  
a = Phylogenic tree of the 45 kinesin superfamily genes in the mouse genome. b = Schematic structures 
of the major mouse kinesins. Reproduced with permission from Hirokawa et al. (2009).   
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The importance of several kinesin sub-types in the CNS has been demonstrated by 
utilising knock-out studies in murine models. Deletion of the ubiquitous kinesin-1 
subtype, KIF5B, in rat models resulted in neonatal death of pups before birth (Tanaka 
et al., 1998). KIF5A knock-out mice also resulted in the neonatal death of pups before 
birth (Xia et al., 2003). Yet mice lacking the KIF5C gene survived yielding viable and 
normal sized mice, albeit with a notably smaller brain mass of approximately 5 % 
(Kanai et al., 2000). In the same study by Kanai et al reported that there was a relative 
loss of motor neurons compared to sensory neurons in these KIF5C mutant mice. The 
role of the kinesin-1 family in the CNS will be discussed in more detail in Section 1.2.3. 
Deletion of KIF3A in knock-out mice models also demonstrated neonatal death 
(Takeda et al., 1999). KIF1B knock-out mice survived birth but died within 30 min. The 
KIF1B knock-out mouse brains were reduced ~ 10 % in size and the organisation and 
development of the brain stem nuclei, hippocampus and commissural fibres were 
significantly affected (Zhao et al., 2001). KIF2A knock-out mice also managed to survive 
birth but died within a day of being born (Homma et al., 2003). Conversely, 
KIFC2 mutant mice were viable and reproduced normally after demonstrating normal 
development (Yang et al., 2001). 
 
1.2.1 Structure of kinesin 
The structure of kinesin in its entirety has not yet been solved, although the structure 
of the motor domain has been solved for many different kinesins, including the 
kinesin-1, kinesin-2, kinesin-3, kinesin-5, kinesin-10, kinesin-13 and kinesin-14 families 
(Hirokawa et al., 2009). However the most well studied has been that of kinesin-1. 
Previous work by Kull et al. (1996) successfully resolved the structure of the motor 
domain of the human kinesin-1 sub-type KIF5B to a 1.8 Å resolution by X-ray 
crystallography. This was carried out using amino acids 7-325 of KIF5B in complex with 
its magnesium adenosine diphosphate (MgADP) ligand in a ratio of 1:1. Kozielski et al. 
(1997) resolved the motor and stalk domains of KIF5B from rat in its native dimeric 
form to a resolution of 3 Å. This study showed that the two dimeric KHC motor 
domains share a similar conformation to one another. The crystal structure also 
showed the neck region to be a coiled-coil domain (Kozielski et al., 1997). The 
structure of the kinesin-1 motor domain is shown in Figure 1.5. 
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Figure 1.5 Structure of dimeric kinesin-1 in a ribbon representation.  
α-Helices are highlighted in pink and purple, β-sheets are highlighted in yellow and loops in grey. The 
image was adapted from Jmol, an open-source Java viewer for chemical structures in 3D 
(www.jmol.org). Data of the crystal structure was obtained from Kozielski et al. (1997).   
 
 
The success in determining a crystal structure of the kinesin-1 motor domain, as well 
as studies utilising electron paramagnetic resonance, fluorescence resonance energy 
transfer (FRET), pre-steady state kinetics and cryo-electron microscopy experiments 
led to the elucidation of the function and mechanism of kinesin-1 movement along 
microtubules (Rice et al., 1999). Movement of kinesin-1 occurs by a process known as 
the “hand-over-hand” model. In this model, every ATP molecule hydrolysed in the ATP 
binding site of a trailing motor domain head is forced from the energy released to 
overtake the “partner head” in front. This action propagates, in effect, to create 
movement along the microtubule (Asbury, 2003; Yildiz et al., 2003; Shao and Gao, 
2005). Due to the alternating biochemistry of the ATP binding site of each motor 
domain, at least one motor domain remains bound to the microtubule in turn helpijg 
to facilitate the stepping action known as processivity (Howard et al., 1999). Each KHC 
motor domain will bind a tubulin heterodimer present on the microtubule and for 
every movement of the motor domain, the kinesin protein will travel 8 nm along the 
microtubule (Song and Mandelkow, 1993; Hua et al., 1997). Switch regions have been 
identified in the motor domain and are known to be responsible for changing 
conformation depending on whether the nucleotide binding site is occupied. These 
switch regions aid in the binding and attachment of the motor domains to 
microtubules (Kull et al., 1996). Due to the high amino acid sequence homology 
between the motor domains of KIFs, this hand-over-hand method can be used as a 
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template to explain the movement along microtubules for nearly every dimeric KIF 
protein. As previously described, KIF1A (kinesin-3 family) is known to be monomeric 
(Okada et al., 1995). Interestingly KIF1A has also been shown to move directionally 
along the length of microtubules (Okada et al., 1999). Hence, the hand-over-hand 
model does not explain the ability of KIF1A to create movement along microtubules. 
Studies by Okada et al. (2000) have demonstrated that an interaction of the negatively 
charged C-terminal hook of tubulin and the positively charged K-loop of KIF1A enables 
the one-dimensional diffusion of KIF1A to the next tubulin binding site in turn allowing 
for progressive movement. Other N-KIFs, such as the kinesin-5 family members, show 
both the ability to carry out hand-over-hand and diffusive movement along 
microtubules (Kapitein et al., 2008). M-KIFs are also known to use a diffusive method 
to create movement along the microtubule, where at the ends of microtubules M-KIFs 
are known to cause microtubule depolymerisation (Helenius et al., 2006). Relatively 
little is known about the exact mechanism of C-KIF motility, although it is known that 
the two heavy chains dimerise using a different mechanism compared to N-KIF and M-
KIF. C-KIFs also lack the neck linker domain hence it is unlikely that they move in a 
similar manner. Thus, kinesins move by at least two known and differing conserved 
mechanisms rather than by mechanisms that are unique to each kinesin molecule 
(Endow, 1999; Hirokawa et al., 2009a).  
The neck linker domain is highly conserved among kinesin sub-families. Within N-KIFs, 
the neck linker domain is approximately 10 amino acids in length and is present just 
above the motor domain. The neck linker domain is known to amplify the 
conformational changes in the motor domain and is essential for the generation of 
movement along microtubules (Rice et al., 1999; Case et al., 2000). The stalk domain 
that follows the neck linker domain in nearly all kinesin family members consists of 
some form of a coiled-coil domain. In the case of kinesin-1 two coiled-coil regions in 
the stalk domain are known to interact to form the dimeric protein. The formation of 
the dimer is needed to create processive movement of kinesin along the microtubule 
using the hand-over-hand method mentioned previously (Hancock and Howard, 1998; 
Hackney, 2007). The stalk domain is known to give flexibility to the kinesin protein and 
hinge domains present within the stalk domain are responsible for allowing the kinesin 
molecule to change conformation (Gutierrez-Medina et al., 2009). Structural 
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information regarding the conformation of the hinge domains in mammalian kinesins 
is relatively unknown, although analysis of a synthetic peptide of the hinge domain of 
rat kinesin-1 has indicated that it consists of short non-helical secondary domains that 
break the stalk domains coiled-coil structure (Seeberger et al., 2000). In the Drosophila 
kinesin-1, there are two known hinge domains, termed hinge 1 and hinge 2. Hinge 1 
contains several proline and glycine residues which are known to give flexibility. The 
stalk domain is further interrupted by hinge 2 whose role has been linked to the ability 
of the dimeric kinesin-1 to fold back on itself (Hirokawa et al., 1989; Hackney et al., 
1992; Gutierrez-Medina et al., 2009). Analysis of the hinge 1 region of fungal kinesin-1 
has also demonstrated its importance for the efficient activity of the motor domain 
(Grummt et al., 1998). Little is known regarding the structure of the cargo binding 
domain of kinesin. The divergence of this domain makes it difficult to compare across 
all kinesin sub-families. This may be due, as mentioned previously, to a number of 
cargoes that can bind the cargo binding domain either directly or indirectly in order to 
facilitate transport throughout the cell.  
 
1.2.2 Kinesin-1 
Kinesin-1 also known as “conventional kinesin” was the first of the kinesins to be 
identified and was originally isolated from the axon of squid and bovine brain (Brady, 
1985; Vale et al., 1985). Human kinesin-1 is a protein heterotetramer consisting of two 
kinesin heavy chains (KHCs) and two KLCs. A schematic representation of the kinesin-1 
heterodimer is shown in Figure 1.4.  
 
 
 
 
 
 
 
 
 
Figure 1.4 A schematic representation of the kinesin-1 heterotetramer molecular motor.  
The kinesin heavy chain is shown in green and the kinesin light chain is shown in yellow. 
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Each KHC has a molecular weight of ~ 120 kDa and contains a globular head region also 
known as the motor domain which is responsible for force generation along the 
microtubule (Section 1.2.1; Yang et al., 1989). This motor domain is connected to a 
long central coiled stalk domain via a neck-linker region which in turn ends in a tail 
region known as the cargo binding domain. The two central stalks intertwine to form a 
dimer via a coiled-coil domain giving flexibility to the kinesin protein. There are three 
kinesin-1 heavy chain family members - KIF5A, KIF5B and KIF5C (Lawrence et al., 2000). 
The two KLCs each have a molecular weight of ~ 64 kDa and bind to each of the KHCs 
acting as an alternative platform for the binding of specific cargo (Cyr et al., 1991). 
Four isoforms of KLC exist in humans. These include KLC1, KLC2, KLC3 and KLC4. 
Despite this interaction not all kinesin-1 proteins exist as heterotetramers with only 
approximately 50 % of dimeric kinesin-1 known to associate with KLCs at any one time 
(Kanai et al., 2000; DeLuca et al., 2001; Palacios and Johnston, 2002; Gyoeva et al., 
2004). Yet KLCs are important components of kinesin-1 as loss of KLC function leads to 
progressive lethargy, crawling defects and paralysis followed by death at the end of 
the second larval instar stage of development in Drosophila knock-out mutants 
(Gindhart et al., 1998). KLC1 knock-out mouse models also resulted in smaller animals 
with pronounced motor disabilities (Rahman et al., 1999). Immunofluorescence studies 
of sensory and motor neuron cells in the same KLC1 mutants also revealed abnormal 
accumulations of KIF5A and KIF5B. (Rahman et al., 1999).  
 
1.2.2.1 Kinesin light chain 
The KLCs have only been seen to bind KHC as a homodimer meaning that only identical 
KLCs can bind the dimeric KHC at any one time (Gyeova et al., 2004). The KLC binding 
site has been mapped to amino acids 771-813 of KIF5B. Within this KHC region are four 
highly conserved heptad repeats present at amino acids 775-802 which are predicted 
to form a tight alpha-helical coiled-coil interaction with the heptad repeat-containing 
N-terminus of the KLC, in particular the amino acid region KLC 106-152 (Diefenbach et 
al., 1998). The C-terminal tail domains of KLCs include several tetratricopeptide 
repeats (TPRs). These 34 amino acid TPRs are known to mediate protein-protein 
interactions and are involved in the binding of KLC to several cargoes. (Gyeova et al., 
2004; Adio et al., 2006). The TPR domains within the various KLC isoforms are almost 
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identical and therefore KLC1 and KLC2, the most studied KLC sub-types, are thought to 
interact with cargo in a similar manner (Rahman et al., 1998). The binding of KLCs to 
their cargoes will be explained in more detail in Section 1.2.4.1. Work by Zhu et al. 
(2012) has successfully resolved the structure of the TPR domains of both KLC1 and 
KLC2 to a 1.9 Å resolution by X-ray crystallography. This was carried out using amino 
acids KLC1 228-495 and KLC2 217-480. This study hypothesised that the six TPR repeats 
of KLC1 can form two polar patches within its groove to interact with negatively 
charged and aromatic residues of various cargo proteins. The structure of the TPR 
domain of KLC1 is shown in Figure 1.6. In contrast to the similarity in the TPR domains 
there is considerable variability in the C-terminal region of the KLCs (McCart et al., 
2003; Wozniak and Allan, 2006). The binding of cargo to kinesin-1 via KLCs is discussed 
in further detail in Section 1.3.2.2. 
 
 
  
 
 
 
 
 
 
 
 
Figure 1.6 Structure of the TPR domains of human KLC1 in a ribbon representation.  
A = TPR domain of KLC1 with the outer loop α-helices highlighted in red, inner loop α-helices highlighted 
in blue, the non-TPR domain highlighted in grey and loops highlighted in green. The groove which is 
known to interact with cargo proteins is also highlighted and the N-terminus and C-terminus of the 
protein fragment indicated. B = TPR domain of KLC2. The figure was adapted from Zhu et al. (2012). 
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1.2.3 Kinesin-1 in the central nervous system 
As discussed in Section 1.2 kinesin-1 is essential for the correct function and survival of 
pups in murine models. All three of the kinesin-1 sub-types are found in neurons 
however they differ with respect to their localisation. KIF5A is distributed evenly 
throughout the nervous system (Reid et al., 2002). KIF5B is known as a ubiquitous 
kinesin-1 since it is found in nearly all cell types including neurons. More specifically in 
neuronal cells, the highest concentration of KIF5B is found in glial cells and in axon-
elongating neurons such as the mossy fibres found in the cerebellum and the olfactory 
primary neurons involved in smell (Kanai et al., 2000). KIF5C is found in the retina and 
spinal cord where it is mainly located in motor neurons (Schafer et al., 2009; Kanai et 
al., 2000). Both the KLC1 and KLC2 isoforms are also highly expressed in neurons. They 
are found in the olfactory bulb, hippocampus, dentate gyrus and in the granular layer 
of the cerebellum. KLC1 has also been shown to have a uniform distribution 
throughout mouse brain. In the peripheral nervous system KLC1 is found only in axons 
whereas KLC2 is found in axons and Schwann cells (Rahman et al., 1998).  
Kinesin-1 is responsible for transporting cargo throughout neuronal cells. The majority 
of cargo transported by kinesin-1 occurs in the axon, although some cargoes such as α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor GluA2 subunits 
(GluR2), huntington and mRNA containing complexes are transported by kinesin-1 in 
the dendrites of neuronal cells (Setou et al., 2002; Kanai et al., 2004; Twelvetrees et 
al., 2010). There are two kinds of axonal transport: fast transport and slow transport. 
In axons, vesicles move quickly at approximately 50–400 mm/day, while soluble 
proteins are known to move more slowly at approximately 2-8 mm/day (Roy et al., 
2008; Hirokawa, 2011). Kinesin-1 is capable of transporting cargos using both fast and 
slow transport. The slow transport of cytoplasmic proteins by kinesin-1 is essential for 
neuronal homeostasis. Slow transport depends on the interaction between the DnaJ-
like domain in the TPRs of KLCs and heat-shock cognate protein of 70 kDa (Hsc70) 
which helps to mediate the interaction between cytoplasmic proteins and kinesin-1. 
This DnaJ-like domain can bind to membranous organelles. The competitive inhibition 
of this Dna-J like domain was shown to disrupt cytoplasmic protein transport and 
increase the transport of membranous organelles in squid axons (Terada et al., 2010). 
This indicates that this DnaJ-like domain might function as a switch between slow and 
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fast transport involving Hsc70. Transgenic mice over-expressing a dominant-negative 
form of this DnaJ-like domain exhibited delayed slow transport, accelerated fast 
transport and the disruption of optic axons. (Terada et al., 2010).  
Kinesin-1 has been shown to have the ability to distinguish between different 
microtubule populations (Cai et al., 2009). Kinesin-1 will associate with microtubules 
with post-translational modifications of tubulin that indicate a more stable form of 
microtubule. An acetylated form of α-tubulin has been shown to help in the promotion 
of binding of kinesin-1 to microtubules (Reed et al., 2006). Whereas the detyrosination 
of α-tubulin leads to kinesin-1 being directed down axons (Konishi et al., 2009). Also 
the motor domain of KIF5B has been shown to preferentially localise to the tips of 
axons as opposed to dendrites in cultures of hippocampal mouse neurons. When these 
hippocampal mouse neurons are treated with a low concentration of paclitaxel, a 
microtubule stabiliser, axonal microtubules lose their polar characteristics and the 
KIF5B motor domain localises in both the axon and dendrites (Nakata and Hirokawa, 
2003). However, a previous study by Dotti and Banker (1991) found that the 
distribution of both acetylated or tyrosinated tubulins are not found in greater 
quantity in axons compared to dendrites. Hence, this work shows no definitive answer 
as to how kinesin-1 can selectively differentiate between microtubules present in 
either the axon or dendrites within a neuron (Hirokawa et al., 2010). Microtubule 
associated proteins (MAPs) such as MAP2c and tau help to regulate the stability and 
organisation of the microtubule network (Vershinin et al., 2007), but the presence of 
these MAPs on microtubules is known to interfere with the movement of motor 
proteins such as kinesins. Work by Marx et al. (2005) has demonstrated that the 
binding regions of MAPs, such as tau, to the tubulin subunits of microtubules overlap 
with the binding of the KHC motor domain. The number of kinesin-1 motors attached 
to mitochondria at any one time are estimated to be anywhere between 2 and 200 
(Gross et al., 2007). This may explain how the dissociation of kinesin-1 from the 
microtubules by various MAP proteins does not prevent the disruption of cargo 
transport as other microtubule bound kinesins helping to transport the same cargo 
could help to retain movement along the microtubule network.  
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1.2.4 Transport of cargo via the cargo binding domain of kinesin-1 
The binding to and movement along the microtubule via the kinesin motor domain has 
been well characterised over the majority of the KIFs. However, the way in which 
kinesin-1 initially binds the cargo to be transported and how this is regulated is only 
now beginning to be understood. It is known that a variety of adaptor proteins can 
help to associate some cargoes to various KIFs. Proteins that interact with kinesin-1 
can be divided into two main categories; those that interact with KHC and those that 
interact with KLC. Proteins that are known to interact with either the KHC or KLC are 
explained in Section 1.2.4.1 and Section 1.2.4.2 respectively. However, some cargoes 
do not require adaptor proteins in order to mediate binding to kinesin-1 and can 
instead bind directly. One such cargo is p180, a ribosome receptor. Yeast two-hybrid 
assays demonstrated the ability of KIF5B 867-907 to bind 1293-1413 of p180. These 
known interacting regions of both KIF5B and p180 are made up of mostly heptad 
repeats which indicate that this protein interaction is mediated via a coiled-coil 
interaction. (Diefenbach et al., 2004).  
The Ran-binding protein 2 (RanBP2) is a large scaffold protein involved in a wide range 
of cellular functions including the movement of proteins between the nuclear and 
cytoplasm compartments of the cell. RanBP2 is known to associate directly both in 
vitro and in vivo with KIF5B and KIF5C but not KIF5A. This interaction demonstrated 
that RanBP2 could interact with the C-terminal amino acids 527–936 of KIF5B (Cai et 
al., 2001; Cho et al., 2007). 
Interestingly herpes simplex virus (HSV), known for the ability to remain dormant in 
sensory ganglion neurons (Kramer et al., 2003), can associate with the KHC of KIF5B. 
This interaction was demonstrated after in vitro binding assays showed that the 
interaction of HSV with the C-terminus of KIF5B was direct. HSV infection occurs at the 
nerve terminus where replication of HSV then manifests in the nucleus and new 
viruses are transported back to the synapse (Diefenbach et al., 2002; Gindhart, 2006).  
The potential cargoes of both KLCs and KHCs can bind simultaneously on the kinesin-1 
protein (Huang et al., 1999; Diefenbach et al., 2002). An exception to this is the 
mitochondrial adaptor protein, Milton, which is known to compete with the KLCs for 
binding to the same KHC domain (Glater et al., 2006; Wozniak and Allan, 2006).  
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1.2.4.1 Adaptor proteins that bind via the kinesin heavy chain 
There are several known kinesin adaptor proteins that are responsible for mediating 
the binding of cargo to KHC. A summary of all the current known KHC adaptor proteins 
and their cargo are shown in Table 1.1.    
Adaptor protein KHC cargo 
Methods used to ascertain 
the interaction between 
the cargo domain of KHC 
and the adaptor protein 
Region of KHC 
interaction 
References 
GRIP-1 (753-987 to 
KHC) 
GluR2 (subunit of 
AMPA receptors) 
Co-immunoprecipitation 
assays and co-localisation 
studies 
KIF5A 
KIF5B 
KIF5C (807-
934) 
Setou et al., 
2002 
Syntabulin 
Syntaxin-1, 
mitochondria 
Co-immunoprecipitation 
assays and co-localisation 
studies 
KIF5B 
Su et al., 2004; 
Cai et al., 
2005; Cai et 
al., 2007 
SNAP23 (1-85 to 
KIF5B) 
Membrane protein 
containing vesicles 
Yeast two-hybrid and in 
vitro pull-down assays 
KIF5B (814-
907) 
Diefenbach et 
al., 2002 
SNAP25 (1-85 to 
KIF5B) 
Membrane protein 
containing vesicles 
Yeast two-hybrid and in 
vitro pull-down assays 
KIF5B (814-
907) 
Diefenbach et 
al., 2002 
UNC-76 (Drosophila) 
FEZ1 is the 
mammalian 
homologue 
Thought to be 
protein kinase C 
(PKC) 
Yeast two-hybrid and co-
purification assays 
Drosophila 
KHC (850-975) 
Gindhart et al., 
2003 
FEZ1 (mammalian 
homologue to UNC-
76) 
Syntaxin 1 and 
Munc19 (synaptic 
vesicle exocytosis 
proteins) also 
mitochondria 
In vivo pull-down assay, co-
immunoprecipitation 
Rat KIF5B 
Fujita et al., 
2007; Chua et 
al., 2012 
TRAK1 (TRAK/Milton 
family member) 
Mitochondria, K
+
 
channel and GABAA 
receptor β2 subunit 
Yeast two-hybrid and co-
immunoprecipitation 
assays, co-localisation 
studies 
KIF5A 
KIF5B 
KIF5C (827-
957) 
Brickley et al., 
2005; Smith et 
al., 2006; 
Brickley and 
Stephenson, 
2011. 
TRAK2 (TRAK/Milton 
family member) 
Mitochondria, K
+
 
channel and GABAA 
receptor β2 subunit 
Yeast two-hybrid and co-
immunoprecipitation 
assays, co-localisation 
studies 
KIF5A 
KIF5B 
KIF5C (827-
957) 
Brickley et al., 
2005; Smith et 
al., 2006; 
Brickley and 
Stephenson, 
2011. 
Milton  
(TRAK/Milton family 
member) 
(Drosophila) (810-
891 interacts with 
Miro) (1-450 
interacts with KIF5B) 
Mitochondria 
Co-immunoprecipitation 
assays and co-localisation 
studies 
KIF5B (810-
891) 
Stowers et al., 
2002; Glater et 
al., 2006 
Table 1.1 A summary of all the known KHC cargo adaptor proteins.  
The table demonstrates the known interacting domains of the relevant protein interactions and the 
experiments used to demonstrate their interaction. 
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One such adaptor protein is glutamate receptor interacting protein (GRIP-1). GRIP-1 is 
an adaptor protein for GluR2, a subunit of excitatory AMPA type glutamate receptors. 
Antibodies directed against all the kinesin-1 subtypes co-immunoprecipitated GRIP1 
from rat brain lysates. GRIP1, GluR2 and kinesin-1 have also been shown to co-localise 
within the dendrites and cell bodies of cultured hippocampal neurons and can also be 
co-immunoprecipitated from vesicle fractions (Setou et al., 2002).  
Syntabulin is an adaptor protein known to mediate the transport of syntaxin-1, a 
transmembrane protein responsible for vesicular fusion. The KHC of KIF5B was shown 
to interact with syntabulin in vitro and both syntaxin-1 and KHC associate with 
syntabulin-linked membrane organelles that were isolated from rat brain 
homogenates (Su et al., 2004). Small interfering ribonucleic acid (siRNA) knockdown of 
syntabulin in cultures of hippocampal neurons led to inhibition of syntaxin-1 
attachment to microtubules as well as the decrease in distribution of syntaxin-1 in 
processes (Su et al., 2004). Work by Cai et al, (2007) demonstrated that the complex of 
syntaxin-1, syntabulin and KIF5B helps to mediate axonal transport components 
essential for presynaptic assembly. These components include active zone precursor 
carriers and Bassoon, a component of the presynaptic cytoskeleton (Dieck et al., 1998). 
Syntabulin knock down in developing neurons delayed the appearance of synaptic 
activity and in mature neurons impaired synaptic transmission, including reducing 
basal activity and slowing recovery rates after depletion of synaptic vesicles. These 
defects have also been linked with the reduced transport of mitochondria in neuronal 
cells (Ma et al., 2009). Synaptosome-associated protein of 25 kDa and synaptosome-
associated protein of 23 kDa (SNAP25 and SNAP23) are thought to be important in 
forming a complex with syntaxin to help synaptic vesicle exocytosis (Lin and Scheller, 
2000). The amino acids KIF5B 814-907 were shown to bind amino acids SNAP25 1-85 in 
yeast two-hybrid assays. The interaction of KIF5B with SNAP25 was further confirmed 
when an in vitro pull-down assay also demonstrated the ability of KIF5B 814–907 to 
bind both SNAP23 1-85 and SNAP25 1-85. Both KIF5B 814-907 and SNAP23/SNAP25 1-
85 amino acid regions that are known to interact are composed almost entirely of 
heptad repeats suggesting the interaction between KIF5B and SNAP25 is that of a 
coiled-coil interaction (Setou et al., 2002).  
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UNC-76 is a cytosolic protein known to help regulate the trafficking of vesicles in axons 
of Drosophila. Yeast two-hybrid analysis revealed that Drosophila KHC 850-975 
interacted with UNC-76. This was further tested when co-purification experiments of 
bacterially expressed KHC and UNC-76 showed that a direct interaction occurred 
between the two proteins (Gindhart et al., 2003). The same study also demonstrated 
that loss of UNC-76 function in Drosophila null mutants resulted in death between the 
second and third instar stage of development. Prior to death, immunostaining of 
Drosophila larvae with the synaptic vesicle precursor marker SYT showed that 
segmental nerves contain aggregates of SYT immunoreactivity, whereas control larvae 
showed a diffuse and punctate staining pattern (Gindhart et al., 2003). This indicates 
that UNC-76 is essential for kinesin-1 transport in the Drosophila nervous system.   
Other proteins known to associate with KHC are FEZ1 (mammalian homologue to UNC-
76), Milton and the TRAKs (Fujita et al., 2007; Stowers et al., 2002; Beck et al., 2002). 
The TRAK/Milton kinesin adaptor protein family, known to act as kinesin adaptors for 
the transport of mitochondria, will be discussed in more detail in Section 1.4.  
 
1.2.4.2 Adaptor proteins that bind kinesin light chain 
As mentioned previously the KLC1 isoform is highly expressed in neurons and can bind 
several proteins that are associated with neurodegeneration or axonal outgrowth.  
Several cargoes are transported by kinesin-1 courtesy of their binding via the KLCs. A 
summary of the known adaptor proteins and the cargo transported by KLCs are shown 
in Table 1.2. 
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Name of KLC 
interactor 
KLC cargo 
Methods used to 
ascertain the interaction 
between KLC and the 
adaptor protein 
Region of 
KLC 
interaction 
References 
  JIP1 (307-700) 
  JIP2  
  JIP3 
JNKs 
Yeast two-hybrid, co-
immunoprecipitations, co-
localisation, dominant 
negative, in vitro motility 
assays 
Rat KLC (TPR 
motif) Also 
KIF5C 
Meyer et al., 1999; 
Stockinger et al., 
2000; Verhey et al., 
2001; Horiuchi et al., 
2005; Sun et al., 
2011 
  HAP1 (rat) huntington 
Yeast two-hybrid, pull-
down, co-
immunoprecipitations 
assays and co-localisation 
studies 
Rat KLC2 
McGuire et al., 2006; 
Rong et al., 2006; Ma 
et al., 2011 
  APP 
Vesicles    
containing APP, β-
secretase and 
presinilin-1 
Co-immunoprecipitations, 
sucrose gradients, in vitro 
binding assays and APP 
knock-out mice 
Mouse KLC1 
Kamal et al., 2000; 
Kamal et al., 2001; 
Hirokawa and 
Takemura, 2003 
  Calsyntenin-1  
  (mouse) 
Neuronal vesicles   
and 
tubulovesicular 
organelles 
Yeast two-hybrid, in vivo 
pull-down assays, co-
immunoprecipitations 
assays and co-localisation 
studies 
Mouse KLC1 
(TPR 
domain), 
mouse KLC2 
Konecna et al., 2006; 
Vagnoni et al., 2011 
  TorsinA  
  (251-332) 
Transmembrane 
proteins LAP1 and 
LULL1 
Yeast two-hybrid and co-
localisation studies 
KLC1 (209-
547) 
Kamm et al., 2004 
  
  CRMP-2  
 
Sra-1/WAVE1 
complex as well as 
tubulin 
Co-localisation studies, co-
immunoprecipitation and 
in vitro pull-down assays 
Mouse KLC1 
(375-542) 
Kimura et al., 2005; 
Kawano et al., 2005 
  UNC-83 
  (C.elegans) 
Docking site for 
the outer nuclear 
membrane 
Yeast two-hybrid, in vitro 
interaction assays 
KLC2 (137-
362). Also 
interacts 
with dynein 
Meyerzon et al., 
2009; Fridolfsson et 
al., 2010 
  Hsc70 
Clathrin-coated 
vesicle containing 
cytoplasmic 
proteins. Also 
creatine kinase 
Co-immunoprecipitations, 
dominant negative, KLC 
mutant mice 
KLC1 
Tsai et al., 2000; 
Terada et al., 2010 
  
  FMRP (386-585)  
  
Ribonucleoprotein 
complexes 
Co-immunoprecipitation 
assays  
Mouse KLC 
Dictenberg et al., 
2008 
  Kidins 220 (rat)  
  (kinase-D- 
  interacting 
  substrate of 220 
  kDa) (1361-1395 
  binds to KLC1) 
No known cargo 
Yeast two-hybrid, pull-
down assays, co-
immunoprecipitations and 
co-localisation studies 
Rat KLC1 (83-
296) 
Bracale et al., 2007 
Table 1.2 A summary of KLC protein interactors.  
The table demonstrates the known interacting domains of the relevant protein interactions and the 
experiments used to demonstrate their interaction. 
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One such cargo that binds to KLC is C-jun N-terminal kinases (JNKs) which are mitogen-
activated protein kinases. These MAP kinases respond to stress stimuli and are known 
to be trafficked by a set of proteins called JNK interacting proteins (JIPs). Three 
proteins, JIP1, JIP2 and JIP3 were identified and are known to bind to the C-terminus of 
the KLCs acting as scaffolding proteins for the JNK pathway (Verhey et al., 2001). The 
three JIP proteins were originally found to interact with the TPR domain of rat KLC1 in 
a yeast two-hybrid screen (Verhey et al., 2001). More specifically JIP1 307-700 was 
shown to interact with the TPR domain of KLC after co-immunoprecipitation of 
transfected constructs in human embryonic kidney 293 (HEK 293) cells. Co-localisation 
of JIP-1 and KLC1 in cultured neuronal cells demonstrated the complex at the tips of 
neuronal processes, with dominant negative experiments leading to a disruption of 
this distribution (Verhey et al., 2001). In addition, interestingly JIP3 has recently been 
shown to bind the KIF5C KHC. Using an in vitro motility assay it was demonstrated that 
JIP3 can activate KHC for microtubule-based transport and it also helps to promote 
efficient motility of KHC along microtubules. This in turn increases both processive run 
length and the velocity of KHC. Importantly, JIP3 binding to KHC is functional in 
neurons as mutated JIP3 that can bind KHC but not KLC are transported to axons and 
dendrites similarly to wild-type JIP3. JIPs have been shown to be essential for correct 
functioning of vesicle transport in axons, with mutated JIP-1 and JIP-3 genes in 
Drosophila and C. elegans models showing similar results to that of stopping general 
kinesin-1 movement (Horiuchi et al., 2005). This work has helped to establish JIP3 as 
an adaptor for both KLC and KHC and it also indicates that JIP3 is a positive regulator of 
kinesin-1 motility in neuronal cells (Sun et al., 2011). In addition, JIP-1 and JIP-2 have 
been found to interact with rhoGEF and with the cell surface receptor for Reelin, 
ApoER2 (Meyer et al., 1999; Stockinger et al., 2000).  
Huntington-associated protein-1 (HAP-1) is a protein found predominantly in neurons. 
It is a 629 amino acid protein with two coiled-coil domains (Li et al., 1995). The 
dysfunction of HAP-1 and its interacting protein partner huntington has been linked to 
Huntington’s disease. HAP-1 has been shown to interact with rat KLC2 using yeast two-
hybrid screens. This was also shown to occur in vivo after co-immunoprecipitation of 
KLC with HAP-1 from mouse brain hypothalamic tissue using antibodies directed to KLC 
(McGuire et al., 2006). The same study also demonstrated that HAP-1 can co-localise 
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with kinesin-1 in pheochromocytoma 12 (PC12) cells, a cell line derived from rat 
adrenal medulla. HAP-1 was also enriched in the end processes of neurites in PC12 
cells. siRNA knock-down of HAP-1 resulted in the reduction of neurite growth in PC12 
cells (McGuire et al., 2006). HAP-1 has also been shown to interact with dynactin p150, 
a member of the dynein family (Engelender et al., 1997). The phosphorylation of HAP-1 
at T598 was shown to be important in mediating the binding interaction between HAP-
1 and both KLC2 and dynactin p150 (Rong et al., 2006). Recent work by Ma et al. 
(2011) showed that the knock-down of KIF5A resulted in reduced levels of HAP-1. This 
work not only indicates that HAP-1 is being utilised as a cargo linker in bi-directional 
transport of its associated cargoes, but it is also associated with KLC via the KIF5A sub-
type of kinesin-1.  
KLC has been shown to interact with and transport amyloid precursor protein (APP). 
The cleavage of APP by β and γ secretase produces the pathogenic form of APP, 
amyloid β, known to cause the plaques that may be responsible for Alzheimer’s 
disease (O’Brien and Wong, 2011). Experiments by Kamal et al. (2000) using co-
immunoprecipitation assays, sucrose gradients and direct in vitro binding assays 
established that the 47 C-terminal amino acids, known to constitute the cytoplasmic 
domain of APP, interacted directly with the TPRs of mouse KLC1. The follow up study 
also showed that kinesin-1 is associated with axonally transported vesicles that contain 
APP and the transmembrane proteins involved in its proteolytic cleavage (Kamal et al., 
2001). Although it is worth noting that the work regarding the binding of APP to KLC 
has been refuted by several different laboratories (Lazarov et al., 2005).  
The type-1 membrane-spanning protein, calsyntenin-1, is also known to interact with 
KLC1. Calsyntenin-1 is involved in the transport of neuronal vesicles and 
tubulovesicular organelles. Yeast two-hybrid and GST pulldown assays demonstrated 
that two highly conserved segments in the cytoplasmic domain of mouse calsyntenin-
1, amino acids 878-924, are known to mediate its binding to the TPR domain of KLC1 
(Konecna et al., 2006). Work by Vagnoni et al. (2011) further demonstrated the 
importance of the KLC1 S460 in the regulation and binding to calsyntenin-1. S460 
residue is known to be phosphorylated and experiments to mimic the pre-
phosphorylation state i.e. mutating the serine to an alanine, resulted in an increase in 
the co-immunoprecipitation of calsyntenin-1 with KLC1 after co-transfection in chinese 
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hamster ovary (CHO) cells. The identical experiment although this time mutating the 
S460 residue to aspartate to mimic a constant phosphorylation state resulted in a 
decrease in co-immunoprecipitation. The same study also showed that KLC1 S460 is 
targeted by extracellular-signal-regulated kinase (ERK) and KLC1 S460D decreased co-
localisation with calsyntenin-1 in the monkey kidney cell line, CV-1. These results 
indicate that the KLC1 S460 may be involved in regulating the binding to calsyntenin-1 
(Vagnoni et al., 2011). 
Fragile X mental retardation protein (FMRP) has been shown to be vital in the 
trafficking of various mRNA, including its own transcript, via the association with KLC. 
Altered expression of FMRP results in Fragile X syndrome, a highly prevalent form of 
inherited mental retardation which is thought to contribute to the spectrum of autism 
disorders (Schaeffer et al., 2003). The association of KLC with FMRP was first shown 
after the C-terminal domain of FMRP, amino acids 386-585, co-immunoprecipitated 
KLC from co-transfected HEK 293 cells using antibodies directed towards the FLAG-tag 
present on FMRP (Dictenberg et al., 2008).  
Collapsin response mediator protein-2 (CRMP-2) has shown to be important in the 
trafficking of the Rac1-associated protein 1 (Sra-1)/WASP family verprolin-homologous 
protein 1 (WAVE1) complex, which is a regulator of the actin cytoskeleton (Kawano et 
al., 2005). Mouse KLC1 was originally shown to co-immunoprecipitate with CRMP2 
from solubulised rat brain lysate. In addition, punctate CRMP-2 immunoreactivities 
were seen to be co-localised with KLC in axonal shafts of primary rat hippocampal 
neurons (Kimura et al., 2005). The same study by Kimura et al. (2005) also used in vitro 
binding assays utilising recombinant His-tagged CRMP-2 and with GST-tagged KLC1 to 
demonstrate that KLC1 168-542 is responsible for binding to CRMP-2. Work carried out 
by Kawano et al. (2005) further refined the CRMP-2 binding site of KLC1 using in vitro 
binding assays to demonstrate that KLC 375-542 is responsible for binding CRMP-2.     
 
Nearly all of the proteins that associate with KLC discussed above have displayed the 
ability to bind with at least two of the KLC sub-types, typically KLC1 and KLC2. In the 
case of the protein TorsinA that is responsible for numerous functions within neuronal 
cells including cytoskeletal dynamics and neurotransmitter release (Chen et al., 2010), 
it can only bind KLC1 and not KLC2. Initially, yeast two-hybrid experiments using the 
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amino acid region 251–332 of TorsinA as bait showed a positive interaction with that 
of KLC1. Co-immunoprecipitation of TorsinA from human hippocampal brain samples 
showed the presence of KLC1 but not KLC2 indicating an in vivo interaction of TorsinA 
with KLC1. These co-immunoprecipitation results demonstrating the interaction 
between KLC1 and TorsinA were further replicated using adult rat brain, rat primary 
cortical neurons and embryonic rat brain samples. TorsinA and kinesin-1 were also 
shown to co-localise to a high degree in rat primary cortical neurons in the cell body, 
neurite extensions and at the end of processes. Mutant TorsinA, which does not bind 
KLC1, is found accumulated in inclusions suggesting that the binding of TorsinA to KLC1 
is required for proper trafficking of TorsinA within the neurons (Kamm et al., 2004). 
The difference in binding properties between KLC1 and KLC2 is unexpected since their 
TPR domains, the putative binding site for these cargoes, share ~ 87 % amino acid 
sequence identity (Zhu et al., 2012). 
As discussed in Section 1.2.3, slow transport depends on the interaction between the 
DnaJ-like domain in the TPRs of KLCs and Hsc70 which helps to mediate the interaction 
between cytoplasmic proteins and kinesin-1. The interaction between KLC1 and Hsc70 
was demonstrated when both anti-KLC1 and anti-Hsc70 antibodies successfully co-
immunoprecipitated the KLC1/Hsc70 complex from the sciatic nerve axons of mouse 
(Terada et al., 2010).   
 
1.3 The TRAK/Milton family of kinesin adaptor proteins 
The family of trafficking kinesin proteins (TRAKs) are kinesin adaptor proteins. The 
TRAK family consists of TRAK1 and TRAK2 both of which are known to bind to the 
cargo binding domain of conventional kinesin-1 heavy chains forming a link between 
the motor protein and cargo (Brickley et al., 2005; Smith et al., 2006; Brickley and 
Stephenson, 2011). Human TRAK1 is 953 amino acids in length and has a calculated 
molecular weight of 105 kDa (Iyer et al., 2003; Brickley et al., 2005). TRAK1 is thought 
to possibly exist as several isoforms, including TRAK1 isoforms 1-5 (isoform 1 being full 
length TRAK1). However, the abundance as well as the tissue specificity of isoforms 2-5 
is as yet unknown. Alternatively, the mouse TRAK1 is a predicted 939 amino acids in 
length and is known to exist as a second isoform, TRAK1 hyrt, which has a truncated C-
terminal domain due to missing the final 16th exon resulting in TRAK1 1-824 (Gilbert et 
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al., 2005). TRAK2 is 913 amino acids in length and has a calculated molecular weight of 
102 kDa and is known to exist as three main isoforms, TRAK2-1a, TRAK2-1b and TRAK2-
1c (Table 1.3). The entire TRAK2 gene contains 16 exons in total, with TRAK2-1b 
missing exons 15 and 16, and TRAK2-1c missing exon 15.  The three TRAK2 isoforms 
are summarised in Table 1.3. TRAK1 is expressed in both excitable and non-excitable 
tissues (Iyer et al., 2003), whereas TRAK2 has been reported to only be expressed in 
excitable tissue (Beck et al., 2002). It is also thought that TRAK2 may exist as at least a 
dimer (Beck, M., Ojla, G., Stephenson, F.A., unpublished observations). However, it is 
currently unknown if the members of the TRAK/Milton family can hetero dimerise with 
one another. 
 
Table 1.3 The studied splice variants of TRAK1 and TRAK2.  
This table includes their amino acid length and distribution within tissue types. 
 
Originally named GRIF-1 (gamma-aminobutyric acid type A (GABAA) receptor 
interacting factor-1), TRAK2 was initially discovered after a yeast two-hybrid screen of 
a rat brain complementary deoxyribonucleic acid (cDNA) library was used to search for 
proteins interacting with the intracellular loop of the GABAA receptor β2 subunit. This 
interaction was confirmed using co-immunoprecipitation assays after co-transfection 
TRAK 
isoform 
Amino acid 
length 
Missing 
TRAK 
domain 
Tissue distribution Reference 
TRAK1 
(Mouse) 
939 - 
Liver, kidney and CNS 
(including the cortex, 
hippocampus, 
thalamus, forebrain 
and midbrain) 
Gilbert et al., 
2005 
TRAK1 hyrt 
(Mouse) 
824 824-939 
Liver, kidney and CNS 
(including the cortex, 
hippocampus, 
thalamus, forebrain 
and midbrain) 
Gilbert et al., 
2005 
TRAK2-1a 
(Rat) 
913 - 
Cerebellum, forebrain, 
heart, skeletal muscle 
and testes 
Beck et al., 
2002 
TRAK2-1b 
(Rat) 
672 673-913 
Forebrain, heart and 
skeletal muscle 
Beck et al., 
2002 
TRAK2-1c 
(Rat) 
848 620-688 
Brain, heart, lung and 
smooth muscle tissue 
Iyer et al., 2003 
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of TRAK2 and GABAA β2 constructs in HEK 293 cells (Beck et al., 2002). Originally 
named OIP106 (O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) 
interacting protein of 106 kDa), TRAK1 was initially shown to interact with OGT via a 
yeast two-hybrid screen (Beck et al., 2002; Iyer et al., 2003). Both TRAK1 and TRAK2 
share an overall 60 % amino acid similarity with one another but share a 76 % amino 
acid similarity within their coiled-coil domains (Iyer et al., 2003). Hence, both TRAK1 
and TRAK2 were proposed to belong to the same family of coiled-coil proteins. Other 
proteins known to share sequence homology with the TRAK protein family are Milton 
and HAP1. TRAK2 shares a 47 % amino acid similarity with Milton, a Drosophila 
protein. It is thought that Milton is the species homologue to both TRAK1 and TRAK2 
(Stowers et al., 2002). HAP1 shares a 56 % amino acid similarity when compared to the 
coiled-coil region of TRAK2. HAP-1 is known to interact with both the KLC of kinesin-1 
and with dynactin/p150Glued, a protein known to associate with dynein (Engelender et 
al., 1997; McGuire et al., 2006; Section 1.2.4.1). HAP1 is also known to transport brain-
derived neurotrophic factor (BNDF) (Wu et al., 2010). Hence, it is possible that HAP1 
may also be a member of the TRAK adaptor protein family.  
Previous experiments to identify the binding domain of kinesin-1 to the TRAK family of 
adaptor proteins utilised KIF5C as the model system. Initially KIF5C was divided into 
two main regions. These regions were amino acids 1-335 and 336-957. KIF5C 1-335 
corresponded to the motor domain and KIF5C 336-957 included the non-motor 
domain. KIF5C 336-957 was shown using yeast two-hybrid interaction assays, co-
immunoprecipitation experiments and FRET studies to interact with TRAK2. Whereas 
yeast two-hybrid interaction assays and co-immunoprecipitation experiments using 
KIF5C 1-335 showed no interaction with TRAK2 (Smith et al., 2006). FRET experiments 
utilising TRAK1 have also concluded that the non-motor domain of KIF5C is responsible 
for correct interaction (Brickley et al., 2011). Further work divided the KIF5C non-
motor domain into three regions; these were amino acids 336-542, 593-804 and 827-
957. Again using yeast two-hybrid interaction assays and co-immunoprecipitation 
experiments it was shown that amino acids 827-957 of KIF5C interact with TRAK2 while 
336-542 and 593-804 do not. Conversely the amino acids 124-283 of TRAK2 but not 
TRAK1 were found to associate with the cargo binding domain of KIF5C, amino acids 
827-957 (Brickley et al., 2005). 
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Work carried out by Smith et al. (2006) has demonstrated that there is no association 
between TRAK2 and KLC. This was shown using both yeast two-hybrid assays and co-
immunoprecipitation of KLC and TRAK2 in mammalian cell lines. Experiments carried 
out by Glater et al. (2006) have demonstrated that the binding of Milton to kinesin-1 is 
also KLC independent. This was shown after a rat KLC1 clone was transfected into COS-
7 cells (kidney cells of the African Green Monkey) both alone and in combination with 
KHC and Milton. In the absence of KLC, KHC is found co-localised to mitochondria. 
However, when Milton, KHC, and KLC were co-expressed, KLC was cytoplasmic and not 
located on the mitochondria. Therefore, KLC expression appeared to inhibit the 
recruitment of KHC to the mitochondria by Milton. Work in the same study also 
showed that via co-immunoprecipitation techniques KLC can in fact inhibit the binding 
of Milton to KHC. In Drosophila homogenates KLC was also not detected in co-
immunoprecipitations of the Milton/KHC complex. (Glater et al., 2006). 
 
1.3.1 Mitochondria as a cargo for the TRAK/Milton adaptor protein family  
As previously mentioned in Section 1.3 both TRAK1 and TRAK2 are responsible for 
acting as kinesin adaptor proteins helping to mediate the interaction between the 
cargo to be transported and the KHC of kinesin-1. The most well established cargo 
known to be transported by that of the TRAK/Milton family are mitochondria. Miro1 
and Miro2 are atypical Rho GTPases present on the outer membrane of mitochondria. 
Both Miro1 and Miro2 are known to bind the TRAK/Milton protein family acting as the 
receptor for mitochondrial trafficking (Fransson et al., 2006; MacAskill et al., 2009a; 
Wang and Schwarz, 2009). Both TRAK1 and TRAK2 have been shown to co-localise with 
mitochondria after co-expression in HEK 293 and COS-7 cells (Brickley et al., 2005; 
Smith et al., 2006). The co-expression of either TRAK1 or TRAK2 with KHC results in the 
localisation of mitochondria to the ends of cellular processes (Smith et al., 2006). Both 
co-localisation studies and co-immunoprecipitation experiments have demonstrated 
the ability of either TRAK1 or TRAK2 to associate with both Miro1 and Miro2 (Fransson 
et al., 2006; MacAskill et al., 2009). The over-expression of Miro1 in cultures of 
hippocampal neuronal cells also showed an increased distribution of mitochondria at 
the ends of axonal processes as well as resulting in an increase in moving mitochondria 
in dendrites (MacAskill et al., 2009a; MacAskill et al., 2009). Inhibition of both TRAK1 
and TRAK2 in primary neuronal cultures from the hippocampus of rats utilising both 
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short hairpin ribonucleic acid interference (shRNAi) and dominant negative gene 
silencing resulted in a decrease in axonal mitochondrial mobility (Brickley and 
Stephenson, 2011). The same study also highlighted differences between TRAK1 and 
TRAK2 regarding their individual contribution towards mitochondrial transport. Both 
the transfection of green fluorescent protein (GFP)-TRAK1 and GFP-TRAK2 were shown 
to rescue mitochondrial transport after TRAK1 shRNAi caused a decrease in 
mitochondrial mobility (Brickley and Stephenson, 2011). This work indicates a distinct 
mechanism for the transport of mitochondria in axons and the differing roles TRAK1 
and TRAK2 may play. The theory of differing methods of mitochondrial transport was 
further highlighted when Macaskill et al. (2009a) demonstrated the ability of Miro to 
associate directly with all three kinesin-1 sub-types KIF5A, KIF5B and KIF5C using in 
vitro pulldown assays, implying that direct transport of mitochondria may occur. A 
schematic representation of the TRAK/kinesin-1/Miro complex is shown in Figure 1.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 A schematic representation of the TRAK/kinesin-1/Miro complex.  
The KHC is shown in green, TRAK in red and Miro in blue. Figure adapted from Brickley et al. (2005). 
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Work by Misko et al. (2010) has also indicated other proteins, mitofusin 1 (Mfn1) and 
mitofusin 2 (Mfn2), that interact with the TRAKs and thus may be involved in the 
mitochondrial trafficking complex. Mfn1 and Mfn2 are dynamin family GTPases which 
are known to form a complex to tether mitochondrial membranes together and in turn 
help to facilitate mitochondrial fusion (Santel and Fuller, 2001). Co-
immunoprecipitation experiments on exogenously expressed Mfn1 and Mfn2 in HEK 
293 cells have demonstrated that Mfn2 and Mfn1 are both capable of interacting with 
Miro1, Miro2, TRAK1 or TRAK2 (Misko et al., 2010). The same study also showed that 
neither Mfn1 nor Mfn2 can interact with KIF5C or KLC in co-immunoprecipitation 
experiments indicating that Mfn1 and Mfn2 are not involved in directly associating 
with kinesin-1. However the knockdown of Mfn2 in cultured rat dorsal root ganglion 
neurons produced mitochondrial transport deficits identical to the loss of Miro2, which 
includes increased pause time and slower movement velocities of mitochondria in 
both anterograde and retrograde directions. The work regarding the involvement of 
Mfn1 and Mfn2 in the mitochondrial trafficking complex is only preliminary but 
indicates that both Mfn2 and Miro2 proteins may be present to help mediate axonal 
mitochondrial transport (Misko et al., 2010).       
 
1.3.2 Proteins interacting with the TRAK/Milton family of kinesin adaptors 
As discussed in Section 1.3.1 the TRAK/Milton family of kinesin adaptors are 
responsible for binding to and transporting mitochondria. However, the TRAK/Milton 
family has also been shown to traffic a number of different cargoes. A summary of the 
known TRAK1, TRAK2 and Milton interacting proteins are shown in Table 1.4.  
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Name of 
protein interactor 
Region of TRAK1, TRAK2  
or Milton where it is  
known to interact 
Methods used 
 to ascertain  
this interaction 
References 
Miro1 (476-750) 
Miro2 
(mitochondrial membrane 
proteins)  
  TRAK1  
  TRAK2 
Transfected HEK 293 
cells, co-
immunoprecipitation 
assays 
Fransson et al., 
2006 
KIF5A 
  TRAK1 
  TRAK2  
  Milton  
Transfected HEK 293 
cells, co-
immunoprecipitation 
assays 
Brickley et al., 
2005 
KIF5B  
  TRAK1 
  TRAK2  
  Milton  
Transfected HEK 293 
cells, co-
immunoprecipitation 
assays 
Brickley et al., 
2005 
KIF5C (827-957) 
  TRAK1 
  TRAK2 (124-293) 
  Milton  
Transfected HEK 293 
cells, co-
immunoprecipitation 
assays 
Brickley et al., 
2005 
Kir2.1 (180-428) (K
+
 channel)   TRAK2 (1-497) 
Yeast two-hybrid 
screen, co-
immunoprecipitation 
assays 
Grishin et al., 
2006 
GABAα receptor β2 subunit    TRAK2 (124-293) 
Yeast two-hybrid 
screen and co-
immunoprecipitation 
assays 
Beck et al., 
2002 
GABAα receptor α1 subunit   TRAK1 
Co-localisation studies 
and in vivo co-
immunoprecipitation 
assays  
Gilbert et al., 
2005 
OGT  
  TRAK1 (639–859)  
  TRAK2 (622-846) 
Yeast two-hybrid 
screen, co-
immunoprecipitation 
assays and co-
localisation studies. 
Iyer et al., 
2003; Brickley 
et al., 2011. 
Hrs (Hepatocyte growth 
factor-regulated tyrosine 
kinase substrate)  
TRAK1   
TRAK2 (359-507) 
Yeast two-hybrid 
screen, co-
immunoprecipitation 
and in vitro binding 
assays 
Kirk et al., 
2006; Webber 
et al., 2008 
Mfn1 and Mfn2 
(mitochondrial membrane 
proteins)  
  TRAK1  
  TRAK2 
Co-
immunoprecipitation 
assays in HEK 293 cells 
Misko et al., 
2010 
Pink1    Milton 
Co-
immunoprecipitation 
assays in HEK 293 cells 
analysed via mass 
spectrometry 
Weihofen et 
al., 2009 
Table 1.4 A summary of the TRAK/Milton protein interactors.  
The table demonstrates the methods to ascertain the interactions and the amino acid regions 
responsible.   
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As discussed previously in Section 1.3 another protein that is known to interact with 
the TRAK family is OGT (Iyer et al., 2003). OGT is a post-translational modification 
enzyme known to catalyse the addition and removal of N-acetylglucosamine (O-
GlyNAc) moieties to the serine and threonine amino acid residues of nuclear and 
cytoplasmic proteins (Hart and Akimoto, 2009). This addition or removal of O-GlycNAc 
is a dynamic modification and can occur at a rapid rate. The formation of stable TRAK1 
and TRAK2 complexes with OGT has been demonstrated in vitro and in vivo (Iyer et al., 
2003; Smith et al., 2004; Brickley et al., 2011). Further work by Brickley et al. (2011) 
showed that OGT co-associates with TRAK2/KIF5C after co-expression in HEK 293 cells. 
Co-immunoprecipitations of KIF5A from rat brain extract also demonstrated the 
presence of either TRAK1 or TRAK2 and OGT. Co-expression of OGT with either of the 
TRAK family members in COS-7 cells resulted in the co-localisation of protein with 
aggregated mitochondria as opposed to a diffuse cytosolic distribution of the TRAKs 
when expressed alone. The same study by Brickley et al. (2011) illustrated that S562 
was O-glycolsylated in TRAK2. The exact involvement of OGT in the 
TRAK/kinesin/mitochondrial trafficking complex is currently unclear, although it is 
possible to speculate that due to its role as a post-translational modification enzyme 
that OGT may be involved in the regulation of mitochondrial trafficking (Brickley et al., 
2011).        
As discussed in Section 1.3, TRAK2 was discovered by virtue of its interaction with 
GABAA receptor β2 subunit in a yeast two-hybrid screen (Beck et al., 2002). The 
interaction of TRAK1 with GABAA receptor α1 subunit has also been demonstrated. Co-
staining of both TRAK1 and GABAA receptor α1 using specific antibodies in mouse and 
spinal cord slices demonstrated positive co-immunofluorescence. Furthermore, when 
TRAK1 was immunoprecipitated from the detergent solubilised extracts of mouse 
brainstem and spinal cord samples using a specific TRAK1 antibody, GABAA receptor α1 
was shown to successfully co-immunoprecipitate (Gilbert et al., 2005). This evidence in 
conjunction with further work by Gilbert et al. (2005) demonstrating that a mutated 
TRAK1 protein lacking the C-terminal domain, found in hyrt mice, can also co-
immunoprecipitate with GABAA receptor α1 indicates that TRAK1 1-824 is necessary 
for the interaction with GABAA receptor α1.    
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Yeast two-hybrid screens using the rat brain hippocampal/cortical cDNA library and 
utilising rat Hrs as bait resulted in TRAK2 199-507 showing a positive interaction. This 
interaction was confirmed when co-immunoprecipitation experiments using the cell 
lysate of TRAK2 and Hrs transfected HeLa cells indicated co-immunoprecipitation of 
TRAK2 and Hrs after using either TRAK2 or Hrs directed antibodies. Additionally, co-
immunoprecipitation of endogenous TRAK2 and Hrs in PC12 cells also indicated the 
existence of the TRAK2/Hrs complex. This interaction was further confirmed in vivo 
when immunoflouresence studies in PC12 cells indicated significant co-localisation of 
TRAK2 and Hrs in early endosomes. Mapping studies of the Hrs binding site on TRAK2, 
again using a co-immunoprecipitation strategy, revealed that that TRAK2 359-507 is 
necessary for TRAK2/Hrs interaction (Kirk et al., 2006). Interestingly, similar work by 
Webber et al. (2008), this time using TRAK1 demonstrated an interaction with Hrs. 
Both TRAK1 and Hrs were shown to specifically co-immunopreciptate from TRAK1 and 
Hrs co-transfected HeLa cell lysates, in addition to the successful co-
immunoprecipition of TRAK1/Hrs from endogenously expressed TRAK1 and Hrs in HeLa 
cells. This study also showed that TRAK1 359-951 is essential for the interaction of 
TRAK1/Hrs as demonstrated by the presence of Hrs in pull-down assays of 
recombinant tagged TRAK1 359-951 protein. TRAK1 359-507 and TRAK2 359-507 share 
a 50 % amino acid similarity and both these regions have been shown to be important 
for the binding of TRAK1 and TRAK2 to Hrs. This may indicate a possible shared 
mechanism of interaction between TRAK1 and TRAK2 in binding to Hrs (Webber et al., 
2008). 
The interaction of TRAK2 with the K+ channel, Kir2.1, was initially discovered after a 
yeast two-hybrid screen of a human brain cDNA library demonstrated a positive 
interaction with that of TRAK2 (Grishin et al., 2006). The interaction of Kir2.1 and 
TRAK2 was further demonstrated by co-immunoprecipitation assays using the lysates 
of Kir2.1 and TRAK2 co-transfected HEK 293 cells. The in vivo association of Kir2.1 and 
GRIF-1 was then demonstrated by co-immunoprecipitation from brain lysate. 
Microscopy analysis of immunolabelled surface GFP-Kir2.1 showed that transfection of 
TRAK2 in COS-7 and HEK 293 cells significantly increases the number of Kir2.1 channels 
in the plasma membrane. Furthermore yeast two-hybrid assays showed that TRAK2 1-
497 interacts specifically with Kir2.1 180-428 (Grishin et al., 2006). These results 
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indicate that TRAK2 binds to Kir2.1 and helps to facilitate the trafficking of Kir2.1 to the 
cell surface of neurons.  
PTEN induced putative kinase 1 (Pink1), is a gene that encodes a serine/threonine 
protein kinase that localises to mitochondria (Weihofen et al., 2008). It is thought to be 
involved in the kinesin-1, Milton and Miro complex since Weihofen et al. (2009) 
showed that over-expression of Miro1, Miro2 or Milton all increase the concentration 
of Pink1 in mitochondrial enriched sub-cellular fractions. These findings indicate a 
possible role for Pink1 in the transport of mitochondria by the TRAK/Milton family 
(Weihofen et al., 2009; Wang et al., 2011). A schematic of TRAK2 and the known 
interacting protein domains is shown in Figure 1.8. 
 
  
 
 
 
 
 
 
 
 
 
Figure 1.8 A schematic of the full length TRAK2 protein.  
The Figure shows the predicted coiled-coil domains in black (amino acids 133-188 and 202-355) and the 
locations of where these known interacting proteins bind. Figure taken from the Stephenson laboratory. 
 
 
1.4 The regulation of kinesin-1 transport of mitochondria in neuronal cells  
The regulation of kinesin-1 cargo transport is critical in order to ensure the correct 
delivery of cargo, such as mitochondria, within the neuron. It is also necessary because 
a constantly active kinesin-1 complex would waste ATP and accumulate at the 
processes of axons. As explained in Section 1.2.4 the number of identified cargoes 
transported by kinesin-1 is increasing. However, the way in which the regulation of 
these cargoes occurs is not as well understood. There are several methods in which the 
transport of cargo by kinesin-1 may be regulated. These include the binding and 
release of cargo, autoinhibition, motor domain activation and the binding of the cargo 
binding domain to the microtubules (Verhey and Hammond, 2009).  
There are two conflicting views of how kinesin-1 is thought to govern regulation of 
movement throughout the cell by utilising the binding relationship with its cargo. The 
first of which was put forward by Wang and Schwarz (2009) and uses the example of 
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mitochondrial transport. Miro proteins are present on the outer membrane of 
mitochondria and have two EF hand Ca2+-binding domains. These EF hands consist of 
two alpha helices positioned roughly perpendicular to one another and are linked 
together by a short loop region that once bound to Ca2+ ions will undergo a 
conformational change (Nelson and Chazin, 1998). Wang and Schwarz (2009) 
demonstrate that the motor domain of kinesin-1 dissociates from the microtubule and 
interacts with Miro present on the outer membrane of the mitochondria in the 
presence of increased levels of Ca2+. Endogenous mammalian KHC, Miro and Milton 
were successfully co-immunoprecipitated from HEK 293 cells, but in the absence of 
Milton, Miro was not sufficient to recruit KHC to the mitochondria in cultured neuronal 
cells. Transfected constructs of Miro which had been mutated to disrupt the EF hand 
domain saw normal distribution and transport of mitochondria in the axons of 
neuronal cultures which did not change with the increase in Ca2+. However, movement 
of mitochondria using transfected non-mutated Miro constructs saw a decrease in bi-
directional transport. The KHC/Milton/Miro complex was also shown to co-localise in 
neurons after transfection of either the wild-type or EF hand mutated Miro in 
conditions of both high and low Ca2+, indicating that Miro remains in complex with KHC 
and Milton. This evidence in conjunction with further experiments from Wang and 
Schwarz (2009) indicating that the presence of Ca2+ causes the KHC to dissociate from 
microtubules and when a construct encoding only the motor domain of KHC was co-
expressed with Miro they exhibited Ca2+-dependent co-immunoprecipitation, shows 
that Miro might be able to interact with KHC in two ways. The first being that the tail 
of KHC is linked to Miro by Milton in a Ca2+-independent manner and the second, that 
the motor domain can interact directly with Miro in the presence of Ca2+. It is this 
conformational change in the EF hand domain of Miro via the binding of Ca2+ that is 
thought to be responsible for changing the binding properties of the motor domain 
such that the KHC motor domain binds to Miro instead of microtubules. This would 
keep the KHC/Milton/Miro trafficking complex intact while at the same time 
preventing transport of mitochondria as the complex is no longer is bound to 
microtubules (Wang and Schwarz, 2009).  
An alternative mechanism put forward by MacAskill et al. (2009a) is that mitochondria 
dissociate from kinesin-1 in the presence of elevating cytosolic Ca2+. In the presence of 
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increased Ca2+, GFP-Miro1 constructs expressed in neuronal cells showed almost 
complete inhibition of mitochondrial transport, whereas expression of the EF hand 
mutated Miro in the presence of increased Ca2+ did not affect mitochondrial transport. 
This concurs with the results seen in the study carried out by Wang and Schwarz 
(2009). In the absence of Ca2+ Miro1 was found to bind directly to each of the kinesin-1 
sub-types, KIF5A, KIF5B and KIF5C by GST fused Miro1 pull-down assays but in the 
presence of Ca2+ the binding of Miro1 to kinesin-1 was inhibited (MacAskill et al., 
2009a). The binding interaction of TRAK2 and Miro1 remained intact after increasing 
Ca2+ implying that Ca2+ does not detach mitochondria from kinesin-1 motors by acting 
at the binding site between Miro1 and TRAK2 (MacAskill et al., 2009a).  
The way in which these two studies differ is in the proposed mechanism of kinesin-1 
association with the trafficking complex, but they do both confirm the importance of 
Ca2+ as a method to pause mitochondrial trafficking in neurons. It is thought that when 
ATP concentrations are low, Ca2+ transport mechanisms are compromised and 
cytosolic Ca2+ increases. If moving mitochondria stop where Ca2+ is elevated they will 
be recruited to regions of low ATP and will remain until ATP concentrations are 
elevated thus decreasing levels of Ca2+ restarting the movement of mitochondria. This 
Ca2+ control mechanism is most likely used to help distribute mitochondria to where 
they are needed throughout the cell (Wang and Schwarz, 2009). The contrasting views 
on the method of mitochondrial regulation by kinesin-1 by both Wang and Schwarz, 
(2008) and MacAskill et al. (2009a) are summarised in Figure 1.9. 
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Figure 1.9 Schematic representations of the two contrasting mechanisms on the method of 
mitochondrial regulation by kinesin-1.  
A = Schematic model of the means by which Ca
2+
 interacts with Miro to regulate the motility of 
mitochondria (Wang and Schwarz, 2009). B = Schematic model of the means by which a rise of Ca
2+
 
dissociates Miro1 from kinesin-1 (MacAskill et al., 2009a). 
 
The regulation of mitochondrial transport by kinesin-1 could also be regulated, in part, 
by another mechanism. Under physiological conditions the kinesin-1 heterodimer 
exists in a folded compact conformation. This conformation is possible due to a 
conserved QIAK amino acid region present in the cargo binding domain that is known 
to interact with the motor and neck regions. Binding of the cargo binding domain to 
the tail domain of conventional Drosophila kinesin-1 was shown to stabilise the 
conformation with bound ADP and further slow the rate of ADP release from the 
motor domain. Only one KHC cargo binding domain molecule is required to prevent 
ATPase activity in the kinesin-1 dimer (Hackney et al., 2009). This interaction can occur 
due to the flexibility of the kinesin-1 protein at the hinge regions of the stalk domain 
(Hackney and Stock, 2000; Hackney, 2007; Seeger and Rice, 2010). Kinesin-1 appears to 
A 
B 
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be turned off in the absence of cargo by a self-inhibition mechanism that depends on 
its tail and involves folding of the KHC dimer (Schnapp, 2003). Work by Friedman and 
Vale (1999) has demonstrated that mutating the hinge 1 domain of KIF5B leads to an 
inability of kinesin-1 to change to the folded conformation, resulting in a constant 
active state kinesin-1 protein. It is the ability of the hinge domain and its flexible 
properties that allows the conserved amino acid QIAK region in the cargo binding 
domain to come into contact with the motor domain, specifically the switch 1 domain, 
to prevent ADP release from the nucleotide binding pocket (Hackney and Stock, 2008; 
Kaan et al., 2011). More recently it has also been demonstrated that amino acids 822-
944 of KIF5B can interact with microtubules with a sub micromolar affinity using 
electrostatic forces to bind the acidic E-hook at the C-terminal end of tubulin (Seeger 
and Rice, 2010). Combined with the work by MacAskill et al. (2009a) indicating that the 
presence of Ca2+ will dissociate cargo and its adaptor protein complex from kinesin-1 
entirely, this indicates that the now cargo free C-terminus of kinesin-1 may interact 
with the KHC dimer and/or the C-terminal end of tubulin to prevent movement along 
the microtubule. These steps may be in part responsible for the regulation of kinesin-
1/mitochondrial movement within the cell. 
The in vivo association of KLC to KHC of kinesin-1 has been shown to inhibit 
microtubule binding (Verhey et al., 1998). The interaction of kinesin-1 with 
microtubules is inhibited when the 64 C-terminal amino acids of KHC are available for 
KLC binding. In deletion mutants without this C-terminal domain the association of 
KHCs with KLCs is not enough to prevent binding of kinesin-1 to the microtubules (Adio 
et al., 2006). This indicates that the KLC may also be involved in the change in 
conformation to regulate microtubule binding of the KHC motor domain to 
microtubules.  
 
1.5 Disease states associated with the malfunction of motor protein complexes in the 
CNS 
The defects of transport within dendrites and axons have been linked to a number of 
diseases. These diseases result from mutations in the motor protein or changes in the 
release/attachment of cargo to motor proteins. The possible member of the 
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TRAK/Milton protein family, HAP1 (Section 1.3), is known to transport huntington 
protein which is responsible for Huntington’s disease. The huntington protein is known 
to be mutated in affected individuals and one of the causes of neuronal cell death is 
that of the resulting aggregates of the mutated huntington protein in cells (Borrell-
Pages et al., 2006). 
The hereditary spastic paraplegias (HSP) are a group of neurodegenerative diseases 
generally characterised by progressive lower limb spasticity and weakness (Reid et al., 
2002). A wide variety of genetic mutations in over 46 different loci have been 
attributed to the HSP disease state (Salinas et al., 2008). One such set of mutations is 
known as spastic gait type 10 (SPG10) and affects the KIF5A locus. Inheritance of 
mutations in SPG10 is known to be autosomal dominant and several missense 
mutations in KIF5A have been linked to the phenotypic effect seen in HSP. One 
mutation, N256S, is present in the motor domain of KIF5A and is thought to slow the 
movement of KIF5A when moving along the microtubule network (Ebbing et al., 2008). 
Another mutant, R280S, is present also in the motor domain and is known to reduce 
the ability of KIF5A to bind the microtubules (Ebbing et al., 2008).      
Charcot–Marie–Tooth disease (CMT) has been classiﬁed into two types, CMT1 and 
CMT2. It is characterised by a progressive loss of touch sensation and muscle tissue 
across various extremities of the body. CMT is known to be caused by defective 
neuronal function, of which CMT1 is thought to be caused by the demyelination of 
Schwann cells and CMT2 by axonal degeneration (Garcia, 1999). CMT2 has been 
further subdivided into eight groups. CMT2A, a member of the CMT2 disease group, is 
linked to chromosome 1p35–p36 and mutation in the KIF1B gene present in 1p35–p36 
has been reported in one family suffering from CMT2A (Zhao et al., 2001). A Q98L 
missense mutation in the ATP binding region of the motor domain of KIF1B 
demonstrated a decreased ATPase activity and motility suggesting this KIF1B mutation 
is responsible for CMT2A neuropathy (Zhao et al., 2001). CMT2A has also been linked 
to point mutations in Mfn2. In some cases CMT2A mutant forms of Mfn2 are unable to 
mediate mitochondrial fusion in fibroblasts, whereas others are completely competent 
to promote fusion. This is thought to be because in some cases Mfn1 can rescue the 
effects of defective Mfn2 (Kijima et al., 2005; Detmer and Chan, 2007).  
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As discussed in Section 1.3.2, Pink1 is a serine/threonine protein kinase that localises 
to mitochondria and it is thought to be involved in the kinesin-1/Milton/Miro 
trafficking complex via an interaction with both Milton and Miro (Weihofen et al., 
2009). Recessive mutations in the Pink1 gene are known to cause a form of early-onset 
Parkinson’s disease that is caused by selective degeneration of dopaminergic neurons 
in the substantia nigra (Gandhi et al., 2006). Loss of Pink function can alter 
mitochondrial morphology and dynamics but exactly how the loss of Pink1 can 
influence mitochondrial function is unclear (Weihofen et al., 2008; Weihofen et al., 
2009).  
 
1.6 Aims of this thesis 
As described previously, transport of mitochondria and other protein complexes 
required for neuronal survival are regulated by several mechanisms. One such 
mechanism utilises the TRAK/Milton family of adaptor proteins to mediate the 
interaction of cargo to the molecular motor protein, kinesin-1. Therefore the overall 
aim of this thesis was to understand further the mode of association between kinesin-
1 and the TRAK/Milton family of kinesin adaptor proteins. The first aim was to 
determine the structure of the cargo binding domain of the kinesin-1 sub-type KIF5A 
as well as the binding of KIF5A/TRAK2 in complex. The second aim was to refine 
further the TRAK1 and TRAK2 binding site within both KIF5A and KIF5C. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 MATERIALS 
The restriction enzymes with their buffers and DNA molecular weight markers were 
purchased from Fermentas (Yorkshire, U.K). Lennox B (LB) broth, SELECT agar powder, 
penicillin and streptomycin (10,000 units/ml), ProBond™ Ni2+ chelating resin and 
SeeBlue® pre-stained standard molecular weight markers were from Invitrogen 
(Paisley, U.K). Isopropyl-ß-D-thio-galactopyranoside (IPTG) and dithiothreitol (DTT) 
were purchased from Melford Laboratories (Suffolk, U.K). The Phusion™ high-fidelity 
DNA polymerase and restriction enzyme FseI was purchased from New England Biolabs 
(Hertfordshire, U.K). Shrimp alkaline phosphatase (SAP) was purchased from Promega 
(Southampton, U.K). Coomassie Brilliant Blue G-250 dye (Coomassie Blue), un-stained 
protein molecular weight markers and poly-prep chromatography columns were 
purchased from BioRad (Hemel Hampstead, U.K). S-Protein agarose was purchased 
from Novagen (Wisconsin, U.S.A). Imidazole was purchased from Acros Organics (Geel, 
Belgium). Protogel (30% [w/v] acrylamide: 0.8% [w/v] bis-acrylamide (37.5:1), 
ammonium persulphate and N,N,N’,N’-tetramethylethylenediamine (TEMED) were 
purchased from National Diagnostics (Yorkshire, U.K). Glycerol, potassium chloride, 
sodium chloride, sodium hydroxide pellets, ethylenediaminetetraacetic acid (EDTA) 
and Tris(hydroxymethyl)aminomethane (Tris) were purchased from VWR International 
Ltd (Dorset, U.K). Protran® nitrocellulose membranes were purchased from Whatman 
(Kent, U.K). Protease inhibitor cocktail tablets were purchased from Roche (Basle, 
Switzerland). Protein A Sepharose and protein G Sepharose were purchased from 
Generon (Berkshire, U.K). HEK 293 cells were purchased from the European Collection 
of Cell Cultures (Wiltshire, U.K). Glycerol-free brain bovine tubulin was purchased from 
Cytoskeleton (Colorado, U.S.A). Paclitaxel was purchased from Calbiochem (Darmstadt, 
Germany). BL21 DE3 codonplus Escherichia coli (E.coli) cells were a kind donation from 
Dr Andy Wilderspin, UCL School of Pharmacy. 5-Amino-2,3-dihydro-1,4-
phthalazinedione (luminol), D-sorbitol, ethylene glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA), sodium acetate anhydrous, sodium dodecyl sulphate 
(SDS), trans-4-hydroxycinnamic acid (p-coumaric acid), Tween-20®, ampicillin, 
ethidium bromide, ß-mercaptoethanol (ß-ME), GenEluteTM HP maxiprep kit, bacitracin, 
benzamidine, phenylmethanesulfonyl fluoride, trypsin inhibitor-chicken egg white, 
sodium bicarbonate solution (7.5 % w/v), Dulbecco’s modified Eagles medium nutrient 
mixture F-12 HAM, Hanks balanced salt solution, foetal bovine serum, 4-(2-
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hydroxyethyl)piperazine-1-ethanesulphonic acid (HEPES), dimethyl sulphoxide (DMSO), 
Triton X-100®, protein molecular weight standards for size exclusion chromatography, 
oligonuclueotide primers used for sequencing of recombinant DNA and 
oligonucleotide primers used for polymerase chain reactions (PCR) were purchased 
from Sigma-Aldrich (Poole, U.K). A summary of the oligonucleotide primers used for 
the bacterial expression of TRAK2 and KIF5A is shown in Table 2.1.  A summary of the 
oligonucleotide primers used for the mammalian expression of KIF5A and KIF5C is 
shown in Table 2.2. All plasmid constructs generated were sent to either MWG-Biotech 
(Ebersberg, Germany) or UCL DNA Sequencing Service for nucleotide sequencing. A 
summary of the oligonulceotide primers used for nucleotide sequencing is shown in 
Table 2.3. 
 
 
 
Table 2.1 A summary of oligonucleotide primer sequences used for the generation of bacterially 
expressed TRAK2 and KIF5A constructs. 
 
Oligonucleotide primer Nucleeotide sequence 
pETDUETTRAK2100-380 Forward (Fwd) 
primer 
5’ AAAAGAATTCAGACAGAGTAG 3’ 
pETDUETTRAK2100-380 Reverse (Rev) 
primer 
5’ AAAAAAGCTTCTACCCTTCAAT 3’ 
pETDUETKIF5A800-1032 Fwd primer 5’ AAAACAATTGGCTGTTCGTTCAA 3’ 
pETDUETKIF5A800-1032 Rev primer 5’ AAAAGGCCGGCCGCGCTGGCTGC 3’ 
pET151D-TOPOKIF5A800-1032 Fwd 
primer 
5’ CACCCTGTTCGTTCAAGACGTC 3’ 
pET151D-TOPOKIF5A800-1032 Rev 
primer 
5’ CTAGTTCTCTGTCGTCGGTCG 3’ 
pETDUETKIF5A800-951 Fwd primer 5’ AAAAGGATCCGCTGTTCGTTCAAGACGTC 3’ 
pETDUETKIF5A800-951 Rev primer 5’ AAAAGAATTCTTAGAAGAGGCTGTTGGTGTA 3’ 
pETDUETKIF5A820-1032 Fwd primer 5’ AAAAGGATCCGAGTGGGGGGATTCACTCC 3’ 
pETDUETKIF5A820-1032 Rev primer 5’ AAAAGAATTCTTAGCTGGCTGCTGTCTCTTG 3’ 
pETDUETKIF5A820-951 Fwd primer 5’ AAAAGGATCCGAGTGGGGGGATTCACTCC 3’ 
pETDUETKIF5A820-951 Rev primer 5’ AAAAGAATTCTTAGAAGAGGCTGTTGGTGTA 3’ 
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Table 2.2 A summary of oligonucleotide primer sequences used for the generation of mammalian 
expressed KIF5A and KIF5C constructs.  
 
 
 
 
 
 
 
 
 
Oligonucleotide primer Nucleotide sequence 
pcDNAKIF5A Fwd primer 5’ AAAAGGATCCATGGCGGAGACCAACAAC 3’ 
pcDNAKIF5A Rev primer 5’ AAAAGAATTCTTAGCTGGCTGCTGTCTC 3’ 
pcDNAKIF5A1-961 Rev primer 5’ AAAGAATTCTTAACAATTTAGGAAGCTCACAACG 3’ 
pcDNAKIF5A1-942 Rev primer 5’ AAAAGAATTCTTACTCAGGGCTCCGGGT 3’ 
pcDNAKIF5A1-909 Rev primer 5’ AAAAGAATTCTTACGAGCTCTTGTAGCGAAC 3’ 
pcDNAKIF5A1-885 Rev primer 5’ AAAAGAATTCTTAGCCCTCCTTGGCCTCCTT 3’ 
pcDNAKIF5A1-883 Rev primer 5’ AAAAGAATTCTTACTTGGCCTCCTTCAG 3’ 
pcDNAKIF5A1-881 Rev primer 5’ AAAAGAATTCTTACTCCTTCAGTGCACCCTC 3’ 
pcDNAKIF5A1-879 Rev primer 5’ AAAAGAATTCTTACAGTGCACCCTCCAGGGCCTT 3’ 
pcDNAKIF5A1-877 Rev primer 5’ AAAAGAATTCTTAACCCTCCAGGGCCTTAAC 3’ 
pcDNAKIF5A1-861 Rev primer 5’ AAAAGAATTCTTACAATTTAGGAAGCTCACAACG 3’ 
pcDNAKIF5A1-825 Rev primer 5’ AAAAGAATTCTTAGGAGTGAATCCCCCCACT 3’ 
pcDNAKIF5AΔ877-883 Primer 2 5’ GTTAAGGCCCTGGAGGGTGAGGGCGCCATGAAGGAC 3’ 
pcDNAKIF5AΔ877-883 Primer 3 5’ GTCCTTCATGGCGCCCTCACCCTCCAGGGCCTTAAC 3’ 
pcDNAKIF5C Fwd primer 5’ AAAAGAATTCATGGCGGATCCAGCCGAA 3’ 
pcDNAKIF5C Rev primer 5’ AAAAGCGGCCGCTTATTATTTCTGGTAGTGAGT 3’ 
pcDNAKIF5C1-889 Rev primer 5’ GCGGCCGCTTAGTTCTCCTTGGCCTCCTT 3’ 
pcDNAKIF5C1-881 Rev primer 5’ AAAAGCGGCCGCTTAGCTCTCCAGAGCCTTGAC 3’ 
pcDNAKIF5C1-828 Rev primer 5’ AAAAGCGGCCGCTTAAGCACTGCCCCCTCCATCAT 3’ 
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Table 2.3 A summary of the oligonucleotide primers used for nucleotide sequencing. 
 
2.1.1 Recombinant clones 
The pETDUET1 and pET151D-TOPO vectors were a kind donation from Dr Carolyn 
Moores (Birkbeck College, London, U.K). The human clone of pBSKIF5A was purchased 
from Addgene (Massachusetts, U.S.A). The clones of rat pCISTRAK2, rat 
pCMVTag4aTRAK2 and human pCMVmycTRAK1 were obtained from Dr Kieran Brickley, 
UCL School of Pharmacy. 
 
2.1.2 Antibodies  
Horseradish peroxidase (HRP) linked anti-rabbit immunoglobin (Ig) antibodies (Ab) and 
HRP linked anti-mouse Ig antibodies were purchased from GE Healthcare (Amersham, 
U.K). All the primary antibodies used are summarised in Table 2.4. 
 
 
 
 
 
Oligonucleotide  sequencing primer Nucleotide sequence 
pETDUET1 multiple cloning site 1 
(MCS1) Fwd sequencing primer 
5’ ATGCGTCCGGCGTAGA 3’ 
pETDUET1 MCS1 Rev sequencing 
primer 
5’ GATTATGCGGCCGTGTACAA 3’ 
pETDUET1 MCS2 Fwd sequencing 
primer 
5’ TTGTACACGGCCGCATAATC 3’ 
pETDUET1 MCS2 Rev sequencing 
primer 
5’ GCTAGTTATTGCTCAGCGG 3’ 
pET151D-TOPO Fwd sequencing primer 5’ TAATACGACTCACTATAGGGAGA 3’ 
pET151D-TOPO Rev sequencing primer 5’ TATGCTAGTTATTGCTCAG 3’ 
pcDNAHisMaxC  Fwd sequencing 
primer 
5’ TAATACGACTCACTATAGGG 3’ 
pcDNAHisMaxC  Rev sequencing primer 5’ TAGAAGGCACAGTCGAGG 3’ 
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Table 2.4 A summary of the primary antibodies used for immunoblotting and immunoprecipitation 
experiments. 
 
Protein name Species 
Nucleotide 
accession number 
Protein accession 
number 
KIF5A Human NM004984 NP004975 
KIF5A Rat NM212523 NP997688 
KIF5C Human NM004522  NP004513 
KIF5C  Rat NM001107730 NP001101200 
TRAK1 Human NM001042646 NP001036111 
TRAK1 Rat NM001134565 NP001128037 
TRAK2 Human NM015049 NP055864 
TRAK2 Rat NM133560 AAH88393 
Table 2.5 A summary of accession numbers of KIF5A, KIF5C and the TRAK family of proteins.  
 
 
 
 
Antibody name Host species Antigen Origin 
TRAK28-633 
Rabbit 
polyclonal 
TRAK28-633 (His-
tagged) 
In house (Beck et al., 
2002) 
S-protein tagged 
(S-tag) 
Rabbit 
polyclonal 
KETAAAKFERQHMDS Abcam (Cambridge, U.K) 
Histidine tagged 
(His-tag) 
Polyclonal HHHHHH Abcam (Cambridge, U.K) 
His-tag 
(conjugated HRP) 
Rabbit 
polyclonal  
HHHHHH 
Sigma-Aldrich (Poole, 
U.K) 
Flag-tag 
Rabbit 
polyclonal 
DYKDDDDK 
In house (Beck et al., 
2002) 
C-Myc 
Mouse 
monoclonal 
EQKLISEEDL 
Thermo Fisher Scientific 
(Massachusetts, U.S.A) 
Non-specific 
polyclonal 
Rabbit N/A In house 
Non-specific 
monoclonal 
Mouse N/A 
Sigma-Aldrich (Poole, 
U.K) 
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2.2 METHODS 
2.2.1 Bacterial methods 
2.2.1.1 Preparation of chemically competent bacterial cells (DH5α or BL21 DE3 
codonplus) 
DH5α or BL21 DE3 codonplus (BL21) E.coli cells were streaked from glycerol stocks 
onto a LB 2 % (w/v) agar plate using a sterile pipette tip. The plate was inverted and 
incubated for 12 - 16 h at 37˚C. A 5 ml LB media pre-culture was inoculated using a 
single colony of cells. The culture was incubated at 37˚C for 12 - 16 h at 250 rpm. A 
pre-culture, 0.5 ml, was added to LB media supplemented with 0.5 ml 1 M MgSO4 and 
0.5 ml 20% (w/v) glucose, (1 ml of this supplemented LB media was removed to serve 
as a re-suspension buffer). The cells were incubated at 37˚C at 250 rpm until an OD λ = 
600 nm of 0.6 - 0.7 was obtained (~ 2 h). The culture was removed and aliquoted into 
50 ml sterile centrifuge tubes and left on ice for ~ 10 min. Cultures were then 
centrifuged at 4,000 x g for 10 min at 4°C. The supernatant was carefully aspirated and 
each pellet was re-suspended in 0.5 ml supplemented LB media (as above). Storage 
buffer (3.6 g polyethylene glycol [PEG], 360 µl MgSO4, 10.8 ml glycerol, made up to 30 
ml with LB media and filter sterilised), 5 ml, was added. The cells were rapidly divided 
into 100 µl aliquots on ice and stored at -80˚C until use. The competent cells were used 
within 6 months. 
 
2.2.1.2 Transformation of chemically competent bacterial cells 
For all routine plasmid DNA amplification and molecular cloning, DH5α E.coli 
chemically competent cells were used. Aliquots of DH5α E.coli chemically competent 
cells were removed from storage at -80˚C and put immediately onto ice and 
subsequently defrosted for ~ 5 min. The plasmid to be transformed (~ 1 µg) was added 
to the cells and incubated for 30 min on ice, followed by a heat shock for 55 sec at 
42˚C. The cells were further incubated on ice for 10 min. The 100 µl of chemically 
competent cells was added to 900 µl LB media solution in a 1.5 ml sterile micro-
centrifuge tube. The cells were incubated at 37˚C for 1 h at 250 rpm and pelleted by 
centrifugation for 1 min at 16,200 x g at room temperature. The supernatant was 
carefully aspirated and the cell pellet gently re-suspended in 100 µl LB media solution. 
The cell suspension was plated onto selective LB plates, 2 % (w/v) agar (50 µg/ml 
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ampicillin or 50 µg/ml kanamycin, depending on the vectors antibiotic resistance), 
using a hockey puck spreader. The plates were inverted and incubated for 12 - 16 h at 
37˚C. Once colonies appeared they were selected for further study. Alternatively the 
plates were wrapped in Clingfilm and stored at 4˚C for a maximum of one week. 
 
2.2.1.3 Glycerol stocks of transformed bacterial cells 
A single colony of E.coli transformed with the desired plasmid was used to inoculate 
5ml of LB media and grown for 12 - 16 h overnight at 37°C, 225 rpm. Culture (1 ml) was 
added to 0.5 ml 50 % (v/v) glycerol, thoroughly mixed by inversion and stored at -80˚C 
until use.   
 
2.2.2 Molecular cloning methods 
2.2.2.1 Bacterial clone design 
Expression of TRAK2 and KIF5A recombinant proteins in bacterial expression systems 
were cloned with the use of several bacterial expression vectors. Double expression of 
both TRAK2100-380 and KIF5A800-1032 was carried out using the bicistronic vector, 
pETDUET1. pETDUET1 contains two multiple cloning sites allowing for simultaneous 
expression in bacterial systems under the same promoter in different regions and 
requires 50 µg/ml ampicillin for selective growth. TRAK2100-380 was inserted in-frame 
using the two restriction enzymes EcoRl and Hindlll to facilitate directional cloning into 
MCS1 of pETDUET1. KIF5A800-1032 was inserted in-frame using the two restriction 
enzymes Fsel and Munl to facilitate directional cloning into MCS2 of pETDUET1. This 
yielded three recombinant clones; pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and 
pETDUETTRAK2100-380/KIF5A800-1032. The bacterial expression vector pETDUET1 was also 
used to singly express different recombinant KIF5A truncations. DNA encoding KIF5A 
truncations were inserted in-frame using the restriction enzymes EcoRl and BamHl to 
facilitate directional cloning into MCS1 to yield pETDUETKIF5A800-951, pETDUETKIF5A820-
1032 and pETDUETKIF5A820-951. KIF5A800-1032 was cloned into the bacterial expression 
vector pET151D-TOPO using blunt ended PCR products to facilitate directional cloning. 
pET151D-TOPO requires 50 µg/ml ampicillin for selective growth. The bacterial 
expression constructs generated and used are summarised in Table 2.6. 
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Cloning vector Description Size (kb) 
pETDUETTRAK2100-380 
Bicistronic bacterial expression vector. N-
terminal His-tag. Ampicillin resistance. 
6.3 
pETDUETKIF5A800-1032 
Bicistronic bacterial expression vector. C-
terminal S-tag. Ampicillin resistance. 
6.1 
pETDUETTRAK2100-
380/KIF5A800-1032 
Bicistronic bacterial expression vector. N-
terminal His-tag on TRAK2100-380 and C-
terminal S-tag on KIF5A800-1032. Ampicillin 
resistance. 
7.0 
pET151D-TOPOKIF5A800-1032 
Bacterial expression vector. C-terminal 
His-tag. Ampicillin resistance. 
6.4 
pETDUETKIF5A800-951 
Bacterial expression vector. C-terminal 
His-tag. Ampicillin resistance. 
5.9 
pETDUETKIF5A820-1032 
Bacterial expression vector. C-terminal 
His-tag. Ampicillin resistance. 
6.1 
pETDUETKIF5A820-951  
Bacterial expression vector. C-terminal 
His-tag. Ampicillin resistance. 
5.8 
Table 2.6 A summary of the bacterial expression constructs generated and used for the expression of 
recombinant TRAK2 and KIF5A. 
 
2.2.2.2 Mammalian clone design 
The expression of recombinant KIF5A and KIF5C truncations in mammalian expression 
systems were cloned with the use of the pcDNAHisMaxC (pcDNA) vector. pcDNA 
requires 50 µg/ml ampicillin for selective growth. DNA encoding KIF5A was inserted in-
frame using the two restriction enzymes EcoRl and BamHl to facilitate directional 
cloning. KIF5C was inserted in-frame using the two restriction enzymes EcoRl and Notl 
to facilitate directional cloning. All of the KIF5A, KIF5C, TRAK1 and TRAK2 recombinant 
clones used are summarised in Table 2.7. 
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Cloning vector Description Size (kb) 
pcDNAKIF5A  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.4 
pcDNAKIF5A1-961  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.2 
pcDNAKIF5A1-942 
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.1 
pcDNAKIF5A1-909  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.0 
pcDNAKIF5A1-885  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.0 
pcDNAKIF5A1-883  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.0 
pcDNAKIF5A1-881  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.9 
pcDNAKIF5A1-879  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.9 
pcDNAKIF5A1-877  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.9 
pcDNAKIF5A1-861  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.9 
pcDNAKIF5A1-825  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.8 
pcDNAKIF5AΔ877-
883  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.4 
pcDNAKIF5C  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.2 
pcDNAKIF5C1-889  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
8.0 
pcDNAKIF5C1-881  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.9 
pcDNAKIF5C1-828  
Mammalian expression vector. C-terminal His-tag. 
Ampicillin resistance. 
7.8 
pCMVTag4aTRAK2  
Mammalian expression vector. C-terminal Flag-tag. 
Kanamycin resistance. 
7.0 
pCMVmycTRAK1  
Mammalian expression vector. N-terminal C-myc tag. 
Kanamycin resistance. 
7.7 
Table 2.7 A summary of the mammalian expression constructs generated and used for the expression 
of recombinant KIF5A, KIF5C, TRAK1 and TRAK2. 
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Figure 2.1 A summary of the overall cloning strategy.  
This diagram shows all the steps necessary to successfully create a recombinant DNA vector from 
separate PCR fragments and a plasmid vector.  
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2.2.2.3 Design of polymerase chain reaction (PCR) and nucleotide sequencing 
oligonucleotide primers 
The following criteria were followed when designing oligonucleotide primers for PCR 
amplification of DNA sequences: 
- The primer must be at least 18 nucleotide bases in length. 
- The optimal melting temperature of an oligonucleotide primer was in the range 
of 50°C - 60°C. The melting temperatures of oligonucleotide primers were 
calculated using the Wallace et al. (1979) rule: 
Melting Temperature (Tm) = (4[G + C] + 2[A + T])   
[G + C] = number of guanine + cytosine bases and [A + T] = number of adenine + 
thymine bases. 
- The melting temperature for a pair of primers must be within 10oC of each 
other. 
- The guanine/cytosine (G/C) content should be between 40 - 60 %. 
- Repeats of the same base were avoided and care was taken to ensure that the 
primers did not have any complementary sequence, either within the 
oligonucleotide or within the other primer in the pair. 
- To facilitate the cloning of PCR products into cloning vectors, restriction 
endonuclease sites were added to the 5’ end of each primer. To assist with the 
binding of the restriction endonuclease to the PCR product additional bases, 
usually AAAA, were included at the 5’ end of each primer.  
 
2.2.2.3.1 PCR cycles 
For the PCR amplification of DNA sequences the following reaction was mixed in a 0.5 
ml sterile PCR tube; 23 µl sterile ddH2O, 1 µl of 10 mM stock of both forward and 
reverse PCR primers, 0.5 µg template DNA, and 25 µl PhusionTM Master Mix. Each PCR 
reaction had two controls carried out in parallel. These were either the absence of the 
template DNA or absence of the PhusionTM Master Mix. This ensured that the resulting 
PCR product was a specific amplification of the desired DNA sequence.    
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The PCR cycle used for amplification was as follows: 
 
 
 
 
 
The PCR reactions were carried out using a G-storm GS1 thermal cycler (Gene 
Technologies, Essex, U.K). 
 
2.2.2.4 Flat bed agarose gel electrophoresis for DNA analysis 
Plasmid DNA or PCR products were analysed by 1 % (w/v) flat bed agarose gel 
electrophoresis. Electrophoresis was carried out using a Flowgen MH 1070 minigel 
apparatus. A 1 % (w/v) agarose solution was made in 1 x Tris-borate-EDTA buffer (TBE, 
90 mM Tris-HCl, pH 8.0, 90 mM boric acid, 4 mM EDTA). The agarose was dissolved by 
boiling for ~ 90 sec in a microwave oven. Once the agarose had cooled to ~ 40˚C, 5 µl 
ethidium bromide was added to the agarose solution and mixed. The agarose solution 
was poured between two metal bars and a comb was placed 2 cm from the top of the 
gel. The agarose solution was allowed to solidify for 20 min at room temperature. The 
metal bars and comb were removed and the agarose gel was covered in 50 ml 1 x TBE 
buffer. Each DNA sample was prepared by the addition of ~ 0.5 µg DNA, 2 µl 6 x DNA 
loading buffer and ddH20 to give a 12 µl total volume. The DNA samples were loaded 
and electrophoresis was carried out at 50 V for 1 h at room temperature. Gels were 
imaged using a Flowgen transilluminator (UV light source λ = 312 nm) in conjunction 
with a Kodak DC120 206 M digital camera. Images were saved in the .tif format for 
storage and analysis. 
 
 
 
 
1. 98°C for 30 sec (once) 
2. 98°C for 10 sec 
                           55°C for 20 sec              (34 cycles)  
                           72°C for 15 sec 
                      3.  72°C for 7 min 
                      4.  4°C hold 
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2.2.2.5 Extraction of DNA fragments from agarose gels 
DNA fragments were separated according to their size by flat bed electrophoresis on a 
1 % agarose gel (Section 2.2.2.4). The DNA fragment of interest was excised from the 
gel using a scalpel and a Dark Reader Transilluminator (Clare Chemical Research, 
Colorado, U.S.A) and extracted using the QIAgen® gel extraction kit. The gel slice was 
weighed and solubilised by adding 3 x volumes of buffer QG and heated at 50°C for 10 
min in a thermomixer. The solubilised gel slice was mixed with 1 volume of 
isopropanol, transferred to a QIAquick spin column and centrifuged for 1 min at 16,200 
x g at room temperature. The DNA was washed by adding 0.5 ml buffer QG and 
centrifuging for 1 min at 16,200 x g at room temperature. A further wash using 0.75 ml 
Buffer PE was added and incubated for 5 min at room temperature, then centrifuged 
for 1 min at 16,200 x g. Elution buffer (EB), 30 µl, was added and incubated for 1 min, 
and the mixture centrifuged for 1 min at 16,200 x g at room temperature. The DNA 
was used immediately, and the purification efficiency was assessed qualitatively by 1 % 
(w/v) flat bed agarose gel electrophoresis (Section 2.2.2.4). 
 
2.2.2.6 Restriction endonuclease (R.E) digestion 
Restriction endonuclease digestions were performed for both the cloning of PCR 
products into the desired vector and diagnostic purposes. When digesting plasmid 
DNA for diagnostic purposes, restriction endonuclease digestions were carried out in 
sterile 0.5 ml micro-centrifuge tubes containing; 0.5 µg (~ 0.5 µl) plasmid DNA, 1 unit 
of each restriction endonuclease, 1 or 2 µl (1 x or 2 x concentrated) Tango™ restriction 
endonuclease buffer (33 mM Tris-acetate, pH 7.9, 10 mM magnesium acetate, 66 
mM potassium acetate, 0.1 mg/ml bovine serum albumin [BSA]) made to a total 
volume of 10 µl with ddH2O. This was gently mixed and incubated for 1 h at 37˚C. The 
reaction was terminated by the addition of 2 µl 6 x DNA loading buffer (50 % (v/v) 
glycerol, 20 % (w/v) EDTA, 100 mM Tris-HCl, pH 8.0, 0.1 % (w/v) bromophenol blue, 0.1 
% (w/v) xylene cyanol). The digestion was verified by 1 % (w/v) flat bed agarose gel 
electrophoresis (Section 2.2.2.4). When digesting PCR products, the above method was 
followed using ~ 500 ng of PCR product, and the restriction endonuclease digestion 
was incubated for 2 h before being terminated by PCR purification. The digested PCR 
products were then ready for ligation into the cloning vector. 
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2.2.2.7 Purification of PCR products 
The Qiagen QIAquick® PCR purification kit was used to purify PCR products from 
molecular cloning enzymes. To the PCR reaction mixture, 5 x volumes of PB buffer 
were added. The solution was transferred to a QIAquick® column and centrifuged at 
16,200 x g for 1 min at room temperature and the flow-through discarded. The column 
was washed with 0.75 ml PE buffer and incubated for 5 min followed by centrifugation 
for 1 min at 16,200 x g at room temperature. The flow-through was removed and the 
column was again centrifuged as above to remove all traces of buffer. The column was 
put into a sterile 1.5 ml micro-centrifuge tube and 30 µl 10 mM Tris-HCl, pH 8.0 was 
added to elute the PCR product. This was incubated at room temperature for 1 min. 
The column was centrifuged at 16,200 x g for 1 min at room temperature. The purified 
PCR product was used immediately for all subsequent reactions. 
 
2.2.2.8 Dephosphorylation of vector 
Vectors were dephosphorylated to minimise the background caused by their 
recircularisation. The following reaction was carried out in a 0.5 ml sterile micro-
centrifuge tube; 1 x shrimp alkaline phosphatase (SAP) buffer (20 mM Tris-HCl, pH 8.0, 
10 mM MgCl2), 1 - 5 µg restriction endonuclease digested vector, made to a total 
volume of 22 µl with ddH2O, was incubated at 37°C for 30 min. SAP enzyme was then 
added, 1 unit, and incubated at 37°C for 1 h. The SAP reaction was terminated by heat 
inactivation at 65˚C for 20 min. Dephosphorylated vectors were used for all 
subsequent cloning of PCR products. 
 
2.2.2.9 Ligation reactions 
Restriction endonuclease digested PCR products were ligated into the restriction 
endonuclease digested and dephosphorylated vectors by the addition of T4 DNA ligase 
and thermocycling. Ratios of insert:vector of 1:1, 1:3 and 1:7 were mixed with 1 unit T4 
DNA ligase in 1 x ligation buffer (66 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1 mM 
dithiothreitol [DTT], 1 mM ATP) to a final volume of 10 µl with ddH20. Test ligations 
were always carried out alongside three control reactions. These were incubation with 
no ligase, incubation with no insert, or incubation with no insert and ligase. The 
reactions were incubated for 16 h cycling between 10˚C for 1 min and 30˚C for 1 min.  
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Ligation samples were then transformed into chemically competent DH5α E.coli cells 
(Section 2.2.1.2).  
 
2.2.2.10 PCR screening of recombinants 
PCR screening was used to ascertain quickly if the colonies gained from the ligation 
reaction had successfully incorporated the PCR product into the cloning vector. 
Colonies from the ligation reactions were picked using a sterile pipette tip and 
carefully dipped into a sterile PCR micro-centrifuge tube containing a PhusionTM 
enzyme amplification mixture (4.6 µl sterile ddH2O, 0.2 µl of 10 mM stocks of both 
forward and reverse PCR primers and 5 µl PhusionTM Master Mix). Samples with 
controls were carried out in parallel. These included samples with no template DNA 
and samples with no forward and reverse primers. The samples were gently mixed and 
run using the PCR cycle as described below. If the PCR screening was positive a DNA 
band should be seen with the same size as the original PCR product. 
 
 
 
 
 
 
2.2.2.11 Mini preparation of plasmid DNA 
A single colony of pre-transformed DH5α E.coli cells from a selective plate was picked 
and used to inoculate 5 ml LB media (12 - 16 h culture, 37˚C at 250 rpm) containing the 
correct selective antibiotic, either 50 µg/ml ampicillin or 50 µg/ml kanamycin. The 16 h 
culture, 1.5 ml, was then transferred into a sterile 1.5 ml micro-centrifuge tube and 
centrifuged at 16,200 x g for 1 min at room temperature. The supernatant was 
aspirated and the pellet re-suspended by gentle pipetting in 200 µl re-suspension 
buffer (50 mM Tris-HCl, pH 8.0, containing 10 mM EDTA and 100 µg/ml RNase A). Lysis 
buffer, 200 µl, (200 mM NaOH, 1% [w/v] SDS) was then added. This was mixed by 
3. 94°C for 1 min (once) 
4. 94°C for 1 min 
                            50°C for 30 sec                 (34 cycles)  
                            72°C for 1 min 
                      3.   72°C for 5 min 
                      4.   4°C hold 
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gentle inversion a total of six times. Neutralisation buffer, 200 µl, (3 M potassium 
acetate) was added, and the mixture was gently inverted six times until a white 
precipitate formed. The tubes were incubated at -20˚C for 10 min. The precipitate was 
removed by centrifugation at 16,200 x g for 10 min at room temperature. The 
supernatant was carefully transferred into a new sterile 1.5 ml micro-centrifuge tube. 
Isopropanol, 400 µl, was added to the supernatant and mixed by inversion. The tubes 
were centrifuged at 16,200 x g for 10 min at room temperature. The supernatant was 
discarded and 200 µl ice-cold 70 % (v/v) ethanol was added to the pellet. The DNA 
pellet was washed by a gentle flicking of the tube and centrifuged at 16,200 x g for 5 
min at room temperature. The supernatant was carefully removed and the plasmid 
DNA pellet was air-dried at room temperature for ~ 20 min. The plasmid DNA was re-
suspended in TE buffer (10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) and stored at -20˚C 
until use. 
 
2.2.2.12 Maxi preparation of plasmid DNA 
The GenElute™ HP plasmid maxiprep kit was used for all large scale plasmid DNA 
extractions. A single colony of pre-transformed DH5α E.coli cells was picked from a 
selective plate and grown in 400 ml LB media containing the correct selective 
antibiotic, either ampicillin or kanamycin. The culture was incubated for 16 h at 37˚C, 
250 rpm. The culture was pelleted by centrifugation at 5,000 x g for 10 min at 4˚C using 
a JLA 16.250 rotor in a Beckman centrifuge. The pellet was re-suspended in 12 ml re-
suspension buffer by gentle pipetting. Lysis buffer, 12 ml, was added, mixed by 
inversion six times and incubated for 4.5 min. The lysis was terminated by the addition 
of 12 ml ice-cold neutralisation buffer. This was mixed by inversion six times until a 
white precipitate formed. Binding buffer, 9 ml, was added and the lysed cell solution 
was poured into a GenElute™ HP maxiprep filter syringe. Plasmid DNA was 
subsequently filtered by passing the lysed cell solution through the filter syringe. The 
GenElute™ HP maxiprep binding column was equilibrated by the addition of 12 ml 
column preparation buffer. This solution was passed through the binding column by 
centrifugation at 3,000 x g for 2 min at 20°C using a Megafuge 1.0 R centrifuge. The 
filtrate from the lysed cells containing the plasmid DNA was added to the equilibrated 
binding column and centrifuged at 3,000 x g for 2 min at 20°C. This step was repeated 
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until all the filtrate had passed through the binding column. Wash buffer 1, 12 ml, was 
added to the binding column and was centrifuged at 3,000 x g for 2 min at 20˚C and 
the supernatant removed. Wash buffer 2, 12 ml, was added and the binding column 
was centrifuged at 3,000 x g for 5 min at 20˚C and the supernatant removed. The 
plasmid DNA was eluted into 2 ml TE buffer (10 mM Tris-HCl, pH 8.0 and 1 mM EDTA) 
by centrifugation at 3,000 x g for 5 min at 20˚C. The plasmid DNA-containing filtrate 
was passed through the binding column an additional time as described above. 
Plasmid DNA was characterised and the concentration of DNA was determined by 
measuring the absorbance at λ = 260 nm, with an absorbance reading of 1 equating to 
50 µg/ml of DNA. The purity of the DNA was calculated from the absorbance ratio OD λ 
= 260 nm /OD λ = 280 nm. This ratio is equal to ~ 1.8 - 2.0 for a pure DNA preparation 
indicative of a low protein to DNA ratio. Plasmid DNA was stored as aliquots of 200 µl 
at -20˚C until use. 
 
2.2.2.13 Ethanol precipitation of plasmid DNA 
Ethanol precipitation of plasmid DNA was used to concentrate plasmid DNA for DNA 
sequencing. To 1 x volume of plasmid DNA (~ 1.5 µg), 0.12 x volume of 3 M sodium 
acetate and 2.5 x volumes of ice-cold ethanol were added into a 1.5 ml sterile micro-
centrifuge tube. The mixture was incubated for 2 h at -80˚C. Plasmid DNA was pelleted 
by centrifugation at 16,200 x g for 30 min at room temperature. The supernatant was 
carefully discarded and 200 µl ice-cold 70 % (v/v) ethanol was added to wash the 
plasmid DNA pellet. The plasmid DNA was pelleted by centrifugation at 16,200 x g for 5 
min at room temperature. The supernatant was removed and the plasmid DNA pellet 
was allowed to air dry for ~ 20 min at room temperature. The plasmid DNA pellet was 
either re-suspended in the appropriate volume of TE buffer (10 mM Tris-HCl, pH 8.0, 1 
mM EDTA) and stored at -20˚C until use or sent immediately to MWG-Biotech 
(Ebersberg, Germany) or UCL DNA Sequencing Service for nucleotide sequencing.  
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2.2.2.14 Deletion mutagenesis by overlap extension PCR 
Deletion mutagenesis by overlap extension PCR was used to remove a specific 
nucleotide sequence from a DNA sequence of interest. In this case this was the 
deletion of 18 nucleotides encoding for amino acid numbers 877-883 of KIF5A. To 
generate a PCR product with a deletion mutation a similar method to designing 
primers for standard sub-cloning (Section 2.2.2.3) was utilised. An overall summary of 
this process is shown in Figure 2.2. An initial PCR step was used to amplify the two 
regions of DNA either side of the deletion region (Section 2.2.2.3.1). Each DNA 
fragment contained an 18 nucleotide overlap specific for the region opposite to the 
deleted sequence. The two PCR products were analysed via flat bed agarose gel 
electrophoresis (Section 2.2.2.4) and subsequently extracted (Section 2.2.2.5). The 
extracted DNA fragments were mixed in an equal ratio to a total of 1 µl which served 
as the hybrid duplex template DNA. This hybrid duplex DNA was PCR amplified to yield 
a recombinant PCR product and was directly cloned into the pcDNAHisMaxC vector 
(Section 2.2.2.4 – Section 2.2.3.11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic of deletion mutagenesis by overlap extension PCR. 
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2.2.3 Bacterial protein expression  
2.2.3.1 Protein extraction from BL21 DE3 codonplus E.coli cells  
A single colony of pre-transformed BL21 E.coli cells from a selective plate was picked 
and used to inoculate 5 ml LB media (12 - 16 h culture) containing the correct selective 
antibiotic (50 µg/ml ampicillin). LB media cultured overnight, 1 ml, was used as a 
starter culture to inoculate 50 ml of LB media (1 % [w/v] glucose) containing 50 µg/ml 
ampicillin, and grown until OD = 600 nm reached 0.6 - 0.7. IPTG, 0.1 mM or 1 mM, was 
used to induce protein production for 4 h at either 18°C, 25°C or 37°C, 225 rpm. The 
culture was centrifuged at 4,000 x g for 15 min at 4°C, the supernatant was aspirated 
and the remaining pellet frozen overnight. The pellet was subsequently defrosted 
slowly on ice, and re-suspended in varying buffers (8 or 16 ml for 100 ml of culture) to 
test optimal conditions. These buffers were either (i) native buffer (250 mM NaH2PO4, 
pH 8.0, 1 mg/ml lysozyme) or (ii), re-suspension buffer (50 mM Tris pH 8.0, 400 mM 
NaCl, 10 % [w/v] glycerol, 5 mM β-ME, 20 µg/ml lysozyme and 1 protease inhibitor 
cocktail tablet). The re-suspended solution was incubated on ice for 30 min and then 
sonicated 6 x for 10 sec each with 10 sec rest in between each sonication. Solubilised 
samples, 1 ml, were removed and aliquoted into 1.5 ml micro-centrifuge tubes and 
termed the total fraction. The remaining solution was centrifuged at 3,000 x g for 15 
min at 4°C. The supernatant was aliquoted into 1.5 ml micro-centrifuge tubes and 
termed the soluble fraction. The remaining protein pellet was carefully re-suspended 
and aliquoted into 1.5 ml micro-centrifuge tubes and was termed the insoluble 
fraction. Samples were snap frozen at -20°C until needed for future analysis.            
 
2.2.3.2 Bradford assay protein quantification 
BSA was diluted to a final concentration of 1 mg/ml using ddH2O. A series of dilutions 
of this stock solution were made in triplicate to give; 10 µg, 8 µg, 6 µg, 4 µg, 2 µg and 0 
µg BSA each in a total volume of 800 µl. The test samples were diluted 1/10 and 1/100 
with ddH2O. Coomassie Brilliant Blue G-250 dye Bio-Rad protein assay, 200 µl, was 
added to each sample. The samples were incubated at room temperature for 30 min. 
The OD λ = 595 nm was measured and a calibration curve was constructed from the 
protein standards. The protein concentrations of the test samples were then 
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determined by comparing to the standard curve.   
 
2.2.3.4 SDS-PAGE 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out under reducing conditions using 7 %, 12 % or 15 % (w/v) polyacrylamide mini gels. 
For each gel, one glass plate (8 cm x 10 cm), one aluminium plate (8 cm x 10 cm) and 
two 0.75 mm spacers were cleaned with 70 % (v/v) ethanol. The two spacers were put 
on either side of the aluminium plate with the glass plate on top, and were assembled 
into a Mighty Small TM dual gel caster (Hoefer, San Francisco, U.S.A). 
 
2.2.3.4.1 Preparation of running gel 
All polyacrylamide gels contained 7 %, 12 % or 15 % (w/v) acrylamide. The running gel 
for a 12 % solution was made with; 4.2 ml ddH2O, 3 ml running gel buffer (1.5 M Tris-
HCl, pH 8.8, 8 mM EDTA, 0.4 % [w/v] SDS), 4.8 ml ProtoGel® (37.5:1 acrylamide to 
bisacrylamide stabilized solution) and 6 µl TEMED. The solution was de-gassed under 
vacuum for 30 min. The polymerisation was initiated by the addition of 60 µl 10 % 
(w/v) ammonium persulphate. The solution was poured gently between the glass plate 
and aluminium plate to reach ~ 3 cm below the top of the glass plate. To ensure an 
even surface on the top of the gel, ~ 250 µl 50 % (v/v) butan-1-ol was added. Gels were 
left to polymerise for ~ 1 h. The butan-1-ol was removed by washing 3 x with ~ 5 ml 
ddH2O. 
 
2.2.3.4.2 Preparation of stacking gel 
The polyacrylamide gels were transferred from the Mighty Small TM gel caster onto 
the Mighty Small TM electrophoresis unit. The stacking gel solution was made with; 2.3 
ml ddH2O, 1 ml stacking buffer (0.5 M Tris-HCl, pH 6.8, 8 mM EDTA, and 0.4 % [w/v] 
SDS), 650 µl ProtoGel® and 6 µl TEMED. The stacking gel solution was degassed under 
vacuum for 30 min. The polymerisation reaction was initiated by the addition of 10 % 
(w/v) ammonium persulphate, 80 µl. The acrylamide solution was added directly to the 
separating gel and a comb immediately positioned. The stacking gels were polymerised 
for ~ 10 min. Once the stacking gels had polymerised, the buffer reservoirs were filled 
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with electrode buffer (50 mM Tris-HCl, pH 8.8, 384 mM glycine, 1.8 mM EDTA, 1.8 % 
[w/v] SDS) and the comb was gently removed. Gel lanes were then washed to remove 
any residual unpolymerised polyacrylamide.  
 
2.2.3.4.3 Methanol/chloroform precipitation of protein samples 
To precipitate protein samples with a volume too large for SDS-PAGE analysis, aliquots 
in the range of 25 – 150 µl were mixed with four volumes of methanol (MeOH) in a 1.5 
ml microcentrifuge tube. The samples were briefly vortexed and centrifuged at 5,000 x 
g for ~ 10 sec at room temperature. One volume of chloroform was added and the 
resulting samples vortexed and centrifuged as above. Three volumes of ddH2O was 
added, vortexed and centrifuged for 1 min, 12,000 x g at room temperature. The 
resulting top aqueous layer was removed and one volume of MeOH added. The 
resulting samples were vortexed and centrifuged for 4 min at room temperature. The 
supernatant was carefully removed and the resulting protein pellet was dried under a 
vacuum for ~ 20 min. The samples were then prepared and run on SDS-PAGE as 
described in Section 2.2.3.4.4.      
 
2.2.3.4.4 Preparation and electrophoresis of protein samples 
To each methanol/chloroform precipitated protein sample; 8.5 µl ddH2O, 5 µl 3 x SDS-
PAGE sample buffer (30 mM NaH2PO4, pH 7, 30 % [v/v] glycerol, 0.05 % [w/v] 
bromophenol blue, 7.5 % [w/v] SDS) and 1.5 µl 1 M DTT were added. The samples 
were briefly vortexed for ~ 5 sec and centrifuged at 13,000 x g for 1 min at room 
temperature. The samples were heated to 75˚C for 8 min whilst shaking at 500 rpm in 
an Eppendorf ThermoMixer. The protein samples were collected in the bottom of the 
micro-centrifuge tubes by another cycle of vortexing as above, and centrifuged for 10 
sec. The protein samples were loaded into the gel lanes using a Hamilton syringe. 
Empty gel lanes were loaded with 15 µl 1 x sample buffer. If the gels were to be 
analysed by immunoblotting, one lane per gel was loaded with 4 µl of SeeBlue® pre-
stained standard protein molecular weight markers. Polyacrylamide gels which were to 
be protein stained using Coomassie Blue were prepared and run as before except for 
the use of an un-stained protein molecular weight marker, in which 15 µl 1 x sample 
buffer with 1 µg of marker protein was loaded. Electrophoresis was carried out at an 8 
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mAmp constant current through the stacking gel then a 10 mAmp constant current 
through the separating gel. For protein gels which were to be used for 
immunoblotting, once the bromophenol blue dyefront had reached the bottom of the 
gel the proteins were transferred onto nitrocellulose membranes (Section 2.2.3.5.1). 
For gels which were directly stained for proteins, once the bromophenol blue dyefront 
had reached the bottom of the gel the gel was incubated in a Coomassie Blue stain 
solution overnight (per 100 ml: 60 ml ddH2O, 30 ml methanol, 10 ml acetic acid, 0.2 g 
Coomassie Blue G-250). The gel was subsequently washed with gentle agitation and 
several changes of destain solution (30% [w/v] methanol, 10% [w/v] acetic acid) until 
background Coomassie Blue staining had been removed. Stained gels were imaged 
using a HP scanjet 4570c scanner. The SeeBlue® pre-stained standard protein 
molecular weight markers contained the following proteins (kDa): myosin, 250; BSA, 
98; glutamate dehydrogenase, 64; alcohol dehydrogenase, 50; carbonic anhydrase, 36; 
myoglobin, 30; lysozyme, 16; aprotinin, 6; insulin B chain, 4. The un-stained standard 
protein molecular weight markers contained the following proteins (kDa): myosin, 200; 
β-galactosidase, 116.25; phosphorylase b, 97.4; serum albumin, 66.2; ovalbumin, 45; 
carbonic anhydrase, 31; trypsin inhibitor, 21.5; lysozyme, 14.4; aprotinin, 6.5. 
 
2.2.3.5 Immunoblotting 
2.2.3.5.1 Transfer of proteins to nitrocellulose membranes 
Once SDS-PAGE was completed, proteins were transferred onto nitrocellulose 
membranes using a wet transfer process. To transfer the proteins a sandwich was 
made of two pieces of blotting paper, pre-soaked in transfer buffer (25 mM Tris, 172 
mM glycine, 20% [v/v] methanol, pH 8.5) and a piece of nitrocellulose membrane 
which had also been pre-soaked in transfer buffer. The polyacrylamide gel was placed 
onto the nitrocellulose membrane and two additional pieces of pre-soaked blotting 
paper were placed on top. A 2 ml pipette was rolled across the sandwich to remove 
any air bubbles. The sandwich was put between two pieces of sponge and into a 
transfer cassette. The cassette was placed into a Mighty SmallTM transfer tank 
containing transfer buffer ensuring that the cassette was fully covered, with the 
polyacrylamide gel facing the cathode. The transfer was conducted for 16 h at 14 V at 
room temperature. When removing the nitrocellulose membrane from the tank, the 
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size of the nitrocellulose was trimmed to exactly the same size as the gel. 
Nitrocellulose membranes were stored in 1 x PBS at 4˚C until immunoblotting was 
conducted (Section 2.2.3.5.2). 
 
2.2.3.5.2 Immunoblotting 
Proteins were visualised by immunoblotting using the appropriate antibodies. The 
nitrocellulose membrane was blocked for 1 h in 5 % (w/v) powdered milk (Marvel, low 
fat powdered milk powder) and 0.05 % (w/v) polyethylene glycol sorbitan monolaurate 
(Tween-20®) in 1 x PBS at 37˚C with gentle rotation. The primary antibodies (0.5 - 2 
µg/ml in 2.5 % [w/v] powdered milk in 1 x PBS) were incubated with the nitrocellulose 
membrane at 37˚C with gentle rotation for 1 h. The membranes were washed 4 x 10 
min in 2.5 % (w/v) powdered milk and 0.05 % (w/v) Tween-20® in 1 X PBS at 37˚C with 
gentle rotation. The secondary antibody, either horseradish peroxidase (HRP)-linked 
anti-rabbit IgG or HRP-linked anti-mouse IgG antibodies were prepared as a 1/2000 
dilution in 2.5 % (w/v) powdered milk. In the case of the directly conjugated HRP anti-
His primary antibodies incubation with secondary antibodies was not required. 
Immunoblots were incubated with secondary antibodies for 1 h at 37˚C with gentle 
rotation. The membranes were washed 4 X 10 min in 2.5 % (w/v) powdered milk and 
0.05 % (w/v) Tween-20® at 37˚C with gentle rotation. The membranes were briefly 
washed in 1 x PBS. A 10 ml aliquot of 0.8 M luminol (100 mM Tris-HCl, pH 8.5 and 0.8 
M luminol) and a 100 µl aliquot of 10 mg/ml hydroxycinnamic acid (p-coumaric acid) 
were defrosted. The 100 µl p-coumaric acid was added to the 10 ml luminol solution 
and mixed. The membrane was put face up into an empty tray. The blot development 
was initiated by the addition of 10 µl hydrogen peroxide to the luminol mixture, which 
was vortexed and poured over the membrane. This was incubated for 1 min and the 
membrane was tapped on tissue to remove the excess liquid. The membrane was then 
put into a plastic sleeve and tracker tape was used to mark the positions of the 
molecular weight markers. The immunoblots were imaged using a GeneGnome 
Chemiluminescence Capture and Analysis System (Syngene, Cambridge, U.K). 
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2.2.3.5.3 Quantitative immunoblot analysis 
When quantitative immunoblotting was carried out the immunoreactive bands were 
quantified using GeneGnome Tools software. An equal sized box was drawn around 
each of the resulting bands, in which the background was calculated and deducted 
from the resulting pixel values for each immunoblot.  
 
2.2.4 Purification of bacterially expressed recombinant proteins 
2.2.4.1 Purification of bacterially expressed His tagged protein using ProBondTM Ni2+ 
chelating resin 
All purification experiments were carried out at 4°C. Purification of bacterially 
expressed His tagged protein was carried out using two methods, these were either (i) 
small scale purification using 0.5 ml of settled ProBondTM Ni2+ chelating resin (Ni2+ 
affinity resin) and 6 ml of soluble protein sample, or (ii) large scale purification using 1 
ml of settled resin and 40 ml of soluble protein sample. Ni2+ affinity resin was prepared 
by washing once in 6 ml ddH20 followed by 3 x with re-suspension buffer minus the 
presence of β-ME (50 mM Tris pH 8.0, 400 mM NaCl, 10 % (w/v) glycerol, 20 µg/ml 
lysozyme, and 1 protease inhibitor cocktail tablet). Between each wash, the resin was 
settled via centrifugation for 1 min at 800 x g and the supernatant carefully removed 
using a 1 ml pipette tip. Fresh soluble protein extract gained from expression 
experiments in BL21 E.coli cells (Section 2.2.3.1) were incubated with the resin for 1 h 
whilst gently rocking. After incubation, the resulting mixture of resin and soluble 
protein was poured gently into a 5 ml poly-prep chromatography column and the 
unbound soluble protein allowed to run through and the resin to settle via gravity. The 
resulting unbound protein was snap frozen in liquid nitrogen and kept at -20°C until 
further analysis. The settled column was subsequently washed with a minimum of 8 x 
column volumes of wash solution (re-suspension buffer with 5 mM β-ME and 20 mM 
imidazole) or until the collected fractions O.D λ = 280 nm = 0. The column was eluted 
via gravity using the same method used to wash the column but using elution buffer 
(50 mM Tris pH 8.0, 400 mM NaCl, 10% (w/v) glycerol, 20 µg/ml lysozyme, 5 mM β-ME, 
250 mM imidazole and 1 protease inhibitor cocktail tablet). All subsequent wash and 
elution fractions were collected as 1 ml fractions and snap frozen in liquid nitrogen and 
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stored at -20°C until further analysis. 
 
2.2.4.2 Purification of bacterially expressed S tagged protein using S-protein agarose 
resin 
All purification experiments were carried out at 4°C. Fresh soluble protein extract 
gained from expression experiments in BL21 E.coli cells (Section 2.2.3.1) was incubated 
with 1 ml S-protein agarose resin (50 % slurry in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 0.02 % sodium azide) for 1 h whilst gently rocking. After incubation the 
resulting mixture of resin and soluble protein was poured gently into a 5 ml poly-prep 
chromatography column and the unbound soluble protein allowed to run through and 
the resin to settle via gravity. The resulting unbound protein was snap frozen in liquid 
nitrogen and kept at -20°C until further analysis. The settled column was subsequently 
washed with a minimum of 8 x column volumes of wash solution (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.1% Triton X-100) or until the collected fractions O.D λ = 280 nm = 
0. S-tagged protein was eluted from the resin using 3 M MgCl2 via gravity. All 
subsequent wash and elution fractions were collected as 1 ml fractions and snap 
frozen in liquid nitrogen and stored at -20°C until further analysis. 
 
2.2.4.3 Buffer exchange and concentration of bacterially expressed protein samples 
Vivaspin 6 ml 10,000 Da filters were used to concentrate and buffer exchange 
bacterially expressed and purified protein samples in preparation for microtubule 
binding co-sedimentation assay experiments. Prior to use the filters were pre-washed 
with ~ 5 ml of re-suspension buffer (50 mM Tris pH 7.4, 150 mM NaCl and 1 protease 
inhibitor cocktail tablet) and centrifuged at 3,200 x g, 4°C for 10 min to remove any 
possible preservatives. Protein samples were subsequently loaded onto the filter and 
centrifuged at 3,200 x g, 4°C for 5 - 30 min depending on the time reached to obtain 
the desired final volume. The sample was subsequently washed 6 x with an equal 
volume of a new buffer and centrifuged as above. Samples were snap frozen in liquid 
nitrogen and stored at -20˚C. 
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2.2.4.4 Aggregation state testing 
To ensure that bacterially expressed protein remained stable after affinity tag 
purification, buffer exchange and snap freezing for storage, tests upon the aggregation 
state of the protein were carried out. Bacterial protein samples were centrifuged at 
100,000 x g for 20 min at 4˚C using a MLA 80 rotor in a Beckman OptimaTM MAX-E 
ultracentrifuge. The protein supernatant was carefully removed without disturbing the 
pellet and placed into a micro-centrifuge tube for further analysis. The resulting pellet 
was re-suspended in an equal volume of appropriate buffer and also placed into a 
micro-centrifuge tube. Each supernatant and re-suspended pellet sample, 75 µl, was 
methanol/chloroform precipitated (Section 2.2.3.4.3). Resulting protein samples were 
mixed with SDS sample preparation buffer and analysed via SDS-PAGE and Coomassie 
Blue staining (Section 2.2.3.4). 
 
2.2.4.5 Size exclusion chromatography  
Size exclusion chromatography was utilised to separate proteins based on their 
molecular weight and native conformation in a given buffer condition. All buffers and 
samples were filtered using a 0.22 µm filter and degassed under a vacuum prior to use. 
All size exclusion chromatography experiments were carried out using a Superose™ 6 
10/300 GL column on an ÄKTAprime plus chromatography system (GE Healthcare, 
Amersham, U.K). Before samples could be run the column was washed with 2 x column 
volumes (48 ml) of ddH2O followed by 2 x column volumes of re-suspension buffer 
(Section 2.2.3.1) minus glycerol. This process of washing the column removed any 
traces of 70 % ethanol, in which the column has been stored, as well as allowing the 
column to equilibrate to the buffer conditions. In order to calibrate the S6 column, 
molecular weight standards (Sigma-Aldrich, Poole, U.K) were re-suspended in re-
suspension buffer minus glycerol at a concentration of ~ 1 mg/ml and run through the 
gel filtration system. These molecular weight standards included (kDa): blue dextran, 
2,000; albumin, 158; albumin (bovine), 66; albumin (egg), 45; carbonic anhydrase, 29; 
chymotriptinogen, 25; cytochrome C, 12.4. 120 µl of molecular weight protein 
standard was injected onto the column and allowed to run for 1.5 column volumes (36 
ml) at a flow rate of 0.2 ml/min, this was repeated until all samples had been run. 
Elution volume peaks were noted and a calibration curve of the log of molecular 
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weight versus elution volume was constructed. Protein samples were injected and run 
as above except elution volumes were collected as 0.5 ml fractions into micro-
centrifuge tubes using a fraction collector (GE Healthcare, Amersham, U.K). Elution 
volumes were analysed via SDS-PAGE using both immunoblotting and Coomassie Blue 
protein staining (Section 2.2.3.4). After use the Superose™ 6 10/300 GL column was 
washed with 2 x column volumes of ddH20 followed by 2 x column volumes of 70 % 
ethanol for long term storage. 
 
2.2.4.6 Preparation of stable and polymerised microtubules 
To prepare stable and polymerised microtubules, 5 mM GTP was mixed with 20 µl 2 x 
microtubule polymerisation buffer (80 mM piperazine-N,N’-bis-(2-ethanesulphonic 
acid) [PIPES], pH 6.8, 10 mM MgCl2). This was subsequently added to 20 µl thawed 
glycerol-free bovine brain tubulin and vortexed. The resulting mixture was incubated 
for 90 min at 37°C and afterwards 0.4 µl paclitaxel dissolved in DMSO (1 mM final) 
added to stabilise the microtubules. The solution was further incubated for 1 h at 37°C. 
The final mixture was left for 24 h at room temperature prior to use to allow complete 
polymerisation of the microtubules. 
 
2.2.4.6.1 Microtubule binding co-sedimentation assay  
To test the binding interaction of purified KIF5A800-951 protein with microtubules a co-
sedimentation assay was carried out. A range of concentrations of purified KIF5A800-951 
protein (6 – 78 µg) were incubated with a fixed microtubule concentration, 1.5 µM. All 
samples were prepared in thick walled polycarbonate tubes to a final volume of 40 µl 
with microtubule binding buffer (50 mM Tris, pH 7.5, 150 mM NaCl and 1 protease 
inhibitor cocktail tablet). Each microtubule binding co-sedimentation assay had two 
controls carried out in parallel. These were the absence of either the KIF5A800-951 
protein or the absence of microtubules. The resulting mixture was briefly vortexed and 
incubated at room temperature for 15 min whilst being covered with Parafilm to 
prevent evaporation. Tubes were centrifuged at 392,000 x g for 15 min at room 
temperature using a TLA 100 rotor in a Beckman OptimaTM MAX-E ultracentrifuge. 
The supernatant was carefully removed without disturbing the pellet and placed into a 
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micro-centrifuge tube for further analysis. The resulting pellet was re-suspended in 40 
µl microtubule binding buffer and also placed into a micro-centrifuge tube. Each 
supernatant (10 µl) and re-suspended pellet sample was mixed with 5 µl 3 x SDS 
sample preparation buffer and analysed via SDS-PAGE and Coomassie Blue protein 
staining (Section 2.2.3.4). 
 
2.2.5 Expression in mammalian cells 
2.2.5.1 Culturing of human embryonic kidney 293 cells 
All cell culture, Section 2.2.5.2 – Section 2.2.5.6, was carried out by Dr Cousins, Dr 
Brickley or Dr Lyn-Adams, UCL School of Pharmacy, U.K. For all cell culture equipment 
sterile techniques were employed throughout. In addition, when removing or placing 
an item in either the laminar flow hood or the mammalian cell incubator each item 
was lightly sprayed with 70 % (v/v) ethanol to maintain sterility. All solutions were 
sterilised either by filtration through a 0.22 µm pore size or by autoclaving at 120˚C for 
20 min.  
 
2.2.5.2 Preparation of cell culture media 
For routine sub-culturing of HEK 293 cells, modified Eagles medium nutrient mixture F-
12 HAM (DMEM/F-12) containing L-glutamine was utilised. Media was prepared by the 
addition of 15.6 g powdered Dulbecco’s modified Eagles medium nutrient mixture F-12 
HAM (DMEM/F-12) to 500 ml sterile ddH2O, 20 ml penicillin/streptomycin (10,000 
units/ml), 40 ml 7.5 % (w/v) NaHCO3 and 100 ml foetal bovine serum (FBS). The total 
volume was made to 1 L and the pH adjusted to 7.6 using 10 M NaOH. The media was 
then filter sterilised through a 0.22 µm Nalgene filter. The above described cell culture 
media was replaced 3 h before transfection with DMEM/F-12 L-glutamine free media. 
This was made by adding 100 ml FBS, 20 ml penicillin/streptomycin (10,000 units/ml) 
and 24 ml 7.5 % (w/v) NaHCO3 to liquid DMEM/F-12 without L-glutamine to a total 
volume 1 L and adjusted to pH 7.6 using 10 M NaOH. The media was then filter 
sterilised through a 0.22 µm Nalgene filter.  
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2.2.5.3 Storage of HEK 293 cells in liquid nitrogen 
HEK 293 cells that had reached 70 % confluence were used to make liquid nitrogen 
stocks.  HEK 293 cells were harvested using the method described in Section 2.2.5.5. 
The 12 ml HEK 293 cell suspension was centrifuged at 1,000 x g for 10 min at room 
temperature in a sterile 15 ml centrifuge tube. The supernatant was discarded and the 
pellet was re-suspended in 600 µl DMSO, 600 µl FBS and 4.8 ml DMEM/F-12 media 
containing L-glutamine. The cell suspension was divided as 1 ml aliquots in 1.8 ml 
cryotubes and frozen for 24 h at -80˚C. The following day the tubes were placed in 
liquid nitrogen until use. 
 
2.2.5.4 Reviving HEK 293 cell stocks from liquid nitrogen storage 
An aliquot of HEK 293 cells was taken from liquid nitrogen storage and rapidly 
defrosted in a water bath at 37˚C. The HEK 293 cell suspension was mixed into 50 ml 
DMEM/F-12 media containing L-glutamin, pre-warmed to 37˚C. The cells were pelleted 
by centrifugation at 1,000 x g for 10 min at room temperature. The supernatant was 
decanted and the pellet re-suspended in 10 ml (preheated to 37˚C) DMEM/F-12 media 
containing L-glutamine. The cell suspension was added to a 250 ml Cellstar™ sterile cell 
culture flask and incubated at 37˚C in the presence of 5 % CO2. The following day the 
media was aspirated and replaced with 10 ml, pre-warmed to 37˚C, DMEM/F-12 media 
containing L-glutamine. Once the HEK 293 cells had reached ~ 90 % confluence they 
were sub-cultured. 
 
2.2.5.5 Sub-culturing of HEK 293 cells 
Once the HEK 293 cells had reached ~ 90 % confluency they required sub-culturing. 
This was approximately every 3 - 5 days. Media was aspirated from a flask of confluent 
cells and washed by gently passing 10 ml (preheated to 37˚C) Hanks buffered salt 
solution (HBSS) gently over the cells. The HBSS was removed and 2 ml trypsin-EDTA 
(0.5 mg/ml porcine trypsin in HBSS) was added and incubated for 50 sec at room 
temperature. The flask was gently tapped to dislodge the cells and 10 ml DMEM/F-12 
containing L-glutamine media (preheated to 37˚C) was added. The cells were mixed 
thoroughly by repeated pipetting up and down. The 12 ml cell suspension was divided 
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equally between four flasks. An additional 9 ml DMEM/F-12 containing L-glutamine 
media (preheated to 37˚C) was added to each flask. The flasks were incubated at 37˚C 
and cultured in the presence of 5 % CO2 for 24 h prior to transfection or until ~ 90 % 
confluent when the HEK 293 cells were sub-cultured again, as above. The HEK 293 cells 
were routinely used for ~ 20 passages (two months) before reviving a new aliquot of 
HEK 293 cells for subsequent use.  
 
2.2.5.6 Transient transfection of HEK 293 cells by the calcium phosphate method 
HEK 293 cells were sub-cultured to be ~ 40 % confluence on the day of transfection, 
(Section 2.2.5.5). Three hours prior to transfection the cell culture media was aspirated 
and replaced with 10 ml (preheated to 37˚C) DMEM/F-12 L-glutamine free media. Each 
flask was incubated for 3 h at 37˚C in the presence of 7.5 % CO2. DNA to be used for 
transfection at 10 µg per flask was prepared as follows:- Two sterile 1.5 ml centrifuge 
tubes were prepared, one containing 500 µl 2 x HEPES buffer saline (2 X HBS, 50 mM 
N-(2-hydroxyethyl) piperazine-N'-(2-ethanesulphonic acid) (HEPES), pH 7.12, 280 mM 
NaCl, 1.1 mM Na2HPO4). The second tube containing 450 µl of the required plasmid 
DNA and 1/10 (v/v) TE buffer (10 mM Tris-HCl, pH 8.0 and 10 mM EDTA, diluted 1/10 
(v/v) with ddH2O). The solution to be transfected was started by the addition of 50 µl 
2.5 M CaCl2 (preheated to 37˚C) to the tube containing the plasmid DNA and 1/10 (v/v) 
TE buffer, and the tube was shaken vigorously for 15 sec. The DNA mixture was added 
drop-wise to the 2 x HBS at a rate of one-drop every ~ 4 sec. This solution was mixed 
by gentle pipetting up and down with a 1 ml pipette tip a total of three times. The 
above described transfection solution was added to the HEK 293 cells by slowly 
pipetting the solution into a corner of the flask under the surface of the media. The 
flask was rotated slowly 3 times to ensure the DNA precipitate was evenly distributed 
over the cells. The cells were then returned to the incubator at 37˚C in the presence of 
5 % CO2. Transfected HEK 293 cells were cultured for either 24 or 48 h post-
transfection and the cell homogenates were collected and analysed by either 
immunoblot analysis (Section 2.2.3.5) or immunoprecipitation experiments (Section 
2.2.5.8). 
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2.2.5.7 Preparation of transfected HEK 293 cell homogenates 
Transfected HEK 293 cell homogenates were used to test expression of newly 
synthesised mammalian expression clones prior to immunoprecipitation experiments 
(Section 2.2.5.8). HEK 293 cells were harvested 24 h post-transfection. The media was 
aspirated and the cells were scraped using a sterile cell scraper into 8 ml ice-cold 
phosphate buffered saline (1 x PBS; 137 mM NaCl, 27 mM KCl, 10 mM Na2HPO4.12H2O, 
1.8 mM KH2PO4, pH 7.6).  The cell suspension was collected and pelleted at 1,000 x g 
for 10 min at 4˚C. The supernatant was discarded and the pellet homogenised in 5 ml 
homogenisation buffer (50 mM Tris-citrate, pH 7.4, 5 mM EDTA, 5 mM EGTA) for ~ 10 
strokes using a tight 7 ml Wheaton Dounce glass-glass homogeniser. Typically a 250 ml 
flask of transfected cells would yield ~ 1 mg protein. The homogenised protein samples 
were either analysed via SDS-PAGE (Section 2.2.3.4) or aliquoted and snap frozen in 
liquid nitrogen then stored at -20˚C until analysis by immunoblotting (Section 2.2.3.5).   
 
2.2.5.8 Detergent solubilisation and co-immunoprecipitation of HEK 293 cell 
homogenates 
Co-immunoprecipitation assays were carried out to ascertain if proteins were able to 
co-immunoprecipitate with each other following their co-expression in HEK 293 cells. 
For co-immunoprecipitations using transfected HEK 293 cells the method of Chazot et 
al. (1994) was followed. Three flasks of HEK 293 cells were harvested 48 h post-
transfection and pooled together. The resulting cell homogenate was re-suspended in 
8 ml solubilisation buffer (50 mM Tris-citrate, pH 7.4, 240 mM NaCl, 5 mM EDTA, 5 mM 
EGTA, 1 mM PMSF, bacitracin (5 g/ml), soyabean trypsin inhibitors (5 g/ml), 
benzamidine HCl (5 g/ml) and 1 % (v/v) Triton X-100®). The cell homogenate was 
thoroughly homogenised with 10 strokes using a tight 7 ml Wheaton Dounce glass-
glass homogeniser followed by incubation for 1 h with gentle rotation at 4˚C. Soluble 
fractions were collected by centrifugation at 100,000 x g for 40 min at 4˚C using a MLA 
80 rotor in a Beckman OptimaTM MAX-E ultracentrifuge. Each detergent-solubilised 
sample was diluted with an equal volume of solubulisation buffer (minus Triton X-
100®) to give a final volume of 12 ml and a final concentration of 0.5 % Triton X-100®. 
Final diluted protein samples, 300 µl, were removed and are referred to as the input 
sample. The remaining sample was split into two aliquots and co-
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immunoprecipitations were initiated by the addition of 10 µg of the appropriate 
primary antibodies to one aliquot and 10 µg non-immune antibodies to the second 
aliquot. The final volumes of each assay were adjusted with 1 x PBS to ensure they 
were both the same final volume. The antibodies were incubated for 16 h with gentle 
rotation at 4˚C. Antibody complexes were precipitated by the addition of 5 mg protein 
A Sepharose and samples were incubated for 1 h with gentle rotation at 4˚C. The 
samples were centrifuged at 600 x g for 15 sec. The supernatants were removed and 
the antibody-protein A Sepharose complex was gently and rapidly washed with 1 ml 
solubilisation buffer followed by centrifugation at 600 x g for 15 sec at room 
temperature. This wash step was repeated a total of three times. On the final wash the 
supernatant was completely removed using a Hamilton syringe. To the pellet, 20 µl 3 x 
SDS-PAGE sample buffer and 5 µl 1 M DTT was added. The samples were heated to 
75˚C for 8 min. The proteins were collected by centrifugation at 600 x g for 15 sec at 
room temperature and the supernatant transferred into a fresh 1.5 ml centrifuge tube 
using a Hamilton syringe. The supernatants were then made up to the required volume 
with 1 x SDS-PAGE sample buffer and analysed by immunoblotting (Section 2.2.3.5). 
The supernatant collected from protein A Sepharose using antibodies specific to my 
protein of interest shall be referred to as the immune pellet and the supernatant from 
the non-immune antibodies as the non-immune pellet. 
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CHAPTER 3 
 
TOWARDS THE STRUCTURAL DETERMINATION OF 
A TRAK2/KIF5A TRAFFICKING COMPLEX   
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3.1 RATIONALE 
As described in the Introduction, the kinesin-1 family are motor proteins that have 
many important functions including roles in cell division and the transport of various 
organelles and protein cargoes within cells. Kinesin-1 consists of three main structural 
domains; a motor domain which binds to and creates movement along microtubule 
tracks using ATP, a stalk domain giving flexibility and stability to the protein and a 
cargo binding domain to which the cargoes that are transported bind (Hirokawa and 
Takemura, 2005). Previous work by Kull et al. (1996) successfully resolved the structure 
of the motor domain of the human kinesin-1 sub-type KIF5B to a 1.8 Å resolution by X-
ray crystallography. Kozielski et al. (1997) resolved the motor and stalk domains of the 
KIF5B KHC from rat in its native dimeric form to a resolution of 3 Å. As discussed in 
Section 1.2.1 the success in determining a crystal structure of the kinesin-1 motor 
domain, as well as a variety of other contributing data, led to the elucidation of the 
function and mechanism behind its ability to travel along microtubules. However, this 
is not the case regarding the structure and function of the cargo binding domain as a 
crystal structure has yet to be determined. Further, it is not known how the binding of 
specific cargoes to kinesin-1 is regulated. The TRAK/Milton family are kinesin-1 adaptor 
proteins which consist of TRAK1 and TRAK2 both of which are known to bind the cargo 
binding domain of conventional kinesin-1 heavy chains forming a link between the 
motor protein and cargo (Brickley et al., 2005; Section 1.3). TRAK2 is known to interact 
with KIF5C via amino acids 124-283 (Brickley et al., 2005). Therefore, it is reasonable to 
hypothesise that the TRAKs may stabilise the kinesin-1 cargo binding domain. Thus, 
TRAKs may help to facilitate studies directed towards the determination of the 
structure of the kinesin-1 cargo binding domain. In this instance it was thought that 
the presence of the TRAK2 protein, the in vivo partner of the kinesin-1 sub-type KIF5A 
in neurons, may help to stabilise the expression of the cargo binding domain of KIF5A 
to allow structural studies.  
In order to gain high quantities of protein needed to carry out structural studies, most 
recombinant protein expression strategies involve transforming cells with a DNA 
expression vector which encodes the nucleotide sequence for the recombinant protein 
of interest. This expression vector allows the cells to transcribe and translate this 
protein and the cells are then subsequently lysed to allow extraction of proteins for 
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purification. There are several systems that can be used to express recombinant 
proteins for structural studies; these include yeast cells, bacterial cells, insect cells and 
mammalian cells. In this instance a bacterial expression system will be utilised, of 
which there are several advantages for the expression of recombinant proteins. 
Bacterial cells possess a simple physiology that is well characterised; they are capable 
of short generation times; they can generate high yields of protein and a simple 
process permits the scale-up of protein expression. Conversely, the quick turnover of 
protein production in the bacterial cells can lead to improper folding causing inclusion 
bodies. Toxicity of synthesised proteins to the bacterial cells can prevent high yields. 
There is also a lack of the eukaryotic post-translational enzymes that might be needed 
for necessary modifications to the protein.  
Studies carried out by Kaan et al. (2011) determined the crystal structure of the motor 
domain of KIF5B binding to a short fragment of the tail domain, equivalent to amino 
acids 937-952, to a resolution of 2.2 Å. This work also highlights that the cargo binding 
domain peptide cross-links to the motor domain at two positions, the coiled coil and 
the tail interface. This cross-linking restricts the movement of the normally mobile 
motor domain indicating a stabilising effect of the expressed kinesin-1 protein 
fragment (Kaan et al., 2011). Although this study utilised a synthetic peptide fragment 
of the cargo binding domain binding to the full dimeric motor domain, this 
demonstrated the ability of both KIF5B proteins to bind together in vitro. 
There have been several examples of successful co-expression of motor proteins in 
bacterial systems. One such example is the co-expression of single-headed kinesin-1 
heterodimers consisting of a full length Drosophila KHC and a mutated KHC which was 
devoid of the 340 amino acid motor domain. These proteins were co-expressed in 
E.coli cells and resulted in an increased level of mutated KHC protein of approximately 
five-fold when compared to the full length KHC (Hancock and Howard, 1998). Another 
example of successful co-expression was that of the myosin light and myosin heavy 
chain. This co-expression in bacterial cells resulted in a purified co-complex consisting 
of a stoichiometric relationship between the heavy and light chain (McNally et al., 
1988).  
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In this Chapter, the aim is to determine the structure of the kinesin-1 C-terminal 
domain. The method that will be employed is that of simultaneous co-expression of 
the TRAK2 and KIF5A protein fragments using a single bacterial expression vector. The 
pETDUET1 vector was selected because it has several advantages over other cloning 
vectors. It has two multiple cloning sites (MCS) to allow both the TRAK2 and KIF5A 
protein fragments to be expressed under the same promoter and also has the DNA 
encoding a His-tag in MCS1 and an S-protein recombinant tag in MCS2. These 
recombinant tags will help to make extraction of protein more efficient at later stages 
of the project. As well as co-expressing the KIF5A and TRAK2 protein fragments 
together each binding region will also be expressed as a single protein. This will allow 
the efficiency of the expression and stability of soluble KIF5A cargo binding domain 
protein to be compared with and without the presence of its natural binding partner 
TRAK2.  
 
3.1.1 Aims of this chapter 
I. Generate pETDUET1 bacterial expression constructs of the known interacting 
domains of TRAK2 and KIF5A, the in vivo partner of TRAK2 in the brain i.e. 
TRAK2100-380 and KIF5A800-1032. 
II. Verify correct TRAK2100-380 and KIF5A800-1032 production after transformation 
and induction of pETDUET1 constructs in bacterial cells. 
III. Optimise the growth and solubilisation conditions needed to maximise soluble 
TRAK2100-380 and KIF5A800-1032 protein expression.  
IV. Purify the TRAK2100-380/KIF5A800-1032 protein co-complex via affinity 
chromatography.   
V. Resolve the three dimensional structure of the TRAK2100-380/KIF5A800-1032 
protein co-complex.  
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3.2 RESULTS 
As discussed in Section 1.3 and Section 3.1, TRAK2 is known to interact with kinesin-1 
via amino acids 124-283 (Brickley et al., 2005). So to incorporate this binding region as 
well as the predicted coiled-coil domain (Figure 1.8), the DNA encoding amino acids 
100-380 of TRAK2 were cloned into MCS1 of the bacterial expression vector 
pETDUET1. MCS1 consists of DNA encoding an N-terminal His-tag. To accomplish this 
oligonucleotide primers specific to amplify the DNA encoding TRAK2100-380 were 
designed and used to create the pETDUETTRAK2100-380 construct. The vector map for 
pETDUET1 is shown in Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
All previous work that demonstrated that the kinesin-1 cargo binding domain is 
responsible for binding to TRAK2 was carried out using KIF5C (Smith et al., 2006; 
Brickley et al., 2011; Brickley and Stephenson, 2011). It was shown that the amino 
acids KIF5C 827-957 mediate association with TRAK2. However, in the brain, TRAK2 
associates predominantly with the KIF5A (Brickley et al., 2005). Thus KIF5A was used in 
this study since it most closely mimicked the in vivo situation. An amino acid 
comparison was carried out between KIF5A and KIF5C. The TRAK2 binding region of 
amino acids KIF5C 827-957 showed a high degree of similarity to KIF5A with an amino 
acid sequence identity of 84 % and amino acid similarity of 91 %. This was deemed 
high enough to warrant using KIF5A and still be confident of sufficient interaction. The 
amino acid alignment of KIF5A and KIF5C is shown in Figure 3.2. KIF5A also has a longer 
C-terminus than that of KIF5C as KIF5A is 1032 amino acids in length as opposed to the 
Figure 3.1 Vector map of pETDUET1.  
To facilitate replication in E.coli cells the cloning 
vector has an ampicillin resistance marker and an 
origin of replication. The transcription of protein is 
induced by that of a T7 polymerase in turn controlled 
by a lac operon which induces protein expression in 
both MSC1 and MCS2. MCS1 has DNA encoding an N-
terminal His-tag. MCS2 has DNA encoding a C-terminal 
S-tag. 
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957 amino acids of KIF5C. So to ensure that the entire TRAK2 binding domain was 
included it was decided to clone the DNA encoding KIF5A 800-1032. To accomplish this 
oligonucleotide primers specific to amplify the DNA encoding KIF5A800-1032 were 
designed and used to create the pETDUETKIF5A800-1032 construct. The DNA encoding 
amino acids KIF5A 800-1032 was cloned into MCS2 of the bacterial expression vector 
pETDUET1, of which MCS2 consists of DNA encoding a C-terminal S-tag.  
    
KIF5A    1 MAETNNECSIKVLCRFRPLNQAEILRGDKFIPIFQGDDSVVIG-GKPYVFDRVFPPNTTQ 
KIF5C    1 -MADPAECSIKVMCRFRPLNEAEILRGDKFIPKFKGDETVVIGQGKPYVFDRVLPPNTTQ 
 
KIF5A   60 EQVYHACAMQIVKDVLAGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIARDIFNH 
KIF5C   60 EQVYNACAKQIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIAHDIFDH 
 
KIF5A  120 IYSMDENLEFHIKVSYFEIYLDKIRDLLDVTKTNLSVHEDKNRVPFVKGCTERFVSSPEE 
KIF5C  120 IYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLAVHEDKNRVPYVKGCTERFVSSPEE 
 
KIF5A  180 ILDVIDEGKSNRHVAVTNMNEHSSRSHSIFLINIKQENMETEQKLSGKLYLVDLAGSEKV 
KiF5C  180 VMDVIDEGKANRHVAVTNMNEHSSRSHSIFLINIKQENVETEKKLSGKLYLVDLAGSEKV 
 
KIF5A  240 SKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKSYVPYRDSKMTRILQDSLGGNCRTT 
KIF5C  240 SKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKTHVPYRDSKMTRILQDSLGGNCRTT 
 
KIF5A  300 MFICCSPSSYNDAETKSTLMFGQRAKTIKNTASVNLELTAEQWKKKYEKEKEKTKAQKET 
KIF5C  300 IVICCSPSVFNEAETKSTLMFGQRAKTIKNTVSVNLELTAEEWKKKYEKEKEKNKTLKNV 
 
KIF5A  360 IAKLEAELSRWRNGENVPETERLAGEEAALGAELCEETPVNDNSSIVVRIAPEERQKYEE 
KIF5C  360 IQHLEMELNRWRNGEAVPEDEQISAKDQKNLEPCDNTPIIDNIAPVVAGISTEEKEKYDE 
 
KIF5A  420 EIRRLYKQLDDKDDEINQQSQLIEKLKQQMLDQEELLVSTRGDNEKVQRELSHLQSENDA 
KIF5C  420 EISSLYRQLDDKDDEINQQSQLAEKLKQQMLDQDELLASTRRDYEKIQEELTRLQIENEA 
 
KIF5A  480 AKDEVKEVLQALEELAVNYDQKSQEVEEKSQQNQLLVDELSQKVATMLSLESELQRLQEV 
KIF5C  480 AKDEVKEVLQALEELAVNYDQKSQEVEDKTRANEQLTDELAQKTTTLTTTQRELSQLQEL 
 
KIF5A  540 SGHQRKRIAEVLNGLMKDLSEFSVIVGNGEIKLPVEISGAIEEEFTVARLYISKIKSEVK 
KIF5C  540 SNHQKKRATEILNLLLKDLGEIGGIIGTNDVKTLADVNGVIEEEFTMARLYISKMKSEVK 
 
KIF5A  600 SVVKRCRQLENLQVECHRKMEVTGRELSSCQLLISQHEAKIRSLTEYMQSVELKKRHLEE 
KIF5C  600 SLVNRSKQLESAQMDSNRKMNASERELAACQLLISQHEAKIKSLTDYMQNMEQKRRQLEE 
 
KIF5A  660 SYDSLSDELAKLQAQETVHEVALKDKEP----DTQDADEVKKALELQMESHREAHHRQLA 
KIF5C  660 SQDSLSEELAKLRAQEKMHEVSFQDKEKEHLTRLQDAEEMKKALEQQMESHREAHQKQLS 
 
KIF5A  716 RLRDEINEKQKTIDELKDLNQKLQLELEKLQADYEKLKSEEHEKSTKLQELTFLYERHEQ 
KIF5C  720 RLRDEIEEKQKIIDEIRDLNQKLQLEQEKLSSDYNKLKIEDQEREMKLEKLLLLNDKREQ 
 
KIF5A  776 SKQDLKGLEETVARELQTLHNLRKLFVQDVTTRVKKSAEMEPEDSGGIHSQKQKISFLEN 
KIF5C  780 AREDLKGLEETVSRELQTLHNLRKLFVQDLTTRVKKSVELDNDDGGGSAAQKQKISFLEN 
 
KIF5A  836 NLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAKEGAMKDKRRYQQ 
KIF5C  840 NLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALESALKEAKENAMRDRKRYQQ 
 
KIF5A  896 EVDRIKEAVRYKSSGKRGHSAQIAKPVRPGHYPASSPTNPYGTRSPECISYTNSLFQNYQ 
KIF5C  900 EVDRIKEAVRAKNMARRAHSAQIAKPIRPGHYPASSPTAVHAIRGGGGSSSNSTHYQK-- 
 
KIF5A  956 NLYLQATPSSTSDMYFANSCTSSGATSSGGPLASYQKANMDNGNATDINDNRSDLPCGYE 
KIF5C      ------------------------------------------------------------ 
 
     KIF5A  1016 AEDQAKLFPLHQETAAS 
     KIF5C       ----------------- 
 
Figure 3.2 The full amino acid sequence alignment of human KIF5A and KIF5C.  
Sequences were aligned using ClustalW. They share an overall 75 % amino acid identity and 87 % amino 
acid similarity. The amino acids highlighted in black are those that are identical while those in grey are 
similar. The known sequence of the TRAK2 binding domain is highlighted with the red boxes. 
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In order to express recombinant TRAK2100-380 and KIF5A800-1032 in a bacterial expression 
system the constructs pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and 
pETDUETTRAK2100-380/KIF5A800-1032 were generated. In this chapter the cloning method 
of the recombinant TRAK2100-380 and KIF5A800-1032 clones are described in detail but 
later chapters will follow the same method presented here. These recombinant 
constructs were subsequently expressed in BL21 E.coli cells and the expressed soluble 
protein assessed and optimised to increase the yield (Section 2.2.3.1). Soluble protein 
was then purified using recombinant tag specific affinity chromatography to isolate the 
proteins of interest (Section 2.2.4).       
 
3.2.1 Oligonucleotide primer design for the amplification of rat TRAK2100-380 
The nucleotide and amino acid sequence of rat TRAK2 was obtained from the National 
Centre for Biotechnology Information (NCBI) website (TRAK2 accession number: 
AJ288898, species: Rattus norvegicus, Table 2.5). The full amino acid and nucleotide 
sequence of TRAK2 with the sequence encoding TRAK2100-380 to be cloned is 
highlighted in Figure 3.3. The nucleotide sequence 298-1140 of TRAK2 which 
corresponds to amino acids 100-380 was used to check which restriction enzymes sites 
could be utilised to ensure directional cloning into pETDUET1. Restriction enzyme 
cutting sites were evaluated using software on the bioinformatics website 
www.justbio.com. Thus, enzymes EcoRl and Hindlll were chosen because they did not 
cut the TRAK2100-380 DNA sequence and were present in MCS1 of the pETDUET1 vector.  
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 1 - ATGAGTCTGTCCCAGAATGCCATTTTCAAGTCACAAACAGGTGAAGAAAACCTCATGAGT - 60 
 1 -  M  S  L  S  Q  N  A  I  F  K  S  Q  T  G  E  E  N  L  M  S  - 20 
 61 - AGCAACCATAGAGACTCGGAGAGCATCACTGATGTCTGCTCCAATGAGGATCTCCCTGAG - 120 
21 -   S  N  H  R  D  S  E  S  I  T  D  V  C  S  N  E  D  L  P  E - 40 
121 - GTCGAGCTGGTCAACTTGCTGGAAGAGCAGCTGCCACAGTATAAGCTAAGAGTGGACTCT - 180 
41 -  V  E  L  V  N  L  L  E  E  Q  L  P  Q  Y  K  L  R  V  D  S  - 60 
181 - CTCTTTCTCTACGAAAACCAAGACTGGTCCCAGTCATCACACCAGCAGCAGGATGCATCT - 240 
61 -  L  F  L  Y  E  N  Q  D  W  S  Q  S  S  H  Q  Q  Q  D  A  S  - 80 
241 - GAGACCCTCTCTCCAGTCCTGGCTGAGGAGACCTTCCGCTACATGATTCTAGGCACAGAC - 300 
 81 -  E  T  L  S  P  V  L  A  E  E  T  F  R  Y  M  I  L  G  T  D  - 100 
301 - AGAGTAGAGCAGATGACCAAAACCTACAATGACATTGACATGGTCACGCATCTCCTGGCA - 360 
101 -  R  V  E  Q  M  T  K  T  Y  N  D  I  D  M  V  T  H  L  L  A  - 120 
361 - GAGAGGGACCGAGATCTAGAGCTGGCTGCTCGGATTGGGCAAGCCCTGCTAAAGCGGAAC - 420 
121 -  E  R  D  R  D  L  E  L  A  A  R  I  G  Q  A  L  L  K  R  N  - 140 
421 - CATGTCTTATCTGAGCAGAATGAATCTCTGGAGGAGCAGCTGGGACAAGCCTTTGATCAA - 480 
141 -  H  V  L  S  E  Q  N  E  S  L  E  E  Q  L  G  Q  A  F  D  Q  - 160 
481 - GTCAATCAGCTGCAGCACGAGCTGTCCAAGAAAGAGGAGCTGCTCCGAATCGTCTCCATC - 540 
161 -  V  N  Q  L  Q  H  E  L  S  K  K  E  E  L  L  R  I  V  S  I  - 180 
541 - GCCTCAGAGGAGAGTGAGACGGATTCCAGCTGTTCCACACCCCTCCGGTTCAATGAGTCC - 600 
181 -  A  S  E  E  S  E  T  D  S  S  C  S  T  P  L  R  F  N  E  S  - 200 
601 - TTCAGCTTATCTCAAGGCCTGCTGCAGCTGGACATGATGCACGAGAAGCTCAAGGAGCTG - 660 
201 -  F  S  L  S  Q  G  L  L  Q  L  D  M  M  H  E  K  L  K  E  L  - 220 
661 - GAAGAAGAGAACATGGCCCTTCGGTCCAAGGCTTGTCACATCAAGACAGAAACATTTACC - 720 
221 -  E  E  E  N  M  A  L  R  S  K  A  C  H  I  K  T  E  T  F  T  - 240 
721 - TATGAAGAGAAGGAACAAAAGCTCATCAATGACTGTGTTAATGAACTCCGTGAGACCAAT - 780 
241 -  Y  E  E  K  E  Q  K  L  I  N  D  C  V  N  E  L  R  E  T  N  - 260 
781 - GCACAGATGTCCAGAATGACTGAAGAGCTGTCGGGAAAGAGCGATGAGCTGCTTCGGTAC - 840 
261 -  A  Q  M  S  R  M  T  E  E  L  S  G  K  S  D  E  L  L  R  Y  - 280 
841 - CAAGAAGAGATCTCTTCCCTGCTGTCTCAGATCGTAGACCTTCAGCACAAACTGAAAGAA - 900 
281 -  Q  E  E  I  S  S  L  L  S  Q  I  V  D  L  Q  H  K  L  K  E  - 300 
901 - CATGTGATCGAGAAGGAAGAACTGAGACTTCACCTGCAGGCGTCCAAAGATGCCCAGCGA - 960 
301 -  H  V  I  E  K  E  E  L  R  L  H  L  Q  A  S  K  D  A  Q  R  - 320 
 961 - CAGCTGACGATGGAGCTTCACGAGTTACAGGACAGAAACATGGAGTGCCTGGGAATGTTA - 1020 
321 -  Q  L  T  M  E  L  H  E  L  Q  D  R  N  M  E  C  L  G  M  L  - 340 
1021 - CATGAGTCTCAAGAAGAAATAAAAGAGCTTCGGAACAAAGCCGGCCCTTCCGCTCATCTC - 1080 
341 -  H  E  S  Q  E  E  I  K  E  L  R  N  K  A  G  P  S  A  H  L  - 360 
1081 - TGCTTCTCCCAGGCTTACGGGGTTTTTGCAGGGGAGTCACTGGCAGCTGAGATTGAAGGG - 1140 
361 -  C  F  S  Q  A  Y  G  V  F  A  G  E  S  L  A  A  E  I  E  G  - 380 
1141 - ACCATGCGTAAAAAGCTGAGTTTGGATGAGGAATCTGTCTTTAAACAAAAGGCCCAGCAA - 1200 
381 -  T  M  R  K  K  L  S  L  D  E  E  S  V  F  K  Q  K  A  Q  Q  - 400 
1201 - AAACGGGTGTTTGATACTGTCAAGGTTGCCAACGACACACGGGGCCGCTCTGTCACATTC - 1260 
401 -  K  R  V  F  D  T  V  K  V  A  N  D  T  R  G  R  S  V  T  F  - 420 
1261 - CCAGTCCTGCTGCCCATCCCAGGCTCCAACCGTTCAAGTGTCATCATGACAGCAAAGCCC - 1320 
421 -  P  V  L  L  P  I  P  G  S  N  R  S  S  V  I  M  T  A  K  P  - 440 
1321 - TTTGAGTCCGGTGTTCAGCAAACAGAGGACAAAACACTCCCGAACCAAGGGAGCAGCACA - 1380 
441 -  F  E  S  G  V  Q  Q  T  E  D  K  T  L  P  N  Q  G  S  S  T  - 460 
1381 - GAGGTTCCAGGGAACTCTCATCCCAGGGACCCCCCAGGACTCCCTGAAGATAGTGACCTG - 1440 
461 -  E  V  P  G  N  S  H  P  R  D  P  P  G  L  P  E  D  S  D  L  - 480 
1441 - GCTACAGCATTGCATCGCCTTAGCCTGAGAAGACAGAACTACCTAAGTGAGAAGCAGTTC - 1500 
481 -  A  T  A  L  H  R  L  S  L  R  R  Q  N  Y  L  S  E  K  Q  F  - 500 
1501 - TTCGCTGAAGAATGGGAACGGAAGCTCCAGATTCTGGCTGAGCAGGAGGAAGAAGTTAGC - 1560 
501 -  F  A  E  E  W  E  R  K  L  Q  I  L  A  E  Q  E  E  E  V  S  - 520 
1561 - AGCTGTGAGGCCCTCACGGAGAACCTTGCCTCATTCTGCACTGACCAGTCAGAGACCACG - 1620 
521 -  S  C  E  A  L  T  E  N  L  A  S  F  C  T  D  Q  S  E  T  T  - 540 
1621 - GAGCTCGGCAGTGCCGGCTGCCTTCGAGGCTTCATGCCAGAAAAGTTACAGATTGTCAAG - 1680 
541 -  E  L  G  S  A  G  C  L  R  G  F  M  P  E  K  L  Q  I  V  K  - 560 
1681 - CCCCTAGAAGGATCACAGACGCTACATCATTGGCAGCAGCTTGCTCAACCAAACTTGGGA - 1740 
561 -  P  L  E  G  S  Q  T  L  H  H  W  Q  Q  L  A  Q  P  N  L  G  - 580 
1741 - ACCATCCTTGATCCACGCCCAGGCGTCATCACTAAAGGCTTCACGCAGATGCCCAAGGAT - 1800 
581 -  T  I  L  D  P  R  P  G  V  I  T  K  G  F  T  Q  M  P  K  D  - 600 
1801 - GCCGTCTATCACATCTCGGATTTGGAGGAGGATGAAGAAGTGGGGATCACTTTTCAGGTT - 1860 
601 -  A  V  Y  H  I  S  D  L  E  E  D  E  E  V  G  I  T  F  Q  V  - 620 
1861 - CAGCAGCCTCTTCAACTGGAGCAGAAGCCTGCACCACCCCCGCCAGTAACGGGTATCTTC - 1920 
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621 -  Q  Q  P  L  Q  L  E  Q  K  P  A  P  P  P  P  V  T  G  I  F  - 640 
1921 - CTGCCGCCCATGACCTCAGCAGGGGGACCAGTCTCAGTTGCAACTTCGAACCCAGGAAAG - 1980 
641 -  L  P  P  M  T  S  A  G  G  P  V  S  V  A  T  S  N  P  G  K  - 660 
1981 - TGTCTCTCATTCACGAACTCAACATTCACCTTCACCACCTGCAGGATCTTACACCCCTCT - 2040 
661 -  C  L  S  F  T  N  S  T  F  T  F  T  T  C  R  I  L  H  P  S  - 680 
2041 - GACATCACTCAGGTCACCCCTAGCTCTGGTTTCCCATCACTGTCCTGTGGAAGCAGTGCG - 2100 
681 -  D  I  T  Q  V  T  P  S  S  G  F  P  S  L  S  C  G  S  S  A  - 700 
2101 - GGCAGTGCATCCAACACGGCTGTGAACTCTCCTGCTGCGTCCTACAGACTGAGCATTGGT - 2160 
701 -  G  S  A  S  N  T  A  V  N  S  P  A  A  S  Y  R  L  S  I  G  - 720 
2161 - GAATCCATCACAAACCGGCGCGACTCCACCATAACGTTCAGTAGCACGAGGAGCTTAGCC - 2220 
721 -  E  S  I  T  N  R  R  D  S  T  I  T  F  S  S  T  R  S  L  A  - 740 
2221 - AAACTCCTGCAGGAGCGAGGCATCTCCGCCAAAGTGTACCACAGCCCAGCTTCAGAAAAC - 2280 
741 -  K  L  L  Q  E  R  G  I  S  A  K  V  Y  H  S  P  A  S  E  N  - 760 
2281 - CCCCTTCTACAGCTTCGCCCCAAGGCCCTGGCCACCCCTTCCACACCACCAAATTCCCCG - 2340 
761 -  P  L  L  Q  L  R  P  K  A  L  A  T  P  S  T  P  P  N  S  P  - 780 
2341 - TCGCAGTCACCATGTTCCTCCCCCGTGCCCTTTGAACCCCGTGTCCATGTCTCCGAGAAT - 2400 
781 -  S  Q  S  P  C  S  S  P  V  P  F  E  P  R  V  H  V  S  E  N  - 800 
2401 - TTCTTGGCTTCCAGACCAGCTGAAACATTCCTGCAAGAAATGTATGGCTTGAGACCTTCA - 2460 
801 -  F  L  A  S  R  P  A  E  T  F  L  Q  E  M  Y  G  L  R  P  S  - 820 
2461 - AGGGCCCCTCCTGATGTTGGCCAGCTGAAGATGAACTTGGTGGACAGGCTGAAGAGGCTG - 2520 
821 -  R  A  P  P  D  V  G  Q  L  K  M  N  L  V  D  R  L  K  R  L  - 840 
2521 - GGAATAGCCAGGGTGGTCAAGACCCCTGTTCCCCGGGAGAATGGGAAAAGCCGAGAGGCA - 2580 
841 -  G  I  A  R  V  V  K  T  P  V  P  R  E  N  G  K  S  R  E  A  - 860 
2581 - GAAATGGGTCTTCAAAAACCAGACTCTGCTGTCTATTTAAATTCTGGTGGCAGTTTATTG - 2640 
861 -  E  M  G  L  Q  K  P  D  S  A  V  Y  L  N  S  G  G  S  L  L  - 880 
2641 - GGTGGACTGAGGAGGAATCAGAGTCTCCCAGTCATGATGGGTAGCTTTGGAGCCCCAGTT - 2700 
881 -  G  G  L  R  R  N  Q  S  L  P  V  M  M  G  S  F  G  A  P  V  - 900 
2701 - TGCACAACCTCGCCCAAAATGGGTATCCTGAAGGAAGACTGA                   - 2742 
901 -  C  T  T  S  P  K  M  G  I  L  K  E  D                       - 920 
 
Figure 3.3 Full nucleotide and amino acid sequence of rat TRAK2.  
The kinesin-1 binding site of TRAK2 is highlighted in blue. The sequences to which the oligonucleotide 
primers for generation of TRAK2100-380 were designed are highlighted in yellow. The nucleotide sequence 
to be cloned is TRAK2 298-1140 (842 base pairs [bp]) encoding for the amino acid sequence TRAK2 100-
380 (280).  
 
 
Forward oligonucleotide primer design: 
In order to design the forward oligonucleotide primer 18 bases were selected at the 
start of the desired sequence and the first enzyme cutting region was inserted (EcoRl). 
5’ GAA TTC GAC AGA GTA GAG CAG ATG 3’ 
Four adenine nucleotides were inserted in the start of the sequence to help with the 
binding of the restriction enzymes.  
5’ AAAA GAA TTC GAC AGA GTA GAG CAG ATG 3’ 
This sequence was checked to ensure that if inserted into the vector it would be 
transcribed in the correct reading frame.  
Current reading frame:   CCG AAT TCG ACA GAG TAG AGC AGA TG 
                             Thr Glu stop    
Desired reading frame:               GAC AGA GTA GAG CAG ATG 
                             Asp Arg Val Glu Gln Met     
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This sequence would not transcribe in the correct reading frame so an extra base was 
added to the start of the sequence. In this case the nucleotide adenine was added so 
that the translated amino acid will remain a serine. The inserted nucleotide sequence 
will now read in the correct reading frame. 
5’ AAAA G AAT TCA GAC AGA GTA GAG CAG ATG 3’ 
Reverse oligonucleotide primer design: 
In order to design the reverse oligonucleotide primer a similar method to that of the 
forward oligonucleotide primer design was employed but with the reverse and 
complementary base pair sequence.  
            original: 5’ GCA GCT GAG ATT GAA GGG 3’ 
complementary bases: 3’ CGT CGA CTC TAA CTT CCC 5’ 
                      reversed:  5’ CCC TTC AAT CTC AGC TGC 3’ 
A stop codon was added to the end of the sequence. In this case TAG (also the reverse 
and complementary base pair sequence). This is because the His-tag will be located at 
the N-terminus of the expressed TRAK2 protein fragment and the stop codon will 
prevent the C-terminus possessing unnecessary amino acids. 
5’ CTA CCC TTC AAT CTC AGC TGC 3’ 
The enzyme binding domain Hindlll was added (not the reverse complementary 
nucleotide sequence).  
5’ AAG CTT CTA CCC TTC AAT CTC AGC TGC 3’ 
Four adenine nucleotides were inserted at the start of the sequence to help with the 
binding of the restriction enzymes. Two bases at the 3’ end were removed to ensure it 
is fewer than 30 bases in length as this will help increase the efficiency in production of 
the oligonucleotide primer. 
5’ AAAA AAG CTT CTA CCC TTC AAT CTC AGC T 3’ 
The GC content and Tm of each of the primers was calculated (Section 2.2.2.3) and 
deemed to be within the set parameters. 
Forward primer GC content = 47 % 
Reverse primer GC content = 50 % 
Forward primer Tm = 56oC 
Reverse primer Tm = 60oC 
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3.2.1.1 Preparation of the pETDUETTRAK2100-380 construct 
The DNA encoding TRAK2100-380 was amplified from pCISTRAK2 using the primers 
designed in Section 3.2.1 and the PCR reaction conditions stated in Section 2.2.2.3.1. 
The resulting PCR product was analysed by 1 % (w/v) flat bed agarose gel (Section 
2.2.2.4) and the results of the PCR amplification are shown in Figure 3.4.  
 
 
 
 
 
 
 
 
Figure 3.4 Flat bed agarose gel electrophoresis analysis of TRAK2100-380 nucleotide amplification by 
PCR.  
Lane 1 = kb DNA standards. Lane 2 = control PCR reaction; i.e. no pCISTRAK2 template DNA. Lane 3 = 
PCR reaction. The band of interest is highlighted on the right by an arrow. 
 
A band of the correct predicted size of ~ 840 bp for the TRAK2100-380 nucleotide 
sequence was present in the reaction lane but not in the control lane. Following 
correct PCR amplification both the DNA encoding TRAK2100-380 and the pETDUET1 
vector were restriction enzyme digested to create “sticky ends” using the restriction 
enzymes EcoRl and Hindlll (Section 2.2.2.6). The restriction enzyme digested vector 
sample was subsequently dephosphorylated to prevent digested vectors from 
annealing to one another (Section 2.2.2.8). The restriction enzyme digested TRAK2100-
380 nucleotide sequence was subsequently ligated into MCS1 of the pETDUET1 vector 
using T4 DNA ligase. The ligation reactions were carried out using vector:insert ratios 
of 1:1 and 1:3 (Section 2.2.2.9). The resulting ligation reactions were transformed into 
DH5α E.coli cells (Section 2.2.1.2). The results of the ligation reactions are summarised 
in Table 3.1.  
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Plate 
number 
Restriciton enzyme 
digested and 
dephosphorylated 
vector 
Restriction 
enzyme 
digested 
insert 
T4 DNA ligase 
Number of 
DH5α E.coli 
colonies after 
transformation 
1 
pETDUET1 
1 μl 
DNA encoding 
TRAK2100-380 
1 μl 
 120 
2 
pETDUET1 
1 μl 
DNA encoding 
TRAK2100-380 
3 μl 
 148 
3 
pETDUET1 
1 μl 
DNA encoding 
TRAK2100-380 
1 μl 
 1 
4 
pETDUET1 
1 μl 
-  0 
5 
pETDUET1 
1 μl 
-  18 
Negative 
control 
(ddH2O) 
- -  0 
Positive  
control  
(pETDUET1) 
- -  1,000+ 
Table 3.1 Summary table of the ligation reactions used to create pETDUETTRAK2100-380.  
 
Plate numbers one and two were the test plates and these showed the numbers of 
colonies to be 120 and 148 respectively. Plate numbers three, four and five were 
controls used to check the efficiency of both the restriction enzyme digestion and the 
dephosphorylation of the plasmid vector. The three control plates showed low colony 
numbers, which when compared to the high colony numbers seen in plates one and 
two indicated a successful ligation experiment. Of the resulting colonies four were 
selected from plate number two. These colonies were grown overnight in 5 ml of LB 
media and a mini preparation of plasmid DNA carried out (Section 2.2.2.11). Plasmid 
DNA samples were restriction enzyme digested with EcoRl and Hindlll and analysed 
using 1 % agarose gel electrophoresis to check for the presence of the TRAK2100-380 
nucleotide sequence. The results of the restriction enzyme digestion are shown in 
Figure 3.5.    
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Figure 3.5 Analysis of putative pETTRAK2100-380 constructs by 1 % (w/v) flat bed agarose gel 
electrophoresis.  
The four potential pETDUETTRAK2100-380 clones are lettered A, B, C and D. Lanes numbered 1 = non-
restriction enzyme digested controls. Lanes numbered 2 = EcoRI and HindIII restriction enzyme digested 
samples. Lane 3 = kb DNA standards. The bands of interest highlighted on the left by an arrow. 
   
 
All four samples show a band of ~ 840 bp in length indicating a successful ligation of 
TRAK2100-380 nucleotide sequence into pETDUET1. The DNA corresponding to lanes C2 
and D2 was precipitated (Section 2.2.2.13) and sequenced by MWG-Biotech 
(Ebersberg, Germany) to confirm the correct insertion of the TRAK2100-380 DNA 
sequence. The entire DNA sequence of the TRAK2100-380 insert was sequenced and an 
example of the results from the sequencing reaction is shown in Figure 3.6. 
 
 
 
 
 
 
 
Figure 3.6 Nucleotide sequencing results of the pETDUETTRAK2100-380 clone.  
The first restriction enzyme site of EcoRI is underlined in blue and the sequence of the TRAK2100-380 DNA 
insert is underlined in black. 
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Sequencing results showed the correct ligation of the TRAK2100-380 nucleotide sequence 
into the pETDUET1 vector. The nucleotide sequence is in the correct reading frame 
with no mutations present. The pETDUETTRAK2100-380 plasmid vector was subsequently 
transformed into DH5α E.coli cells and a maxi-preparation of the resulting DNA carried 
out (Section 2.2.2.12). The purified pETDUETTRAK2100-380 clone was stored as 100 µl 
aliquots at -20°C until further use. 
 
3.2.2 Oligonucleotide primer design for the amplification of human KIF5A800-1032 
The nucleotide and amino acid sequence of KIF5A was obtained from the NCBI website 
(KIF5A accession number: HSU06698, species: Homo sapiens, Table 2.5). The full amino 
acid and nucleotide sequence of KIF5A with the sequence encoding KIF5A800-1032 to be 
cloned is highlighted in Figure 3.7. The nucleotide sequence 2398-3097 of KIF5A which 
corresponds to amino acids 800-1032 was used to check which restriction enzyme sites 
could be utilised to ensure directional cloning into the pETDUET1 vector. Restriction 
enzyme cutting sites were evaluated using software on the bioinformatics website 
www.justbio.com. Thus, enzymes MunI and FseI were chosen because they did not cut 
the KIF5A800-1032 sequence and were present in MCS2 of the pETDUET1 vector.  
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 1 - ATGGCGGAAACCAACAACGAATGCAGCATTAAAGTGCTGTGCCGCTTTCGCCCGCTGAAC - 60 
 1 -  M  A  E  T  N  N  E  C  S  I  K  V  L  C  R  F  R  P  L  N  - 20 
 61 - CAGGCGGAAATTCTGCGCGGCGATAAATTTATTCCGATTTTTCAGGGCGATGATAGCGTG - 120 
21 -  Q  A  E  I  L  R  G  D  K  F  I  P  I  F  Q  G  D  D  S  V  - 40 
121 - GTGATTGGCGGCAAACCGTATGTGTTTGATCGCGTGTTTCCGCCGAACACCACCCAGGAA - 180 
41 -  V  I  G  G  K  P  Y  V  F  D  R  V  F  P  P  N  T  T  Q  E  - 60 
181 - CAGGTGTATCATGCGTGCGCGATGCAGATTGTGAAAGATGTGCTGGCGGGCTATAACGGC - 240 
61 -  Q  V  Y  H  A  C  A  M  Q  I  V  K  D  V  L  A  G  Y  N  G  - 80 
241 - ACCATTTTTGCGTATGGCCAGACCAGCAGCGGCAAAACCCATACCATGGAAGGCAAACTG - 300 
 81 -  T  I  F  A  Y  G  Q  T  S  S  G  K  T  H  T  M  E  G  K  L  - 100 
301 - CATGATCCGCAGCTGATGGGCATTATTCCGCGCATTGCGCGCGATATTTTTAACCATATT - 360 
101 -  H  D  P  Q  L  M  G  I  I  P  R  I  A  R  D  I  F  N  H  I  - 120 
361 - TATAGCATGGATGAAAACCTGGAATTTCATATTAAAGTGAGCTATTTTGAAATTTATCTG - 420 
121 -  Y  S  M  D  E  N  L  E  F  H  I  K  V  S  Y  F  E  I  Y  L  - 140 
421 - GATAAAATTCGCGATCTGCTGGATGTGACCAAAACCAACCTGAGCGTGCATGAAGATAAA - 480 
141 -  D  K  I  R  D  L  L  D  V  T  K  T  N  L  S  V  H  E  D  K  - 160 
481 - AACCGCGTGCCGTTTGTGAAAGGCTGCACCGAACGCTTTGTGAGCAGCCCGGAAGAAATT - 540 
161 -  N  R  V  P  F  V  K  G  C  T  E  R  F  V  S  S  P  E  E  I  - 180 
541 - CTGGATGTGATTGATGAAGGCAAAAGCAACCGCCATGTGGCGGTGACCAACATGAACGAA - 600 
181 -  L  D  V  I  D  E  G  K  S  N  R  H  V  A  V  T  N  M  N  E  - 200 
601 - CATAGCAGCCGCAGCCATAGCATTTTTCTGATTAACATTAAACAGGAAAACATGGAAACC - 660 
201 -  H  S  S  R  S  H  S  I  F  L  I  N  I  K  Q  E  N  M  E  T  - 220 
661 - GAACAGAAACTGAGCGGCAAACTGTATCTGGTGGATCTGGCGGGCAGCGAAAAAGTGAGC - 720 
221 -  E  Q  K  L  S  G  K  L  Y  L  V  D  L  A  G  S  E  K  V  S  - 240 
721 - AAAACCGGCGCGGAAGGCGCGGTGCTGGATGAAGCGAAAAACATTAACAAAAGCCTGAGC - 780 
241 -  K  T  G  A  E  G  A  V  L  D  E  A  K  N  I  N  K  S  L  S  - 260 
781 - GCGCTGGGCAACGTGATTAGCGCGCTGGCGGAAGGCACCAAAAGCTATGTGCCGTATCGC - 840 
261 -  A  L  G  N  V  I  S  A  L  A  E  G  T  K  S  Y  V  P  Y  R  - 280 
841 - GATAGCAAAATGACCCGCATTCTGCAGGATAGCCTGGGCGGCAACTGCCGCACCACCATG - 900 
281 -  D  S  K  M  T  R  I  L  Q  D  S  L  G  G  N  C  R  T  T  M  - 300 
901 - TTTATTTGCTGCAGCCCGAGCAGCTATAACGATGCGGAAACCAAAAGCACCCTGATGTTT - 960 
301 -  F  I  C  C  S  P  S  S  Y  N  D  A  E  T  K  S  T  L  M  F  - 320 
 961 - GGCCAGCGCGCGAAAACCATTAAAAACACCGCGAGCGTGAACCTGGAACTGACCGCGGAA - 1020 
321 -  G  Q  R  A  K  T  I  K  N  T  A  S  V  N  L  E  L  T  A  E  - 340 
1021 - CAGTGGAAAAAAAAATATGAAAAAGAAAAAGAAAAAACCAAAGCGCAGAAAGAAACCATT - 1080 
341 -  Q  W  K  K  K  Y  E  K  E  K  E  K  T  K  A  Q  K  E  T  I  - 360 
1081 - GCGAAACTGGAAGCGGAACTGAGCCGCTGGCGCAACGGCGAAAACGTGCCGGAAACCGAA - 1140 
361 -  A  K  L  E  A  E  L  S  R  W  R  N  G  E  N  V  P  E  T  E  - 380 
1141 - CGCCTGGCGGGCGAAGAAGCGGCGCTGGGCGCGGAACTGTGCGAAGAAACCCCGGTGAAC - 1200 
381 -  R  L  A  G  E  E  A  A  L  G  A  E  L  C  E  E  T  P  V  N  - 400 
1201 - GATAACAGCAGCATTGTGGTGCGCATTGCGCCGGAAGAACGCCAGAAATATGAAGAAGAA - 1260 
401 -  D  N  S  S  I  V  V  R  I  A  P  E  E  R  Q  K  Y  E  E  E  - 420 
1261 - ATTCGCCGCCTGTATAAACAGCTGGATGATAAAGATGATGAAATTAACCAGCAGAGCCAG - 1320 
421 -  I  R  R  L  Y  K  Q  L  D  D  K  D  D  E  I  N  Q  Q  S  Q  - 440 
1321 - CTGATTGAAAAACTGAAACAGCAGATGCTGGATCAGGAAGAACTGCTGGTGAGCACCCGC - 1380 
441 -  L  I  E  K  L  K  Q  Q  M  L  D  Q  E  E  L  L  V  S  T  R  - 460 
1381 - GGCGATAACGAAAAAGTGCAGCGCGAACTGAGCCATCTGCAGAGCGAAAACGATGCGGCG - 1440 
461 -  G  D  N  E  K  V  Q  R  E  L  S  H  L  Q  S  E  N  D  A  A  - 480 
1441 - AAAGATGAAGTGAAAGAAGTGCTGCAGGCGCTGGAAGAACTGGCGGTGAACTATGATCAG - 1500 
481 -  K  D  E  V  K  E  V  L  Q  A  L  E  E  L  A  V  N  Y  D  Q  - 500 
1501 - AAAAGCCAGGAAGTGGAAGAAAAAAGCCAGCAGAACCAGCTGCTGGTGGATGAACTGAGC - 1560 
501 -  K  S  Q  E  V  E  E  K  S  Q  Q  N  Q  L  L  V  D  E  L  S  - 520 
1561 - CAGAAAGTGGCGACCATGCTGAGCCTGGAAAGCGAACTGCAGCGCCTGCAGGAAGTGAGC - 1620 
521 -  Q  K  V  A  T  M  L  S  L  E  S  E  L  Q  R  L  Q  E  V  S  - 540 
1621 - GGCCATCAGCGCAAACGCATTGCGGAAGTGCTGAACGGCCTGATGAAAGATCTGAGCGAA - 1680 
541 -  G  H  Q  R  K  R  I  A  E  V  L  N  G  L  M  K  D  L  S  E  - 560 
1681 - TTTAGCGTGATTGTGGGCAACGGCGAAATTAAACTGCCGGTGGAAATTAGCGGCGCGATT - 1740 
561 -  F  S  V  I  V  G  N  G  E  I  K  L  P  V  E  I  S  G  A  I  - 580 
1741 - GAAGAAGAATTTACCGTGGCGCGCCTGTATATTAGCAAAATTAAAAGCGAAGTGAAAAGC - 1800 
581 -  E  E  E  F  T  V  A  R  L  Y  I  S  K  I  K  S  E  V  K  S  - 600 
1801 - GTGGTGAAACGCTGCCGCCAGCTGGAAAACCTGCAGGTGGAATGCCATCGCAAAATGGAA - 1860 
601 -  V  V  K  R  C  R  Q  L  E  N  L  Q  V  E  C  H  R  K  M  E  - 620 
1861 - GTGACCGGCCGCGAACTGAGCAGCTGCCAGCTGCTGATTAGCCAGCATGAAGCGAAAATT - 1920 
621 -  V  T  G  R  E  L  S  S  C  Q  L  L  I  S  Q  H  E  A  K  I  - 640 
1921 - CGCAGCCTGACCGAATATATGCAGAGCGTGGAACTGAAAAAACGCCATCTGGAAGAAAGC - 1980 
641 -  R  S  L  T  E  Y  M  Q  S  V  E  L  K  K  R  H  L  E  E  S  - 660 
1981 - TATGATAGCCTGAGCGATGAACTGGCGAAACTGCAGGCGCAGGAAACCGTGCATGAAGTG - 2040 
661 -  Y  D  S  L  S  D  E  L  A  K  L  Q  A  Q  E  T  V  H  E  V  - 680 
2041 - GCGCTGAAAGATAAAGAACCGGATACCCAGGATGCGGATGAAGTGAAAAAAGCGCTGGAA - 2100 
681 -  A  L  K  D  K  E  P  D  T  Q  D  A  D  E  V  K  K  A  L  E  - 700 
2101 - CTGCAGATGGAAAGCCATCGCGAAGCGCATCATCGCCAGCTGGCGCGCCTGCGCGATGAA - 2160 
701 -  L  Q  M  E  S  H  R  E  A  H  H  R  Q  L  A  R  L  R  D  E  - 720 
2161 - ATTAACGAAAAACAGAAAACCATTGATGAACTGAAAGATCTGAACCAGAAACTGCAGCTG - 2220 
721 -  I  N  E  K  Q  K  T  I  D  E  L  K  D  L  N  Q  K  L  Q  L  - 740 
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2221 - GAACTGGAAAAACTGCAGGCGGATTATGAAAAACTGAAAAGCGAAGAACATGAAAAAAGC - 2280 
741 -  E  L  E  K  L  Q  A  D  Y  E  K  L  K  S  E  E  H  E  K  S  - 760 
2281 - ACCAAACTGCAGGAACTGACCTTTCTGTATGAACGCCATGAACAGAGCAAACAGGATCTG - 2340 
761 -  T  K  L  Q  E  L  T  F  L  Y  E  R  H  E  Q  S  K  Q  D  L  - 780 
2341 - AAGGGTCTGGAGGAGACAGTTGCCCGGGAACTCCAGACCCTCCACAACCTTCGCAAGCTG - 2400 
781 -  K  G  L  E  E  T  V  A  R  E  L  Q  T  L  H  N  L  R  K  L  - 800 
2401 - TTCGTTCAAGACGTCACGACTCGAGTCAAGAAAAGTGCAGAAATGGAGCCCGAAGACAGT - 2460 
801 -  F  V  Q  D  V  T  T  R  V  K  K  S  A  E  M  E  P  E  D  S  - 820 
2461 - GGGGGGATTCACTCCCAAAAGCAGAAGATTTCCTTTCTTGAGAACAACCTGGAACAGCTT - 2520 
821 -  G  G  I  H  S  Q  K  Q  K  I  S  F  L  E  N  N  L  E  Q  L  - 840 
2521 - ACAAAGGTTCACAAACAGCTGGTACGTGACAATGCAGATCTGCGTTGTGAGCTTCCTAAA - 2580 
841 -  T  K  V  H  K  Q  L  V  R  D  N  A  D  L  R  C  E  L  P  K  - 860 
2581 - TTGGAAAAACGACTTAGGGCTACGGCTGAGAGAGTTAAGGCCCTGGAGGGTGCACTGAAG - 2640 
861 -  L  E  K  R  L  R  A  T  A  E  R  V  K  A  L  E  G  A  L  K  - 880 
2641 - GAGGCCAAGGAGGGCGCCATGAAGGACAAGCGCCGGTACCAGCAGGAGGTGGACCGCATC - 2700 
881 -  E  A  K  E  G  A  M  K  D  K  R  R  Y  Q  Q  E  V  D  R  I  - 900 
2701 - AAGGAGGCCGTTCGCTACAAGAGCTCGGGCAAACGGGCGCATTCTGCCCAGATTGCCAAA - 2760 
901 -  K  E  A  V  R  Y  K  S  S  G  K  R  A  H  S  A  Q  I  A  K  - 920 
2761 - CCCGTCCGGCCTGGCCACTACCCAGCATCCTCACCCACCAACCCCTATGGCACCCGGAGC - 2820 
921 -  P  V  R  P  G  H  Y  P  A  S  S  P  T  N  P  Y  G  T  R  S  - 940 
2821 - CCTGAGTGCATCAGTTACACCAACAGCCTCTTCCAGAACTACCAGAATCTCTACCTGCAG - 2880 
941 -  P  E  C  I  S  Y  T  N  S  L  F  Q  N  Y  Q  N  L  Y  L  Q  - 960 
2881 - GCCACACCCAGCTCCACCTCAGATATGTACTTTGCAAACTCCTGTACCAGCAGTGGAGCC - 2940 
961 -  A  T  P  S  S  T  S  D  M  Y  F  A  N  S  C  T  S  S  G  A  - 980 
2941 - ACATCTTCTGGCGGCCCCTTGGCTTCCTACCAGAAGGCCAACATGGACAATGGAAATGCC - 3000 
 981 -  T  S  S  G  G  P  L  A  S  Y  Q  K  A  N  M  D  N  G  N  A  - 1000 
3001 - ACAGATATCAATGACAATAGGAGTGACCTGCCGTGTGGCTATGAGGCTGAGGACCAGGCC - 3060 
1001 -  T  D  I  N  D  N  R  S  D  L  P  C  G  Y  E  A  E  D  Q  A  - 1020 
       3061 - AAGCTTTTCCCTCTCCACCAAGAGACAGCAGCCAGC - 3097 
       1021 -  K  L  F  P  L  H  Q  E  T  A  A  S  - 1032  
Figure 3.7 The full nucleotide and amino acid sequence of human KIF5A.  
The predicted TRAK2 binding site of KIF5A is highlighted in blue. The sequences to which the 
oligonucleotide primers for generation of KIF5A800-1032 were designed are highlighted in yellow. The 
amino acid sequence to be cloned are KIF5A 800-1032 (232) and the nucleotide sequence KIF5A 2398-
3097 (696 bp). 
 
Forward oligonucleotide primer design: 
In order to design the forward oligonucleotide primer 18 bases were selected at the 
start of the desired sequence and the first enzyme cutting region was inserted (Munl). 
5’ CAA TTG CTG TTC GTT CAA GAC GTC 3’ 
Four adenine nucleotides were inserted in the start of the sequence to help with the 
binding of the restriction enzymes.  
5’ AAAA CAA TTG CTG TTC GTT CAA GAC GTC 3’ 
This sequence was checked to ensure that if inserted into the vector it would read in 
the correct frame.  
Current reading frame:   C AAT TGC TGT TCG TTC AAG ACG TC 
                           Cys Ser Phe Lys Thr    
Desired reading frame:             CTG TTC GTT CAA GAC GTC 
                           Leu Phe Val Gln Asp Val  
          
This sequence would not transcribe in the correct reading frame so an extra base was 
added to the start of the sequence. In this case the nucleotide guanine was added so 
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that the amino acid will remain a tryptophan. The inserted nucleotide sequence will 
read in the correct frame. 
5’ AAAA C AAT TGG CTG TTC GTT CAA GAC GTC 3’ 
Reverse oligonucleotide primer design: 
In order to design the reverse oligonucleotide primer a similar method to that of the 
forward oligonucleotide primer design was employed but with the reverse 
complementary base pair sequence.  
           original:   5’ CAA GAG ACA GCA GCC AGC 3’ 
complementary bases: 3’ GTT CTC TGT CGT CGG TCG 5’ 
                          reverse: 5’ GCT GGC TGC TGT CTC TTG 3’ 
The enzyme binding domain Fsel was added (not the reverse complementary 
nucleotide sequence).  
5’ GGCCGGCC GCT GGC TGC TGT CTC TTG 3’ 
Four adenine nucleotides were inserted at the start of the sequence to help with the 
binding of the restriction enzymes.  
5’ AAAA GGCCGGCC GCT GGC TGC TGT CTC TTG 3’ 
A guanine and a cytosine nucleotide were added to make alanine; this keeps the 
sequence in frame for the S-tag which occurs after the KIF5A800-1032 nucleotide 
sequence. Two bases at the 3’ end were removed to ensure it is fewer 30 bases in 
length as this will help increase the efficiency in production of the oligonucleotide 
primer. 
5’ AAAA G GCC GGC CGC GCT GGC TGC TGT CTC T 3’ 
 
The GC and Tm of each of the primers was calculated (Section 2.2.2.3) and deemed to 
be within the set parameters. 
 
Forward primer GC content = 53 % 
Reverse primer GC content = 67 % 
Forward primer Tm = 58°C 
Reverse primer Tm = 60°C 
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3.2.2.1 Preparation of the pETDUETKIF5A800-1032 construct 
The DNA encoding KIF5A800-1032 was amplified from pBSKIF5A using the primers 
designed in Section 3.2.2 and the PCR reaction conditions stated in Section 2.2.2.3.1. 
The resulting PCR product was analysed by a 1 % (w/v) flat bed agarose gel (Section 
2.2.2.4) and the results of the PCR amplification is shown in Figure 3.8. 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Flat bed agarose gel electrophoresis analysis of KIF5A800-1032 nucleotide amplification by 
PCR.  
Lane 1 = kb DNA standards. Lane 2 = KIF5A800-1032 PCR reaction. Lane 3 = control PCR reaction; i.e. no 
pBSKIF5A template DNA. The band of interest is highlighted on the right by an arrow. 
 
 
A band of the correct predicted size of ~ 700 bp for the KIF5A800-1032 nucleotide 
sequence was present in the reaction lane but not the control lane. This is as expected 
and demonstrates that the PCR amplification of the KIF5A80-1032 sequence was 
successful. Following correct PCR amplification both the KIF5A800-1032 nucleotide 
sequence and pETDUET1 vector were restriction enzyme digested to create “sticky 
ends” using the restriction enzymes FseI and MunI. Due to several failed attempts to 
ligate the KIF5A800-1032 nucleotide sequence into pETDUET1 the buffer conditions for 
the restriction enzyme digestions were optimised. This was achieved through a series 
of sequential and double digestions and also a variety of different buffer conditions. It 
was found that the optimal conditions for that of a successful digestion was a double 
digestion using two units of both Fsel and Munl and 1 × concentrated TangoTM 
restriction endonuclease buffer (of which none were the recommended conditions or 
buffers for the Fsel and Munl enzymes). The restriction enzyme digested KIF5A800-1032 
nucleotide sequence was subsequently ligated into MCS2 of the pETDUET1 vector 
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using T4 DNA ligase. The ligation reactions were carried out using vector:insert ratios 
of 1:4 and 1:7 as previously described in Section 2.2.2.9. The resulting ligation 
reactions were transformed into DH5α E.coli cells (Section 2.2.1.2). The results of the 
ligation reactions are summarised in Table 3.2.  
 
Plate 
number 
Restriciton enzyme 
digested and 
dephosphorylated 
vector 
Restriction 
enzyme 
digested 
insert 
T4 DNA ligase 
Number of 
DH5α E.coli 
colonies after 
transformation 
1 
pETDUET1 
1 μl 
KIF5A800-1032 
4 μl  0 
2 
pETDUET1 
1 μl 
KIF5A800-1032 
7 μl  7 
3 
pETDUET1 
1 μl 
KIF5A800-1032 
1 μl  0 
4 
pETDUET1 
1 μl 
-  0 
5 
pETDUET1 
1 μl 
-  0 
Negative 
control 
(ddH2O) 
- -  0 
Positive  
control  
(pETDUET1) 
- -  1,000+ 
Table 3.2 Summary table of the ligation reactions used to create pETDUETKIF5A800-1032. 
 
Plate numbers one and two were the test plates and these showed the numbers of 
colonies to be zero and seven respectively. Plate numbers three, four and five were 
controls used to check the efficiency of both the restriction enzyme digestion and the 
dephosphorylation of the plasmid vector. The three control plates showed no colony 
numbers, which when compared to the seven colony numbers seen in plate two 
indicated a successful ligation experiment. Of the resulting colonies all seven were 
selected from plate number two. These colonies were grown overnight in 5 ml of LB 
media and a mini preparation of plasmid DNA subsequently carried out (Section 
2.2.2.11). PCR screening (Section 2.2.2.10) was used to determine the presence of the 
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KIF5A800-1032 nucleotide insert due to the previous difficulties in obtaining efficient 
restriction enzyme digestion with FseI and MunI. PCR screening was carried out using 
the sequencing oligonucleotide primers designed to the MCS2 of the pETDUET1 vector. 
The sequencing oligonucleotide primers were used because previous PCR screens 
using the KIF5A800-1032 oligonucleotide primers had yielded false positive bands of ~ 700 
bp. This was found to be the result of a sequence similarity between these primers and 
the pETDUET1 vector sequence yielding a band of the same size. If positive for the 
KIF5A800-1032 nucleotide insert a band of ~ 900 bases in length would be produced. The 
results were then analysed using a 1 % (w/v) flat bed agarose gel. The results of the 
PCR screen are shown in Figure 3.9.    
 
   
 
 
 
 
Figure 3.9 Analysis of putative pETDUETKIF5A800-1032 constructs using a PCR screen by 1 % (w/v) flat 
bed agarose gel electrophoresis. 
Lane 1 contains the DNA standards in kb. Lane 2 shows the control PCR reaction; i.e. no pBSKIF5A 
template DNA. Lanes 3-9 show the ligated colonies tested for a successful KIF5A800-1032 nucleotide insert. 
Lane 10 shows the empty pETDUET1 vector control. The bands of interest are highlighted on the right by 
an arrow.  
 
Lanes 3-9 show a band of ~ 900 bases in length indicating a successful ligation of the 
KIF5A800-1032 nucleotide sequence into pETDUET1. The DNA corresponding to lane 
three was precipitated (Section 2.2.2.13) and sequenced by MWG-Biotech (Ebersberg, 
Germany) to confirm the correct insertion of the KIF5A800-1032 sequence. The entire 
DNA sequence of the KIF5A800-1032 insert was sequenced and an example of the results 
from the sequencing reaction is shown in Figure 3.10. 
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Figure 3.10 Nucleotide sequencing results of the pETDUETKIF5A800-1032 clone.  
The first restriction enzyme site of MunI is underlined in blue and the sequence of the KIF5A800-1032 insert 
DNA is underlined in black. 
 
 
Sequencing results show the correct ligation of the KIF5A800-1032 nucleotide sequence 
into the pETDUET1 vector. The nucleotide sequence is in the correct reading frame and 
has no mutations present. The pETDUETKIF5A800-1032 plasmid vector was subsequently 
transformed into DH5α E.coli cells and a maxi-preparation of the resulting DNA carried 
out (Section 2.2.2.12). The purified pETDUETKIF5A800-1032 clone was stored as 100 µl 
aliquots at -20°C until further use. 
 
3.2.3 Preparation of the pETDUETTRAK2100-380/KIF5A800-1032 construct  
Generation of pETDUETTRAK2100-380/KIF5A800-1032 involved inserting the DNA encoding 
for KIF5A800-1032 into MCS2 of pETDUETTRAK2100-380. The TRAK2100-380 DNA sequence 
was unable to be inserted into pETDUETKIF5A800-1032 due to the restriction enzymes 
EcoRl and Hindlll both digesting within the KIF5A800-1032 DNA sequence. Whereas the 
Fsel and Munl enzymes used for KIF5A800-1032 cloning did not digest anywhere in the 
TRAK2100-380 DNA sequence and so could be inserted into pETDUETTRAK2100-380. The 
KIF5A800-1032 DNA sequence was inserted into pETDUETTRAK2100-380 as in Section 
3.2.2.1. pETDUETTRAK2100-380/KIF5A800-1032 was precipitated (Section 2.2.2.13) and 
sequenced by MWG-Biotech (Ebersberg, Germany) to confirm the correct insertion of 
the KIF5A800-1032 sequence. Additionally MCS1 was sequenced to confirm the presence 
of TRAK2100-380 DNA. A summary of all three pETDUET1 clones are shown in Figure 
3.11. 
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Figure 3.11 Summary of the pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and pETDUETTRAK2100-
380/KIF5A800-1032 recombinant clones.  
The vector maps are shown on the left and a schematic of the primary structure of the resultant 
proteins and their predicted molecular weights are shown on the right. 
A = pETDUETTRAK2100-380 B = pETDUETKIF5A800-1032 C = pETDUETTRAK2100-380/KIF5A800-1032. 
 
 
 
 
 
 
Predicted molecular weight of 34.6 kDa 
Predicted molecular weight of 30.2 kDa 
His-tag SQDP TRAK2 100-380
S-tagHAIADVGTLESGKIF5A 800-1032
S-tagHAIADVGTLESGKIF5A 800-1032
His-tag SQDP TRAK2 100-380
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3.2.4 Optimisation of TRAK2100-380, KIF5A800-1032 and TRAK2100-380/KIF5A800-1032 protein 
expression  
Previous work in this chapter has demonstrated the successful generation of the 
recombinant expression constructs pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and 
pETDUETTRAK2100-380/KIF5A800-1032. To determine if these three clones can express the 
expected recombinant proteins, the pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and 
pETDUETTRAK2100-380/KIF5A800-1032 constructs were transformed into chemically 
competent BL21 E.coli cells and protein expression induced (Section 2.2.3.1). Initial 
protein expression experiments utilised 1 mM IPTG to induce expression for a total of 
4 h at 37°C. The resulting total expressed protein was re-suspended in 8 ml of native 
buffer, centrifuged to separate protein into soluble and insoluble protein fractions and 
~ 1.5 µg of each protein fraction analysed via 12 % SDS-PAGE (Section 2.2.3.4). The 
resulting Coomassie Blue stained SDS-PAGE gels are shown in Figure 3.12. Each 
construct was successfully expressed as demonstrated by bands corresponding to their 
predicted sizes in the total and insoluble protein fractions, i.e. TRAK2100-380 = 35.6 ± 2.3 
kDa (n = 20, where n = number of SDS-PAGE), KIF5A800-1032 = 35.4 ± 2.5 kDa (n = 20) and 
TRAK2100-380/KIF5A800-1032 = 35.2 ± 1.9 kDa (n = 10)/35.2 ± 2.1 kDa (n = 10). In the 
pETDUETTRAK2100-380/KIF5A800-1032 induced vector two bands are present indicating 
that both the TRAK2100-380 and KIF5A800-1032 protein fragments are able to be expressed 
simultaneously. No TRAK2100-380 and KIF5A800-1032 expressed protein could be visualised 
via Coomassie Blue staining in the soluble fractions derived from pETDUETTRAK2100-380, 
pETDUETKIF5A800-1032 and pETDUETTRAK2100-380/KIF5A800-1032 expression. Although the 
average molecular weights seen in SDS-PAGE experiments are the same for TRAK2100-
380 and KIF5A800-1032, KIF5A800-1032 is seen to be the larger of the two bands. This is 
unexpected as the predicted molecular weight for KIF5A800-1032 is larger than that of 
TRAK2100-380 (Figure 3.11) and this may be due to SDS resistance of KIF5A800-1032 
resulting in the protein band running slightly higher than expected. Alternatively 
inherent differences between both KIF5A800-1032 and TRAK2100-380 in their charge 
distribution may also alter the position at which they are seen via SDS-PAGE.      
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Figure 3.12 Demonstration of the expression of TRAK2100-380, KIF5A800-1032 and TRAK2100-380/KIF5A800-1032 
in BL21 E.coli cells.  
BL21 E.coli cells were transformed with pETDUETTRAK2100-380, pETDUETKIF5A800-1032 or 
pETDUETTRAK2100-380/KIF5A800-1032. Cell homogenates were prepared after induction of protein 
expression using 1 mM IPTG for 4 hours at 37°C. In all Coomassie Blue stained gels the total, soluble and 
insoluble protein of the induced plasmids are shown. The induced pETDUET1 vector and uninduced 
controls were included. The positions of molecular weight standards (kDa) are shown on the right. 
Arrows indicate the positions of bands of interest.  
A = TRAK2100-380 B = KIF5A800-1032 C = TRAK2100-380/KIF5A800-1032.    
 
To verify that the pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and pETDUETTRAK2100-
380/KIF5A800-1032 constructs were the desired TRAK2100-380 and KIF5A800-1032 proteins, 
immunoblotting was carried out using anti-TRAK28-633 (TRAK2100-380) and anti-S-tag 
(KIF5A800-1032) antibodies (Figure 3.11). The resulting immunoblots are shown in figure 
3.13.   
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Figure 3.13 Demonstration of the expression of TRAK2100-380, KIF5A800-1032 and TRAK2100-380/KIF5A800-1032 
in BL21 E.coli cells.  
BL21 E.coli cells were transformed with pETDUETTRAK2100-380, pETDUETKIF5A800-1032 or 
pETDUETTRAK2100-380/KIF5A800-1032. Cell homogenates were prepared after induction of protein 
expression using 1 mM IPTG for 4 hours at 37°C. In all immunoblots total, soluble and insoluble protein 
of the induced and uninduced plasmids are shown. The positions of molecular weight standards (kDa) 
are shown on the right. Arrows indicate the positions of bands of interest.  
A = TRAK2100-380 probed with anti-TRAK28-633 antibodies. B = KIF5A800-1032 probed with anti-S-tag 
antibodies. C = TRAK2100-380/KIF5A800-1032 probed with anti-TRAK28-633 antibodies. D = TRAK2100-
380/KIF5A800-1032 probed with anti-S-tag antibodies.  
 
Immunoblotting with the anti-TRAK28-633 and anti-S-tag antibodies confirms the correct 
transcription of TRAK2100-380 and KIF5A800-1032 with immunoreactive bands present in all 
total, soluble and insoluble fractions. Anti-TRAK28-633 as opposed to anti-His antibodies 
was used due to the ease of readily available in house anti-TRAK28-633 antibodies. Anti-
TRAK28-633 can also detect the presence of the His-tag sequence (Table 2.4). Overall a 
lower concentration of TRAK2100-380 and KIF5A800-1032 protein is present in the soluble 
extract when compared to both the total and insoluble fractions. In all total and 
insoluble fractions the presence of several higher molecular weight bands were seen at 
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weights in the range of 70 - 250 kDa. These bands are most likely aggregated TRAK2100-
380 and KIF5A800-1032 protein sample. Anti-TRAK28-633 antibodies also recognised two 
major immunoreactive bands lower than the predicted molecular weight of TRAK2100-
380 in the pETDUETTRAK2100-380 and pETDUETTRAK2100-380/KIF5A800-1032 induced 
constructs. These lower molecular weight bands may be the result of proteolytic 
degradation. Protein expression was also noted in the uninduced control. The 
presence of transcribed protein in the uninduced control is indicative of “leaky 
expression”. Leaky expression occurs when the lac operon responsible for controlling 
the T7 promoter is no longer being repressed due to the presence of lactose within the 
E.coli cell. E.coli cells prefer glucose as a carbon source but when glucose is not 
available then the cells use lactose, which in turn can promote this leaky expression 
(Alberts et al., 2007). To prevent uninduced protein expression 1 % w/v glucose was 
added to the LB growth media. The resulting immunoblots are shown in Figure 3.14.   
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Figure 3.14 Demonstration of the expression of TRAK2100-380, KIF5A800-1032 and TRAK2100-380/KIF5A800-1032 
in BL21 E.coli cells with 1 % w/v glucose supplemented LB media.  
BL21 E.coli cells were transformed with pETDUETTRAK2100-380, pETDUETKIF5A800-1032 or 
pETDUETTRAK2100-380/KIF5A800-1032. Cell homogenates were prepared after growth conditions of 1 % w/v 
glucose supplemented LB media, with the induction of protein expression using 1 mM IPTG for 4 hours 
at 37°C. In all immunoblots total, soluble and insoluble protein of the induced and uninduced plasmids 
are shown. The positions of molecular weight standards (kDa) are shown on the right. Arrows indicate 
the positions of bands of interest.  
A = TRAK2100-380 probed with anti-TRAK28-633 antibodies. B = KIF5A800-1032 probed with anti-S-tag 
antibodies. C = TRAK2100-380/KIF5A800-1032 probed with anti-TRAK28-633 antibodies. D = TRAK2100-
380/KIF5A800-1032 probed with anti-S-tag antibodies.  
 
No immunoreactive bands are present in any of the uninduced samples after growth of 
BL21 E.coli and induction of protein expression in 1 % w/v glucose supplemented LB 
media, with the exception of a faint band in the total fraction of the TRAK2100-
380/KIF5A800-1032 anti-S-tag antibody probed immunoblot. Overall a lower concentration 
of TRAK2100-380 and KIF5A800-1032 protein present in the soluble extract compared to 
both the total and insoluble fractions is noted. The ratio of protein in the soluble 
compared to the insoluble is important because if large scale protein purification is to 
be efficient a high concentration of protein in the soluble fraction is required. Proteins 
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in the insoluble fraction aggregate into inclusion bodies which in turn require the 
proteins to be denatured and subsequently refolded in vitro to generate viable protein. 
This method can result in incorrect refolding of protein which is not ideal for structural 
studies. In order to increase the ratio of soluble:insoluble expressed protein as well as 
increasing protein yield different growth and re-suspension conditions were tested. 
These included lowering the concentration of IPTG used to induce protein expression, 
increasing the induction time and altering buffer re-suspension conditions. All of the 
immunoblots representing the differing growth and re-suspension conditions were 
analysed semi-quantitatively using GeneGnome Tools software (Section 2.2.3.5.3). The 
ratio of immunoreactivity of the soluble fraction was taken and expressed as a 
percentage of both the soluble and insoluble fraction combined which is 100 %. Not 
only was the percentage solubility of the protein used to assess the efficiency of 
protein expression, but also the yield of protein expression was taken into account i.e. 
can the expressed soluble protein band be visualised after Coomassie Blue staining? 
Optimisation of the expression and solubilisation conditions of TRAK2100-380 is 
summarized in Table 3.3.  
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Growth 
conditions 
Re-suspension 
conditions 
Immunoblot analysis 
Coomassie Blue  
staining analysis 
% 
Solubilis
ation 
N 
number 
37°C, 1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 mM 
NaH2PO4 [pH 8.0] 1 mg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
18 % 1 
37°C, 0.1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 mM 
NaH2PO4 [pH 8.0] 1 mg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
31 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 mM 
NaH2PO4 [pH 8.0] 1 mg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
22 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 mM 
NaH2PO4 [pH 8.0] 1 mg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = No Visible band 
Insoluble = No Visible 
band 
Soluble = No Visible band 
35 % 3 
1 % glucose 
media, 25°C, 
0.1 mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 mM 
NaH2PO4 [pH 8.0] 1 mg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Faint band 
Insoluble = Faint band 
Soluble = No Visible band 
27 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME) 1 
mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Faint band 
Insoluble = Faint band 
Soluble = No Visible band 
34 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 1 
mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Faint band 
Insoluble = Faint band 
Soluble = No Visible band 
35 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 20 
µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Faint band 
Insoluble = Faint band 
Soluble = No Visible band 
24 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 16 
hour induction 
8 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 20 
µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Faint band 
Insoluble = Faint band 
Soluble = No Visible band 
16 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
1 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 20 
µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
16 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 16 
hour induction 
8 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 20 
µg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
24 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 
hours 
induction 
1 ml re-suspension buffer 
(50 mM TRIS [pH 8.0], 400 
mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, 
protease inhibitors) 20 
µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible band 
22 % 1 
Table 3.3 A summary of growth conditions to establish optimal conditions for the expression and 
solubilisation of TRAK2100-380.  
Text highlighted in red indicates a change from the previous condition tested.  
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Results from optimisation of the expressed pETDUETTRAK2100-380 clone found poor 
overall expression in all conditions tested. The growth conditions of 1 mM IPTG and 4 
hours induction at 25°C show clear bands in the total and insoluble but not in the 
soluble fractions after staining protein with Coomassie Blue. Optimisation of the 
expression and solubilisation conditions of KIF5A800-1032 is summarised in Table 3.4.  
Growth 
conditions 
Re-suspension 
conditions 
Immunoblot analysis 
Coomassie Blue 
staining analysis 
% 
Solubilis
ation 
N 
number 
37°C, 1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible 
band 
4 % 1 
37°C, 0.1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible 
band 
9 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible 
band 
13 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Faint band 
30 % 3 
1 % glucose 
media, 25°C, 
0.1 mM IPTG, 4 
hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Faint band 
48 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME) 1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible 
band 
8 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Faint band 
13 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Faint band 
35 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 16 
hour induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = No Visible 
band 
16 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours 
induction 
1 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
24 % 1 
Table 3.4 A summary of growth conditions to establish optimal conditions for the expression and 
solubilisation of KIF5A800-1032.  
Text highlighted in red indicates a change from the previous condition tested.  
121 
 
Results from optimisation of the expression and solubilisation of the pETDUETKIF5A800-
1032 clone show good overall expression in all conditions tested. The optimal growth 
conditions of 1 mM IPTG and 4 hours induction at 25°C show clear bands in the total, 
soluble and insoluble fractions after staining protein with Coomassie Blue. 
Optimisation of the expression and solubilisation conditions of co-expressed TRAK2100-
380 and KIF5A800-1032 is summarised in Table 3.5 (TRAK2100-380) and Table 3.6 (KIF5A800-
1032).   
Growth 
conditions 
Re-suspension 
conditions 
Immunoblot analysis 
Coomassie Blue 
staining analysis 
% 
Solubilis
ation 
N 
number 
37°C, 1 mM IPTG, 
4 hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
40 % 1 
37°C, 0.1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
2 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
18 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
29 % 3 
1 % glucose 
media, 25°C, 0.1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 faint bands 
Soluble = No visible bands 
32 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME) 1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 faint bands 
Soluble = 2 faint bands 
67 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
33 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = 2 faint bands 
38 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 16 
hour induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
21 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
1 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
34 % 1 
Table 3.5 A summary of growth conditions to establish optimal conditions for the expression and 
solubilisation of TRAK2100-380/KIF5A800-1032.  
Immunoblot and percentage solubilisation data relates to TRAK2100-380. Text highlighted in red indicates 
a change from the previous condition tested.  
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Growth 
conditions 
Re-suspension 
conditions 
Immunoblot analysis 
Coomassie Blue 
staining analysis 
% 
Solubilis
ation 
N 
number 
37°C, 1 mM IPTG, 
4 hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
4 % 1 
37°C, 0.1 mM 
IPTG, 4 hours 
induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
5 % 1 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
21 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
21 % 3 
1 % glucose 
media, 25°C, 0.1 
mM IPTG, 4 
hours induction 
8 ml native buffer 250 
mM NaH2PO4 [pH 8.0] 1 
mg/ml lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 faint bands 
Soluble = No visible bands 
26 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME) 1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 faint bands 
Insoluble = 2 faint bands 
Soluble = 2 faint bands 
36 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
1 mg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
12 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = 2 faint bands 
24 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 16 
hour induction 
8 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
19 % 1 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 
hours induction 
1 ml re-suspension 
buffer (50 mM TRIS [pH 
8.0], 400 mM NaCL, 10 
% w/v glycerol, 5 mM β-
ME, protease inhibitors) 
20 µg/ml lyzozyme) 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = 2 visible bands 
Insoluble = 2 visible bands 
Soluble = No visible bands 
22 % 1 
Table 3.6 A summary of growth conditions to establish optimal conditions for the expression and 
solubilisation of TRAK2100-380/KIF5A800-1032.  
Immunoblot and percentage solubilisation data relates to KIF5A800-1032. Text highlighted in red indicates 
a change from the previous condition tested.  
 
 
Results from the optimisation of soluble protein expression experiments for the 
pETDUETTRAK2100-380/KIF5A800-1032 clone show an average overall expression in all 
conditions tested. The optimal growth conditions of 1 mM IPTG and 4 hours induction 
at 25°C found visible bands for both TRAK2100-380 and KIF5A800-1032 in the total and 
insoluble, with faint bands in the soluble fraction after staining protein with Coomassie 
Blue. 
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Uninduced Induced
pETDUETTRAK2 100-380
- 200
- 116.25
- 97.4
- 66.2
- 45
- 31
- 21.5
- 14.4
- 250
- 98
- 64
- 50
- 36
- 30
- 16
- 6
Induced
Antibody = 
TRAK2 8-633
C 
B 
- 200
- 116.25
- 97.4
- 66.2
- 45
- 31
- 21.5
- 14.4
Uninduced Induced
pETDUETKIF5A800-1032
- 250
- 98
- 64
- 50
- 36
- 30
- 16
Induced
Antibody = S-tag
Induced
- 250
- 98
- 64
- 50
- 36
- 30
- 16
- 6
- 250
- 98
- 64
- 50
- 36
- 30
- 16
- 6
Induced
Antibody = 
TRAK28-633
Antibody = S-tag
Uninduced Induced
pETDUETTRAK2100-380 / KIF5A800-1032
- 200
- 116.25
- 97.4
- 66.2
- 45
- 31
- 21.5
- 14.4
A 
Standard growth and solubilisation conditions for all three constructs were thus 
established. These were the induction of construct expression with 1 mM IPTG for 4 h 
at 25°C. Protein was solubilised in 8 ml re-suspension buffer, 50 mM TRIS [pH 8.0], 400 
mM NaCl, 10 % w/v glycerol, 5 mM β-ME, protease inhibitors, 20 µg/ml lyzozyme 
treatment for 30 min and sonication on ice with 6 bursts of 10 sec with 10 sec rest 
intervals. Representative Coomassie Blue stained gels and immunoblots are shown in 
Figure 3.15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Demonstration of the optimised expression of TRAK2100-380, KIF5A800-1032 and TRAK2100-
380/KIF5A800-1032 in BL21 E.coli cells.  
BL21 E.coli cells were transformed with pETDUETTRAK2100-380, pETDUETKIF5A800-1032 or 
pETDUETTRAK2100-380/KIF5A800-1032. Cell homogenates were prepared after growth conditions of 1 % w/v 
glucose supplemented LB media, with the induction of protein expression using 1 mM IPTG for 4 hours 
at 25°C. In all Coomassie Blue stained gels the total, soluble and insoluble protein of the induced and 
uninduced plasmids are shown. In all immunoblots the total, soluble and insoluble protein of the 
induced plasmids are shown. The positions of molecular weight standards (kDa) are shown on the right. 
Arrows indicate the positions of bands of interest.  
A = TRAK2100-380. Immunoblot probed with anti-TRAK28-633 antibodies. B = KIF5A800-1032. Immunoblot 
probed with anti-S-tag antibodies. C = TRAK2100-380/KIF5A800-1032. Immunoblot probed with either anti-
TRAK28-633 or anti-S-tag antibodies.   
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For single protein experiments, KIF5A800-1032 expression and solubilisation was 
satisfactory but both expression and solubilisation of TRAK2100-380 was inefficient. 
However, transformation of the double construct, pETDUETTRAK2100-380/KIF5A800-1032, 
resulted in expression of TRAK2100-380 and KIF5A800-1032 in approximately equal ratios, 
albeit at the expense of KIF5A800-1032 expression. This result suggests stabilisation of the 
TRAK2100-380/KIF5A800-1032 protein co-complex. A summary of the overall cloning, 
expression and expression optimisation of TRAK2100-380, KIF5A800-1032 and TRAK2100-
380/KIF5A800-1032 is shown in Table 3.7. 
 
Protein name 
Generation 
of 
construct 
Correct 
expression 
in E.coli 
Analysis of soluble fraction 
yield via Coomassie Blue 
staining 
% Solubilisation 
TRAK2100-380    No clear band in the soluble fraction 22 % 
KIF5A800-1032    Clear band in the soluble fraction  35 % 
TRAK2100-380/KIF5A800-
1032   
Two clear bands in the soluble 
fraction  
TRAK2100-380 = 24 % 
KIF5A800-1032 = 35 % 
Table 3.7 Summary of the overall cloning, expression and expression optimisation for 
pETDUETTRAK2100-380, pETDUETKIF5A800-1032 and pETDUETTRAK2100-380/KIF5A800-1032. 
 
 
3.2.5 Affinity tag purification of soluble TRAK2100-380/KIF5A800-1032 
Experiments carried out in Section 3.2.4 demonstrated the ability of the dual 
construct, TRAK2100-380/KIF5A800-1032, to express in a bacterial expression system. In 
order to investigate if the expressed TRAK2100-380/KIF5A800-1032 co-complex could be 
purified via affinity chromatography initial experiments using Ni2+ affinity resin were 
carried out (Section 2.2.4.1). Ni2+ affinity resin will specifically interact with the His-tag 
present on the N-terminus of TRAK2100-380. Hence, this method will be used to purify 
TRAK2100-380 in the hope that KIF5A800-1032 will co-purify. Soluble protein extract (20 ml) 
of transformed pETDUETTRAK2100-380/KIF5A800-1032 bacterial cultures induced with 1 
mM IPTG for 4 h at 25°C were incubated with the Ni2+ affinity resin for 1 h, washed 
with 20 mM imidazole to remove non-specifically bound protein and eluted with 250 
mM imidazole. Soluble, unbound, washed and eluted fractions were analysed by SDS-
PAGE using Coomassie Blue staining and immunoblotting with anti-TRAK28-633 and anti-
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S-tag antibodies. The results of the affinity purification of TRAK2100-380/KIF5A800-1032 are 
shown in Figure 3.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Purification of TRAK2100-380/KIF5A800-1032 under native conditions using Ni
2+
 affinity resin. 
BL21 E.coli cells were transformed with pETDUETTRAK2100-380/KIF5A800-1032 and the cell homogenate 
prepared after growth conditions of 1 % w/v glucose supplemented LB media, with the induction of 
protein expression using 1 mM IPTG for 4 hours at 25°C. Soluble cell homogenate was incubated with 
Ni
2+
 affinity resin for 1 h and washed and eluted from the resin as 1 ml fractions. Results are 
representative of n = 1 co-purification experiments. The positions of molecular weight standards (kDa) 
are shown on the right. Arrows indicate the positions of bands of interest.  
A = TRAK2100-380/KIF5A800-1032 purification probed with anti-TRAK28-633 antibodies. B = TRAK2100-
380/KIF5A800-1032 purification probed with anti-S-tag antibodies. C = Coomassie Blue stained TRAK2100-
380/KIF5A800-1032 purification. 
 
Initial chromatography experiments show the presence of both TRAK2100-380 and 
KIF5A800-1032 in the soluble fractions of immunoblots indicating the correct expression 
and solubilisation of the TRAK2100-380/KIF5A800-1032 co-complex. There is no decrease in 
TRAK2100-380 or KIF5A800-1032 in the supernatant sample compared to the soluble sample 
indicating that the TRAK2100-380/KIF5A800-1032 co-complex is not efficiently binding the 
Ni2+ affinity resin and is hence remaining in the supernatant. Background protein is 
also still being eluted, albeit at lower concentrations, from the resin after 4 ml of 20 
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mM imidazole wash buffer. The concentration of eluted TRAK2100-380/KIF5A800-1032 in 
both the Coomassie Blue stained gel and immunoblots appears to be low with a high 
concentration of background binding proteins. This purification strategy, as discussed 
previously, should result in the purification of TRAK2100-380 and by virtue of their 
interaction KIF5A800-1032 should also purify as a TRAK2100-380/KIF5A800-1032 co-complex. 
Although the efficiency of the purification of the co-complex appears to be low it has 
remained in approximately equal ratio throughout the purification experiments 
indicating that TRAK2100-380 and KIF5A800-1032 are still remaining bound to one another.     
To assess the efficiency of affinity chromatography experiments several factors need 
to be considered. These include the specific activity of the purified proteins and the 
purification factor. The specific activity gives information regarding the purity of the 
isolated TRAK2100-380/KIF5A800-1032 co-complex, whereas the purification factor 
compares the concentration of TRAK2100-380/KIF5A800-1032 in the purified sample to the 
concentration of TRAK2100-380/KIF5A800-1032 in the soluble cell homogenate. It is by using 
the specific activity, purification factor and visually analysing the Coomassie Blue 
stained gels and immunoblots that a good idea of the overall affinity chromatography 
efficiency can be gained. In order to assess the specific activity and purification factor a 
Coomassie Blue stained gel comparing the soluble extract and the elution volume with 
varying known concentrations of standard molecular weight proteins was carried out. 
The resulting Coomassie Blue stained gel is shown in Figure 3.17. 
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Figure 3.17 Assessment of the specific activity and purification factor after the purification of 
TRAK2100-380/KIF5A800-1032 under native conditions using Ni
2+
 affinity resin. 
SDS-PAGE of varying concentrations of soluble TRAK2100-380/KIF5A800-1032 co-complex, eluted purified 
TRAK2100-380/KIF5A800-1032 co-complex and molecular weight protein standards. The positions of molecular 
weight standards (kDa) are shown on the right. The arrow indicates the positions of bands of interest. 
 
 
Estimating the TRAK2100-380/KIF5A800-1032 content of the soluble fraction: 
 5 μl of soluble TRAK2100-380/KIF5A800-1032 looks to be approximately the same as 
the 300 ng standard band. 
 300 ng in 5 μl = 60 μg in 1 ml = 1.2 mg per 20 ml of soluble extract added to the 
resin. 
Estimating the specific activity of TRAK2100-380/KIF5A800-1032 in the soluble fraction: 
The total protein of the soluble extract (20 ml) was calculated via Bradford assay 
(Section 2.2.3.2) was 0.19 mg protein/ml. Therefore the specific activity of TRAK2100-
380/KIF5A800-1032 is 0.38 mg/1 mg of soluble protein. 
Estimating the TRAK2100-380/KIF5A800-1032 content of elution volume 1: 
 75 μl of elution volume 3 looks to be approximately the same as the 300 ng 
standard band. 
 300 ng in 75 μl = 4 μg per 1 ml of elution volume 1. 
Estimating specific activity of TRAK2100-380/KIF5A800-1032 of elution volume 1: 
The amount of soluble protein was unable to be efficiently calculated via a Bradford 
assay due to the low concentration. Hence the lowest measurable protein 
concentration was used to help estimate specific activity, which in this case was 0.1 mg 
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protein/ml. Therefore the specific activity of TRAK2100-380/KIF5A800-1032 is 0.04 mg/1 mg 
of total protein from elution volume 1. 
Estimating the purification factor: 
Purification factor = Specific activity in the purified = 0.04 mg/1 mg purified = 0.125 
                                     Specific activity in the soluble  = 0.32 mg/1 mg soluble 
   
A purification factor value of less than one indicates that not all of the affinity tagged 
protein present in the soluble sample is binding the resin hence resulting in a poor 
yield of eluted protein sample. The purification factor value of 0.125 from the affinity 
purification of TRAK2100-380/KIF5A800-1032, although only an estimate, shows that the 
TRAK2100-380/KIF5A800-1032 co-complex is not efficiently binding the column to be eluted. 
Combined with the low specific activity of TRAK2100-380/KIF5A800-1032 in the eluted 
fraction, as well as the visual analysis, this indicates overall a poor yield of the purified 
TRAK2100-380/KIF5A800-1032 co-complex. In order to increase the yield and purity of 
TRAK2100-380/KIF5A800-1032 optimisation of the affinity purification process was carried 
out. The optimisation involved altering the concentration of imidazole in the wash 
buffer, changing the affinity resin specific for the His-tag and using S-protein affinity 
resin to target the S-tag present on KIF5A800-1032. The different methods and affinity 
resins used to purify the TRAK2100-380/KIF5A800-1032 co-complex are summarised in Table 
3.8. 
 
 
 
 
 
 
 
 
129 
 
TRAK2100-380/KIF5A800-1032 
purification conditions 
Visual analysis of Commassie 
Blue stained gels and 
immunoblots  
Estimated specific 
activity of purified co-
complex 
(mg/mg protein) 
Estimated 
purification 
factor of the 
co-complex 
Ni
2+ 
affinity resin (1 mg/ml 
protein binding capacity), 20 
mM imidazole wash, 250 
mM imidazole elution 
conditions  
No decrease in TRAK2100-380 or 
KIF5A800-1032 in supernatant 
compared to soluble. No 
enrichment of protein being 
eluted from the resin. High 
background binding. Low yield. 
0.085 0.125 
Ni
2+ 
affinity resin (1 mg/ml 
protein binding capacity), 75 
mM imidazole wash, 250 
mM imidazole elution 
conditions  
No decrease in TRAK2100-380 or 
KIF5A800-1032 in supernatant 
compared to soluble. Enrichment 
of protein being eluted from the 
resin, with lower background 
binding. Low yield.  
0.04 2.08 
Ni
2+ 
affinity resin (1 mg/ml 
protein binding capacity), 20 
mM imidazole in re-
suspension solution, 75 mM 
wash, 250 mM imidazole 
elution conditions  
No decrease in TRAK2100-380 or 
KIF5A800-1032 in supernatant 
compared to soluble. No 
enrichment of protein being 
eluted from the resin. Slightly 
higher background binding than 
75 mM imidazole wash. Low 
yield.  
0.029 2.6 
Talon (Co
3+
) affinity resin (5 
mg/ml protein binding 
capacity), 150 mM imidazole 
elution conditions  
No decrease in TRAK2100-380 or 
KIF5A800-1032 in supernatant 
compared to soluble. No 
enrichment of protein being 
eluted from the resin. Very high 
background binding but also poor 
protein enrichment. Very low 
yield.  
0.004 0.057 
S-tag protein resin (500 
μg/ml protein binding 
capacity), elution with 3 M 
MgCl2  
No decrease in TRAK2100-380 or 
KIF5A800-1032 in supernatant 
compared to soluble. No 
enrichment of protein being 
eluted from the resin. Very low 
background binding but also poor 
protein enrichment. Low yield.  
0.21 1.1 
Table 3.8 Table summarising the different conditions and affinity chromatography resins tested to 
purify the TRAK2100-380/KIF5A800-1032 co-complex. 
 
Overall, purification of the TRAK2100-380/KIF5A800-1032 co-complex was poor with respect 
to the estimated specific activity of the purified protein co-complex. Further, the 
purification factor indicated a low yield of purified TRAK2100-380/KIF5A800-1032 co-
complex in all the conditions tested. The efficiency of TRAK2100-380 binding to the Ni
2+ 
and Co3+ affinity resins has been poor as demonstrated by the high concentration of 
TRAK2100-380/KIF5A800-1032 co-complex remaining in the supernatant after incubation. 
Therefore, this inefficient purification could be due to poor accessibility of the His-tag 
to the resin. Although each purification is only representative of an n = 1 experiment 
the results were sufficient to ascertain if the purification conditions were suitable for 
further consideration. A change in strategy to use the S-tag present on KIF5A800-1032 to 
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purify the TRAK2100-380/KIF5A800-1032 co-complex as opposed to the His-tag present on 
TRAK2100-380 also did not purify the protein co-complex to a sufficient yield. 
Optimisation of S-tag purification conditions were also confined due to the limitations 
of the resin itself when compared to the relatively flexible His-tag purification system. 
The S-protein affinity resin system is limited because relatively harsh elution conditions 
of 3M MgCl2 are needed to disrupt the S-tag present on KIF5A800-1032 binding to the 
affinity resin. Hence, the elution conditions are difficult to optimise and only one 
purification condition could be tested. Due to the poor yield of eluted protein and the 
high concentration of the TRAK2100-380/KIF5A800-1032 co-complex remaining in the 
supernatant sample after incubation with the S-tag protein affinity resin, this result 
indicates that the S-tag may also be being obscured either by the tertiary structure of 
KIF5A800-1032 or the binding of TRAK2100-380.   
In order to assess if either the tertiary structure or the co-complex itself is inhibiting 
affinity tag binding to the affinity resin, purification of the TRAK2100-380/KIF5A800-1032 co-
complex was carried out under denaturing conditions using Ni2+ affinity resin. S-protein 
affinity resin could not be used as the specificity relies on a protein-protein interaction 
and denaturing conditions would abolish this. Soluble TRAK2100-380/KIF5A800-1032 protein 
was incubated with 3 M urea prior to purification, in order to denature the soluble 
TRAK2100-380/KIF5A800-1032 protein sample, using the same conditions as Figure 3.17. The 
results of the purification under denaturing conditions are shown in Figure 3.18. 
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Figure 3.18 Purification of TRAK2100-380/KIF5A800-1032 under denaturing conditions using Ni
2+
 affinity 
resin. 
BL21 E.coli cells were transformed with pETDUETTRAK2100-380/KIF5A800-1032 and the cell homogenate 
prepared after growth conditions of 1 % w/v glucose supplemented LB media, with the induction of 
protein expression using 1 mM IPTG for 4 hours at 25°C.  Soluble cell homogenate was denatured using 
3 M urea and incubated with Ni
2+
 affinity resin for 1 h and washed and eluted from the resin as 1 ml 
fractions. Results are representative of n = 1 co-purification experiments. The positions of molecular 
weight standards (kDa) are shown on the right. Arrows indicate the positions of bands of interest.  
A = TRAK2100-380/KIF5A800-1032 purification probed with anti-TRAK28-633 antibodies. B = TRAK2100-
380/KIF5A800-1032 purification probed with anti-S-tag antibodies. C = Coomassie Blue stained TRAK2100-
380/KIF5A800-1032 purification. 
 
 
 
Ni2+ affinity chromatography under denaturing conditions shows the presence of both 
TRAK2100-380 and KIF5A800-1032 in immunoblots indicating the co-purification of 
TRAK2100-380/KIF5A800-1032. In immunoblots there is a marked decrease of TRAK2100-380 in 
the supernatant compared to the soluble sample, whereas levels of KIF5A800-1032 in 
both the supernatant and soluble fractions remained the same. This large difference in 
soluble versus supernatant concentration of TRAK2100-380 was not seen in any of the 
previous native purification conditions tested and indicates that the His-tag is now 
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efficiently binding to the Ni2+ affinity resin. This result also indicates that TRAK2100-380 
but not KIF5A800-1032 is binding the Ni
2+ affinity resin efficiently. Purification under 
denaturing conditions has improved the yield of eluted TRAK2100-380 and also resulted 
in decreased levels of co-purifying KIF5A800-1032 when compared to TRAK2100-380. An 
estimated purification factor value of 58 indicates that TRAK2100-380 is efficiently 
binding the column and is able to be eluted from the resin with a high yield. Overall 
this result suggests that in the native TRAK2100-380/KIF5A800-1032 co-complex the His 
affinity tag may not be accessible for binding to the affinity resin. 
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3.3 DISCUSSION 
The aim of this chapter was to generate a functional and pure TRAK2100-380/KIF5A800-1032 
protein co-complex. This would allow for structural studies to be carried out upon the 
co-complex and valuable insight gained into how the TRAK2 kinesin adaptor protein 
may function. In this chapter three bacterial expression constructs, pETDUETTRAK2100-
380, pETDUETKIF5A800-1032 and pETDUETTRAK2100-380/KIF5A800-1032 were generated. 
TRAK2100-380 and KIF5A800-1032 were successfully expressed in BL21 E.coli cells. TRAK2100-
380/KIF5A800-1032 was also shown to successfully co-express in BL21 E.coli cells. 
Optimisation of the expression of soluble protein using different induction, growth and 
re-suspension conditions resulted in an improvement of the yield of TRAK2100-380, 
KIF5A800-1032 and TRAK2100-380/KIF5A800-1032 compared to original test conditions. As 
previously discussed in Section 3.1 the expression of soluble protein at a high yield is 
essential for large scale purification of recombinant proteins from bacterial systems. 
The protein present in inclusion bodies would be required to be denatured and 
subsequently refolded in vitro to generate viable protein. There is no guarantee that 
protein recovered from inclusion bodies will refold correctly and hence a high yield of 
soluble as opposed to insoluble protein is needed for structural studies. The best 
condition for the overall yield and solubility of TRAK2100-380 was the induction of 
protein expression using 1 mM IPTG for 4 hours at 25°C. TRAK2100-380 was subsequently 
solubilised in 8 ml re-suspension buffer, 50 mM TRIS [pH 8.0], 400 mM NaCl, 10 % w/v 
glycerol, 5 mM β-ME, protease inhibitors, 20 µg/ml lysozyme treatment for 30 min and 
sonication on ice with 6 bursts of 10 sec with 10 sec rest intervals. This resulted in a 22 
% solubilisation of TRAK2100-380 under these conditions. However, the overall the yield 
of soluble TRAK2100-380 was poor. Conversely, the optimisation of KIF5A800-1032 using the 
above conditions resulted in solubilisation levels of 35 % and showed a high yield of 
expressed protein. Interestingly, when co-expressed together, TRAK2100-380/KIF5A800-
1032 was in approximately equal ratios in all growth conditions tested indicating that 
TRAK2100-380/KIF5A800-1032 forms a co-complex.  
Although the original hypothesis behind co-expressing TRAK2100-380/KIF5A800-1032 
together was aimed at helping to stabilise KIF5A800-1032, the presence of KIF5A800-1032 
appeared to rescue TRAK2100-380 yield when co-expressed together. The increase in 
stability of TRAK2100-380 solubility by KIF5A800-1032 also demonstrated a decrease in the 
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yield of KIF5A800-1032 expression, indicating that KIF5A800-1032 expression is being 
sacrificed in order to improve the poor expression of TRAK2100-380 seen when expressed 
alone. As previously discussed in Section 3.1, the ability of a co-expressing protein 
binding partner can significantly increase soluble expression. Hancock and Howard 
(1998) demonstrated that the co-expression of a Drosophila KHC mutant lacking the 
motor domain increased soluble expression by approximately five-fold when co-
expressed with wild-type KHC in E.coli cells. Although not a kinesin protein, co-
expression of myosin light and heavy chain was shown to result in stoichiometric 
expression of both proteins in E.coli cells (McNally et al., 1998). The work presented in 
this chapter has shown that not only does KIF5A800-1032 co-expression with TRAK2100-380 
increase soluble TRAK2100-380, but the TRAK2100-380/KIF5A800-1032 co-complex appears to 
be stoichiometric. 
The same conditions found to be most efficient for single TRAK2100-380 and KIF5A800-1032 
expression, as discussed above, also resulted in an overall increase of TRAK2100-
380/KIF5A800-1032 yield and solubility. Several factors including temperature of growth, 
the temperature of protein induction and the re-suspension conditions can help to 
affect the solubility and yield of protein expression in bacterial cells. In the case of all 
three constructs it was found that a lowered induction temperature of 25°C helped to 
increase the expression of soluble protein. This may be due to the lowered 
temperature slowing the formation of expressed protein in the bacterial cell leading to 
less chance for the protein to aggregate into inclusion bodies.    
Affinity chromatography purification targeting either the His-tag present on TRAK2100-
380 or the S-tag on KIF5A800-1032 was designed to purify each respective protein in the 
hope that due to the association with their interacting protein, co-purification would 
occur. Both TRAK2100-380 and KIF5A800-1032 immunoreactivities were co-purified by Ni
2+ 
affinity resin suggesting that the two proteins associate to form a TRAK2100-
380/KIF5A800-1032 co-complex. Despite using different affinity resins and resin 
wash/elution conditions the yield of the purified co-complex remained poor. 
Purification under denaturing conditions to inhibit TRAK2100-380/KIF5A800-1032 co-
complex formation improved the yield of TRAK2100-380 and also resulted in decreased 
amounts of co-purifying KIF5A800-1032 after purification using Ni
2+ affinity resin. It is 
interesting that the co-purification of KIF5A800-1032 with TRAK2100-380 is not completely 
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abolished under denaturing conditions as theoretically KIF5A800-1032 should no longer 
interact with TRAK2100-380 due to the loss of the secondary and tertiary structures of 
both proteins. Although the exact mechanism behind the TRAK2100-380/KIF5A800-1032 
interaction is unknown, it is possible to speculate that under denaturing conditions 
charged regions of amino acids may be in part responsible for the remaining 
interaction of KIF5A800-1032 with TRAK2100-380, which in turn results in the, albeit 
reduced, levels of co-purification. The presence of KIF5A800-1032 is unlikely to be due to 
a specific interaction between KIF5A800-1032 and the Ni
2+ affinity resin as there are no 
obvious histidine sequences within KIF5A800-1032, although any region of negatively 
charged amino acids present on the denatured KIF5A800-1032 may weakly bind the 
positively charged Ni2+. The poor binding of the tagged TRAK2100-380/KIF5A800-1032 co-
complex to the differing affinity resins could be due to saturation of the protein 
binding sites, although this is unlikely due to the high binding capacity of each of the 
affinity resins used (Table 3.8). Overall these purification experiments suggest that in 
the TRAK2100-380/KIF5A800-1032 co-complex the His affinity tag may not be accessible for 
binding to the affinity resin. Unfortunately it is difficult to deduce whether this His-tag 
obscurity is due to the tertiary folding of the TRAK2100-380 protein or the binding of 
KIF5A800-1032 to TRAK2100-380. 
Gaining a functional purified protein for structural studies is dependent on many 
factors, including yield and solubility of the expressed protein as well as the yield and 
efficiency of purification. All of these factors need to be optimised in order to gain a 
protein of a high enough yield that could be considered suitable for structural studies. 
These factors can be influenced by a variety of subtle differences including changes in 
amino acid composition, protein charge, tertiary structure or type and location of 
affinity tag. Although work in this chapter has shown optimisation of nearly all of the 
above factors, ultimately TRAK2100-380/KIF5A800-1032 was shown to be unsuitable for 
structural studies due to its inability to co-purify to a sufficient yield. Hence, work in 
the next chapter will focus upon the single expression and purification of KIF5A, 
including KIF5A800-1032, in an attempt to gain pure protein of sufficient yield to carry out 
structural studies.    
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3.3.1 Overall conclusions 
 The bacterial expression constructs, pETDUETTRAK2100-380, pETDUETKIF5A800-
1032 and pETDUETTRAK2100-380/KIF5A800-1032 were successfully generated. 
Expressed tagged proteins, TRAK2100-380 and KIF5A800-1032, with the correct 
predicted sizes were verified by immunoblotting.  
 Optimal growth and solubilisation conditions for all three constructs were 
established. Under these conditions, high levels of expression and solubilisation 
of KIF5A800-1032 and the TRAK2100-380/KIF5A800-1032 co-complex were obtained. 
Levels of TRAK2100-380 when expressed alone were low suggesting that in the 
presence of its binding partner, KIF5A800-1032, TRAK2100-380 is stabilised. 
 Both TRAK2100-380 and KIF5A800-1032 immunoreactivities were co-purified by 
ProBond Ni2+ resin affinity chromatography suggesting that the two proteins 
associate to form a TRAK2100-380/KIF5A800-1032 co-complex. The yield of the 
purified co-complex was, however, poor. Purification under denaturing 
conditions to inhibit TRAK2100-380/KIF5A800-1032 co-complex formation improved 
the yield of TRAK2100-380 and also resulted in decreased amounts of co-purifying 
KIF5A800-1032. This result suggests that in the TRAK2100-380/KIF5A800-1032 co-
complex the His affinity tag may not be accessible for binding to the affinity 
resin. 
 The yield of co-purified TRAK2100-380/KIF5A800-1032 was found to be too low for 
further structural studies. 
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CHAPTER 4 
 
TOWARDS THE STRUCTURAL  
DETERMINATION OF THE KIF5A  
CARGO BINDING DOMAIN  
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4.1 RATIONALE  
Previous work from Chapter 3 showed that KIF5A800-1032 does co-express with TRAK2100-
380 in a bacterial expression system. It was also demonstrated that the presence of 
KIF5A800-1032 increased the stability of TRAK2100-380 after co-expression. Unfortunately 
although the TRAK2100-380/KIF5A800-1032 co-complex could be purified, the yield after 
optimization of affinity chromatography was not sufficient. This was most likely due to 
either the interaction of the TRAK2100-380/KIF5A800-1032 co-complex or the tertiary 
structure of TRAK2100-380 and KIF5A800-1032 inhibiting the affinity tags from binding the 
resin. Therefore a different approach was needed in order to gain pure and stable 
KIF5A cargo binding domain for further structural studies. The first aim of this chapter 
was to gain pure and stable KIF5A cargo binding domain protein that would be suitable 
for structural studies, such as X-ray crystallography. 
As mentioned in the Introduction (Section 1.4), there are two proposed methods of 
how kinesin-1 is thought to govern self regulation of movement throughout the 
neuron. The first of these is where the motor domain of kinesin-1 dissociates from the 
microtubule and interacts with Miro, an atypical Rho GTPase, present on the outer 
membrane of the mitochondria. This would keep the entire trafficking complex intact 
whilst no longer being bound to the microtubule (Wang and Schwarz, 2008). The 
second proposed method is that cargo dissociates from kinesin-1 and subsequently the 
cargo binding domain binds directly to the motor domain and microtubule 
simultaneously to prevent movement (Dietrich et al., 2008; Hackney et al., 2009; Wong 
et al., 2009; Seeger and Rice, 2010; Kaan et al., 2011). Previous work regarding the 
association of the cargo binding domain of kinesin-1 to microtubules has been carried 
out using the kinesin-1 sub-type, KIF5B (Seeger and Rice, 2010). This study showed that 
amino acids KIF5B 822-944 can interact with microtubules with a submicromolar 
affinity using electrostatic forces to bind the acidic E-hook at the C-terminal end of 
tubulin. However, whether this possible regulatory binding mechanism is shared by 
KIF5A is unknown.  Therefore, the second aim of this chapter was to gain pure and 
stable KIF5A cargo binding domain protein to ascertain if the cargo binding domain, 
like KIF5B, can interact with microtubules and hence may be involved in the regulation 
of KIF5A movement throughout the cell. 
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4.1.1 Aims of this chapter 
I. Generate bacterial expression constructs of the cargo binding domain of the 
kinesin-1 sub-type, KIF5A. 
II. Verify correct KIF5A production after transformation and induction of 
constructs in bacterial cells. 
III. Optimize the growth and solubilisation conditions needed to maximise soluble 
KIF5A cargo binding domain protein expression.  
IV. Purify in mg quantities the expressed KIF5A protein via affinity chromatography 
in a form suitable for further structural studies. 
V. Assess the ability of purified KIF5A cargo binding domain to bind microtubules 
in vitro. 
VI. Resolve the three dimensional structure of the KIF5A cargo binding domain.  
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             Predicted molecular weight of 30.25 kDa 
S-tagHAIADVGTLESGKIF5A800-1032
His-tag GKPIPNPLLGLDSTENLYQGIDPFT KIF5A 800-1032
His-tag SQ KIF5A820-1032HGSS
His-tag SQ KIF5A800-951HGSS
His-tag SQ KIF5A820-951HGSS
pETDUETKIF5A820-1032
pETDUETKIF5A800-951
pETDUETKIF5A820-951
pET151TOPOKIF5A800-1032
pETDUETKIF5A800-1032
S-tagHAIADVGTLESGKIF5A800-1032
His-tag GKPIPNPLLGLDSTENLYQGIDPFT KIF5A 800-1032
His-tag SQ KIF5A820-1032HGSS
His-tag SQ KIF5A800-951HGSS
His-tag SQ KIF5A820-951HGSS
pETDUETKIF5A820-1032
pETDUETKIF5A800-951
pETDUETKIF5A820-951
pET151TOPOKIF5A800-1032
pETDUETKIF5A800-1032
S-tagHAIADVGTLESGKIF5A800-1032
His-tag GKPIPNPLLGLDSTENLYQGIDPFT KIF5A 800-1032
His-tag SQ KIF5A820-1032HGSS
His-tag SQ KIF5A800-951HGSS
His-tag SQ KIF5A820-951HGSS
pETDUETKIF5A820-1032
pETDUETKIF5A800-951
pETDUETKIF5A820-951
pET151TOPOKIF5A800-1032
pETDUETKIF5A800-1032
S-tagHAIADVGTLESGKIF5A800-1032
His-tag GKPIPNPLLGLDSTENLYQGIDPFT KIF5A 800-1032
His-tag SQ KIF5A820-1032HGSS
His-tag SQ KIF5A800-951HGSS
His-tag SQ KIF5A820-951HGSS
pETDUETKIF5A820-1032
pETDUETKIF5A800-951
pETDUETKIF5A820-951
151TOPOKIF5A800-1032
I 800-1032
S-tagHAIADVGTLESGKIF5A800-1032
His-tag GKPIPNPLLGLDSTENLYQGIDPFT KIF5A 800-1032
His-tag SQ KIF5A820-1032HGSS
His-tag SQ KIF5A800-951HGSS
His-tag SQ KIF5A820-951HGSS
pETDUETKIF5A820-1032
pETDUETKIF5A800-951
pETDUETKIF5A820-951
pET151TOPOKIF5A800-1032
pETDUETKIF5A800-1032
          Predicted molecular weight of 29.7 kDa 
         Predicted molecular weight of 25.2 kDa 
         Predicted molecular weight of 18.8 kDa 
         Predicted molecular weight of 16.5 kDa 
4.2 RESULTS  
As described in the rationale, the aim of this chapter was to determine the structure of 
the cargo binding domain of KIF5A as well as to understand more fully the mechanism 
as to how the movement of KIF5A along microtubules is regulated. In order to do this, 
tagged recombinant clones of the cargo binding domain of KIF5A were expressed in 
BL21 E.coli cells and their relative expression, solubilisation, purification and 
aggregation state were optimized.  Initially five recombinant KIF5A constructs were 
generated following PCR amplification from pBSKIF5A (Section 2.2.2.3.1). These were 
pETDUETKIF5A800-1032, pET151TOPOKIF5A800-1032, pETDUETKIF5A820-1032, 
pETDUETKIF5A800-951 and pETDUETKIF5A820-951. pETDUETKIF5A800-1032 was generated as 
described in Section 3.2.2 and possesses DNA encoding for a C-terminal S-tag. 
pET151TOPOKIF5A800-1032 was sub-cloned in frame using directional cloning of a blunt 
ended PCR product and possesses DNA encoding an N-terminal His-tag. 
pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951 were sub-cloned 
in frame using the restriction sites BamHI/EcoRI and all possess DNA encoding a N–
terminal His tag. All recombinant clones were verified via DNA sequencing (Section 
2.2.2.13). Figure 4.1 shows schematics of the recombinant KIF5A proteins. 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic representations of the recombinant tagged KIF5A cargo binding domain 
constructs. 
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4.2.1 Assessment of KIF5A800-1032 as a suitable recombinant protein for structural 
studies 
The results in Chapter 3 demonstrated that the transformation of pETDUETKIF5A800-1032 
in BL21 E.coli cells resulted in high expression, yield and solubilisation of KIF5A800-1032. 
Therefore the next step was to purify soluble KIF5A800-1032. KIF5A800-1032 possesses an S-
tag on the C-terminus and thus it can be purified using this affinity tag. Hence, initial 
experiments using S-tag protein affinity resin were carried out. The same conditions 
used to purify TRAK2100-380/KIF5A800-1032 were utilised to purify KIF5A800-1032 (Table 3.8). 
A soluble protein extract of transformed pETDUETKIF5A800-1032 bacterial cultures 
induced with 1 mM IPTG for 4 h at 25°C (20 ml) were incubated with the S-tag protein 
affinity resin for 1 h, washed to remove non-specifically bound protein and eluted with 
3 M MgCl2 (Section 2.2.4.2). Soluble, unbound, washed and eluted fractions were 
analysed by SDS-PAGE using Coomassie Blue staining and immunoblotting with anti-S-
tag antibodies (Section 2.2.3.4; Section 2.2.3.5). The results of the affinity purification 
are shown in Figure 4.2. 
 
 
 
 
 
 
 
Figure 4.2 Purification of KIF5A800-1032 under native conditions using S-tag protein affinity resin. 
BL21 E.coli cells were transformed with pETDUETKIF5A800-1032 and the cell homogenates were prepared 
after growth conditions of 1 % w/v glucose supplemented LB media, with the induction of protein 
expression using 1 mM IPTG for 4 hours at 25°C. The soluble cell homogenate was incubated with S-tag 
protein affinity resin for 1 h and washed and eluted from the resin as 1 ml fractions. The positions of 
molecular weight standards (kDa) are shown on the right. Arrows indicate the positions of bands of 
interest.  
A = KIF5A800-1032 purification probed with anti-S-tag antibodies. B = Coomassie Blue stained KIF5A800-1032 
purification. 
 
A B 
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Immunoblots of the samples show the presence of KIF5A800-1032 (molecular weight of 
35.4 ± 2.5 kDa, n = 20) in the soluble fraction indicating correct expression and 
solubilisation. There is no decrease in KIF5A800-1032 in the supernatant compared to the 
soluble sample indicating that KIF5A800-1032 is not efficiently binding the S-protein 
affinity resin. Background protein is also still being eluted, albeit at lower 
concentrations, from the resin after 4 ml of wash buffer. The concentration of eluted 
KIF5A800-1032 in both the Coomassie Blue stained gel and immunoblot appears to be low 
with a high concentration of background binding proteins. These results combined 
with the results seen in Section 3.2.5, where S-tag purification of TRAK2100-380/KIF5A800-
1032 is inhibited by either the binding of the co-complex or the tertiary structure of 
KIF5A800-1032, indicate that the tertiary structure of the KIF5A800-1032 protein may be 
preventing the binding of the S-tag to the S-tag protein affinity resin. Therefore, due to 
the poor yield seen after purification KIF5A800-1032 was deemed to be unsuitable for 
further characterisation for structural studies.  
 
4.2.2 Assessment of His-tagged KIF5A800-1032 as a suitable recombinant protein for 
structural studies 
Section 4.2.1 demonstrated that KIF5A800-1032 is unable to be purified to a sufficient 
yield using the S-tag present on the C-terminus. This is most likely due to the location 
of the affinity tag and/or the tertiary structure of the KIF5A protein inhibiting binding 
of the affinity tag to the resin. Hence, in order to increase efficiency of binding to the 
affinity, the pET151TOPOKIF5A800-1032 construct was generated. The pET151TOPO 
vector was chosen to facilitate the cloning of KIF5A800-1032 due to the presence of DNA 
encoding an N-terminus His-tag. pET151TOPO also utilises blunt ended directional 
cloning, this removes the need for restriction enzyme sites and also facilitates a less 
complicated cloning process. The change in position of the affinity tag from the C-
terminus to the N-terminus of KIF5A800-1032 may help to improve the binding of 
KIF5A800-1032 to the affinity resin.  
pET151TOPOKIF5A800-1032 was transformed into chemically competent BL21 E.coli cells 
and protein expression induced (Section 2.2.3.1). Initial protein expression 
experiments utilized 1 mM IPTG to induce expression for a total of 4 h at 37°C. The 
resulting expressed protein was re-suspended in 8 ml of re-suspension buffer, 
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centrifuged to separate protein into soluble and insoluble protein fraction and ~ 10 µg 
of each protein fraction analysed via 12 % SDS-PAGE (Section 2.2.3.4). The Coomassie 
Blue stained SDS-PAGE of the resulting fractions are shown in Figure 4.3. His-tagged 
KIF5A800-1032 was successfully expressed as demonstrated by bands corresponding to 
the predicted size in the total and insoluble protein fractions, i.e. KIF5A800-1032 = 35.2 ± 
2.3 kDa (n = 30). No His-tagged KIF5A800-1032 expressed protein could be visualized 
clearly via Coomassie Blue staining in the soluble fractions derived from 
pET151TOPOKIF5A800-1032 transformations. This was a result of the large concentration 
of His-tagged KIF5A800-1032 in the total and insoluble fractions obscuring the soluble gel 
lane.  
 
 
 
 
 
 
 
 
To verify that the pET151TOPOKIF5A800-1032 construct was the desired His-tagged 
KIF5A800-1032 protein, immunoblotting was carried out using anti-His antibodies. Due to 
His-tagged KIF5A800-1032 being difficult to visualize in the soluble fraction (Figure 4.3) all 
experiments subsequently employed the loading of ~ 0.1 µg of protein from the total 
and insoluble fractions for SDS-PAGE analysis. The resulting immunoblot is shown in 
Figure 4.4.   
 
 
 
 
 
Figure 4.3 Demonstration of the expression of 
KIF5A800-1032 in BL21 E.coli cells.  
BL21 E.coli cells were transformed with 
pET151TOPOKIF5A800-1032. Cell homogenates were 
prepared after growth conditions of 1 % w/v 
glucose supplemented LB media, with the 
induction of protein expression using 1 mM IPTG 
for 4 hours at 37°C.  In the Coomassie Blue 
stained gel the total, soluble and insoluble 
protein of the expressed KIF5A800-1032 is shown. 
The induced total control was included. The 
positions of molecular weight standards (kDa) are 
shown on the right. The arrow indicates the 
positions of bands of interest.  
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Immunoblotting with anti-His antibodies confirms the correct transcription of His-
tagged KIF5A800-1032 with immunoreactive bands present in all total, soluble and 
insoluble fractions. Overall a lower concentration of His-tagged KIF5A800-1032 is present 
in the soluble extract when compared to both the total and insoluble fractions. In both 
total and insoluble fractions the presence of several higher molecular weight bands 
were seen at weights in the range of 60-90 kDa and these bands are most likely 
aggregated His-tagged KIF5A800-1032. Anti-His antibodies also recognised two 
immunoreactive bands at a lower molecular weight than the most significant His-
tagged KIF5A800-1032 band in the total and insoluble fractions. These lower molecular 
weight bands may be the result of proteolytic degradation. In order to increase the 
ratio of soluble:insoluble expressed protein as well as increasing the protein yield, 
differing growth and re-suspension conditions were tested. These included lowering 
the concentration of IPTG to induce protein expression, lowering the temperature at 
which protein expression is induced and altering re-suspension buffer conditions. All of 
the immunoblots representing the differing growth and re-suspension conditions were 
analysed semi-quantitatively using GeneGnome Tools software (Section 2.2.3.5.3). The 
ratio of immunoreactivity of the soluble fraction was taken and expressed as a 
percentage of both the soluble and insoluble fraction combined which is 100 %. Not 
only was the percentage solubility of the protein used to assess the efficiency of 
protein expression, but also the yield of protein expression was taken into account i.e. 
can the expressed soluble protein band be visualised after Coomassie Blue staining? 
Figure 4.4 Demonstration of the expression of 
KIF5A800-1032 in BL21 E.coli cells.  
BL21 E.coli cells were transformed with 
pET151TOPOKIF5A800-1032. Cell homogenates were  
prepared after growth conditions of 1 % w/v 
glucose supplemented LB media, with the 
induction of protein expression using 1 mM IPTG 
for 4 hours at 37°C. In the immunoblot the total, 
soluble and insoluble protein of the expressed 
KIF5A800-1032 is shown. The induced total control 
was included. The immunoblot is probed with anti-
His antibodies. The positions of molecular weight 
standards (kDa) are shown on the right. The arrow 
indicates the positions of bands of interest.  
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Optimization of the expression and solubilisation conditions of His-tagged KIF5A800-1032 
is summarized in Table 4.1.  
 
Growth 
conditions 
Re-suspension 
conditions 
Immunoblot analysis 
Coomassie Blue  
staining analysis 
% 
Solubilis
ation 
N 
number 
1 % glucose 
media, 37°C, 1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 37°C, 0.1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 37°C, 1 
mM IPTG, 16 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 25°C, 1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 25°C, 0.1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 25°C, 1 
mM IPTG, 16 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
1 % glucose 
media, 18°C, 1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
2 % 3 
1 % glucose 
media, 18°C, 0.1 
mM IPTG, 4 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
1 % 3 
1 % glucose 
media, 18°C, 1 
mM IPTG, 16 h 
induction 
8 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
0.5 % 3 
250 ml culture, 1 
% glucose media, 
18°C, 1 mM IPTG, 
4 h induction 
40 ml re-suspension 
buffer [pH 8.0] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
4 % 3 
250 ml culture, 1 
% glucose media, 
18°C, 1 mM IPTG, 
4 h induction 
40 ml re-suspension 
buffer [pH 7.4] 20 µg/ml 
lyzozyme 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
Total = Visible band 
Insoluble = Visible band 
Soluble = Visible band 
2 % 3 
Table 4.1 A summary of growth conditions to establish optimal conditions for the expression and 
solubilisation of His-tagged KIF5A800-1032.  
Text highlighted in red indicates a change from the previous condition tested.  
 
 
Results from optimization of the expression and solubilisation of His-tagged KIF5A800-
1032 show good overall expression in all conditions tested. The optimal growth 
conditions of 1 mM IPTG and 4 h induction at 18°C show clear bands in the total, 
soluble and insoluble fractions after staining protein with Coomassie Blue. The 
percentage of soluble:insoluble His-tagged KIF5A800-1032 was found to be 4 % when 
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induced using a 250 ml culture as opposed to 2 % with a 50 ml culture. This increase of 
the ratio of soluble:insoluble KIF5A800-1032 could be due to greater aeration of BL21 
E.coli cells caused by the increase in flask size used to accommodate the larger culture. 
The yield of expressed His-tagged KIF5A800-1032 was also high enough to compensate for 
the low soluble:insoluble ratio and was deemed suitable for purification using affinity 
chromatography. Standard growth and solubilisation conditions for 
pET151TOPOKIF5A800-1032 were thus established. This was the induction of construct 
expression in a 250 ml BL21 E.coli culture with 1 mM IPTG for 4 h at 18°C. Protein was 
solubilised in 40 ml re-suspension buffer, 50 mM TRIS-HCl pH 8.0, 400 mM NaCl, 10 % 
w/v glycerol, 5 mM β-ME, protease inhibitors and 20 µg/ml lyzozyme treatment for 30 
min and sonication on ice with 6 bursts of 10 sec with 10 sec rest intervals. A 
representative Coomassie Blue stained gel and immunoblot is shown in Figure 4.5. 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Demonstration of the optimized expression of His-tagged KIF5A800-1032 in BL21 E.coli cells.  
BL21 E.coli cells were transformed with pET151TOPOKIF5A800-1032. Cell homogenates were prepared 
after 250 ml cultures supplemented with 1 % w/v glucose were induced with 1 mM IPTG for 4 h at 18°C. 
In all Coomassie Blue stained gels and immunoblots the total, soluble and insoluble protein of the 
expressed KIF5A800-1032 is shown. The induced total control was included. The positions of molecular 
weight standards (kDa) are shown on the right. Arrows indicate the positions of bands of interest.  
A = KIF5A800-1032. Immunoblot probed with anti-His antibodies. B = KIF5A800-1032.  
 
To investigate if the expressed His-tagged KIF5A800-1032 could be purified via affinity 
chromatography initial experiments using Ni2+ affinity resin were carried out. Ni2+ 
A B 
147 
 
1 2 3 4 5 6 7 8
Wash fractions
Antibody = His
1 2 3 4 5 6 7
Elution fractions
Antibody = His
89 10
- 250
- 98
- 64
- 50
- 36
- 30
- 250
- 98
- 64
- 50
- 36
- 30
- 200
- 116.25
- 97.4
- 66.2
- 45
- 31
Elution fractions
1 2 3 5 6 74 8
- 200
- 116.25
- 97.4
- 66.2
- 45
- 31
1 2 3 4 5 76 8
Wash fractions
9 10
A
B
affinity resin will bind the His-tag present on the N-terminus of the KIF5A800-1032 protein 
with micromolar affinity. A soluble protein extract (40 ml) of transformed  
pET151TOPOKIF5A800-1032 bacterial cultures induced with 1 mM IPTG for 4 h at 18°C 
was incubated with the Ni2+ affinity resin for 1 h, washed with 20 mM imidazole to 
remove non-specifically bound protein and eluted with 250 mM imidazole (Section 
2.2.4.1). Soluble, unbound, washed and eluted fractions were analysed by SDS-PAGE 
using Coomassie Blue staining and immunoblotting with anti-His antibodies. The 
results of the affinity purification are shown in Figure 4.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Initial purification of His-tagged KIF5A800-1032 under native conditions using Ni
2+
 affinity resin. 
BL21 E.coli cells were transformed with pET151TOPOKIF5A800-1032 and the cell homogenates were 
prepared after 250 ml cultures supplemented with 1 % w/v glucose were induced with 1 mM IPTG for 4 
h at 18°C. The soluble cell homogenate was incubated with Ni
2+ 
affinity resin for 1 h and washed and 
eluted from the resin as 1 ml fractions. Results are representative of n = 1 purification experiments. The 
positions of molecular weight standards (kDa) are shown on the right. Arrows indicate the positions of 
bands of interest.  
A = KIF5A800-1032 purification probed with anti-His antibodies. B = Coomassie Blue stained KIF5A800-1032 
purification. 
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Initial affinity chromatography experiments show the presence of His-tagged KIF5A800-
1032 in the soluble fraction indicating correct expression and solubilisation. There is no 
visible decrease in His-tagged KIF5A800-1032 in the supernatant compared to the soluble 
sample indicating that His-tagged KIF5A800-1032 is not efficiently binding the Ni
2+ affinity 
resin. The concentration of His-tagged KIF5A800-1032 of the eluted fractions in both the 
Coomassie Blue stained gels and immunoblots appears to be low with a high 
concentration of background binding proteins. Attempts to optimize further the 
purification conditions included increasing the concentration of imidazole present in 
the wash buffer to reduce the binding of background binding of E.coli proteins to the 
resin, as well as eluting His-tagged KIF5A800-1032 from the resin using a step-wise 
increase of imidazole concentration. However, it was not until the KIF5A800-1032 bound 
resin was incubated with the elution buffer containing 250 mM imidazole for three h 
that a high yield of purified His-tagged KIF5A800-1032 was recovered. Representative 
results of the affinity purification under these conditions are shown in Figure 4.7. 
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Figure 4.7 Optimal purification of KIF5A800-1032 under native conditions using Ni
2+
 affinity resin. 
BL21 E.coli cells were transformed with pET151TOPOKIF5A800-1032 and the cell homogenates were 
prepared after 250 ml cultures supplemented with 1 % w/v glucose were induced with 1 mM IPTG for 4 
h at 18°C. A soluble cell homogenate was incubated with Ni
2+ 
affinity resin for 1 h and washed and 
eluted from the resin as 1 ml fractions. Results are representative of n = 5 purification experiments. 
Elution fraction numbers 7-10 represent eluted KIF5A800-1032 after incubation with elution buffer for 3 h. 
The positions of molecular weight standards (kDa) are shown on the right. Arrows indicate the positions 
of bands of interest.  
A = KIF5A800-1032 purification probed with anti-His antibodies. B = Coomassie Blue stained KIF5A800-1032 
purification. 
 
Affinity chromatography experiments show the presence of His-tagged KIF5A800-1032 in 
the soluble fraction indicating correct expression and solubilisation. There is no visible 
decrease of His-tagged KIF5A800-1032 in the supernatant compared to the soluble 
sample indicating that KIF5A800-1032 is not efficiently binding the Ni
2+ affinity resin. This 
is similar to previous affinity chromatography purification results seen in Section 3.2.5, 
and Section 4.2.1 where both TRAK2100-380/KIF5A800-1032 and KIF5A800-1032 showed no 
visible decrease in the supernatant compared to the soluble sample. The 
concentration of His-tagged KIF5A800-1032 from eluted fractions one to six in both 
immunoblots and Coomassie Blue stained gels appears to be low. A high concentration 
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of background binding proteins is also seen after Coomassie Blue staining. It was not 
until incubation of the Ni2+ affinity resin with elution buffer containing 250 mM 
imidazole for a period of three h that a higher yield of eluted KIF5A800-1032 protein with 
relatively low background protein was seen in elution fraction number seven. This 
result indicates that the strong interaction of the His-tag present on KIF5A800-1032 
requires a more thorough elution regime. 
In an attempt to further purify as well as to assess the native state of His-tagged 
KIF5A800-1032 an additional step of size exclusion chromatography was carried out 
(Section 2.2.4.5). Size exclusion chromatography involves separating a protein sample 
by the size of its native constituents using a specific column packed with a resin of a set 
pore size. In this case a Superpose™ 6 column was used which can separate proteins 
from 5–5,000 kDa in size. Unfortunately, results from the size exclusion 
chromatography proved inconclusive as no His-tagged KIF5A800-1032 was detected in 
any eluted fractions either via immunoblotting or Coomassie Blue staining (data not 
shown). The most likely explanation for this result is that the purified His-tagged 
KIF5A800-1032 from affinity chromatography experiments could be aggregating and in 
turn being collected on the filter before the sample enters the Superpose™ 6 column. 
Hence in order to test if the His-tagged KIF5A800-1032 protein is in fact aggregating after 
affinity chromatography experiments, affinity chromatography purified His-tagged 
KIF5A800-1032 was centrifuged at 100,000 x g for 20 min and the resulting pellet and 
soluble protein sample analysed. The results of the assessment of the aggregation 
state of His-tagged KIF5A800-1032 are shown in Figure 4.8.      
 
 
 
 
 
 
 
Figure 4.8 Assessment of the aggregation state 
of KIF5A800-1032. 
Bacterial protein samples were centrifuged at 
100,000 x g for 20 min at 4˚C and the resulting 
protein pellet and soluble supernatant analysed 
via SDS-PAGE and Coomassie Blue staining.  
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High speed centrifugation demonstrated that the majority of the affinity 
chromatography purified KIF5A800-1032 is in fact aggregating and hence does not make 
an ideal candidate to carry out further structural studies. 
 
4.2.3 Assessment of KIF5A820-1032, KIF5A800-951 and KIF5A820-951 as suitable recombinant 
proteins for structural studies  
Previous work carried out by Seeger and Rice (2010) has demonstrated the successful 
expression and purification of two kinesin-1 cargo binding domain protein fragments 
from a bacterial expression system. These were amino acids 822-963 and 822-945 of 
KIF5B. Both KIF5B cargo binding domain fragments possessed an N-terminal His-tag for 
affinity purification. Hence, it is reasonable to hypothesise that a similar region of 
KIF5A could be purified more efficiently than the previous KIF5A cargo binding domain 
proteins shown in Section 4.2.1 and Section 4.2.2. Amino acid sequence alignment 
analysis demonstrated that the equivalent amino acid region 822-945 of KIF5B was 
amino acids 820-951 of KIF5A. Thus, bacterial expression constructs pETDUETKIF5A820-
1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951 were generated. The pETDUET1 
vector was chosen because MCS1 possesses DNA encoding for an N-terminal His-tag 
and previous work in Section 4.2.2 has demonstrated that expressed KIF5A with an N-
terminal His-tag was soluble and able to be purified via affinity chromatography to a 
high yield. pETDUETKIF5A820-1032 possessed DNA encoding for the same start region of 
amino acids used in the two expressed clones from the Seeger and Rice (2010) study. 
pETDUETKIF5A800-951 was the same as previous KIF5A cargo binding domain clones but 
with a shorter C-terminus in an attempt to avoid the proteolytic cleavage seen in KIF5B 
822-963 (Seeger and Rice, 2010). pETDUETKIF5A800-951 was the closest equivalent of the 
successfully expressed KIF5B construct.  
pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951 were transformed 
into chemically competent BL21 E.coli cells and protein expression induced (Section 
2.2.3). Previous work carried out in Section 4.2.2 has demonstrated the optimization of 
expression of the KIF5A800-1032 constructs to be the induction of protein expression 
using 250 ml cultures and 1 mM IPTG to induce expression for a total of 4 h at 18°C. 
Hence, these same conditions were used for expression of pETDUETKIF5A820-1032, 
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pETDUETKIF5A800-951 and pETDUETKIF5A820-951. The resulting expressed protein was re-
suspended in 40 ml of re-suspension buffer, centrifuged to separate protein into 
soluble and insoluble protein pellets and ~ 10 µg of each protein fraction analysed via 
15 % SDS-PAGE (Section 2.2.3.4). The resulting Coomassie Blue stained gels are shown 
in Figure 4.9. KIF5A820-1032, KIF5A800-951 and KIF5A820-951 were successfully expressed as 
demonstrated by bands corresponding to the predicted sizes in the total, soluble and 
insoluble protein fractions, i.e. KIF5A820-1032 = 31.4 ± 1.1 kDa (n = 3), KIF5A800-951 = 22.5 
± 1.2 kDa (n = 3) and KIF5A820-951 = 19.2 ± 0.5 kDa (n = 3).  
 
 
 
 
 
 
 
 
Figure 4.9 Demonstration of the expression of KIF5A820-1032, KIF5A800-951 and KIF5A820-951 in BL21 E.coli 
cells.  
BL21 E.coli cells were transformed with pETDUETKIF5A820-1032, pETDUETKIF5A800-951 or pETDUETKIF5A820-
951. Cell homogenates were prepared after 250 ml cultures supplemented with 1 % w/v glucose were 
induced with 1 mM IPTG for 4 h at 18°C. In the Coomassie Blue stained gel the total, soluble and 
insoluble protein of the induced plasmid is shown. The induced total protein control was included. The 
positions of molecular weight standards (kDa) are shown on the right. Arrows indicate the positions of 
bands of interest.  
 
 
To verify that the pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951 
constructs were the desired KIF5A820-1032, KIF5A800-951 and KIF5A820-951 proteins, 
immunoblotting was carried out using anti-His antibodies. The resulting immunoblot is 
shown in Figure 4.10.   
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Figure 4.10 Demonstration of the expression of KIF5A820-1032, KIF5A800-951 and KIF5A820-951 in BL21 E.coli 
cells.  
BL21 E.coli cells were transformed with pETDUETKIF5A820-1032, pETDUETKIF5A800-951 or pETDUETKIF5A820-
951. Cell homogenates were prepared after 250 ml cultures supplemented with 1 % w/v glucose were 
induced with 1 mM IPTG for 4 h at 18°C. In the immunoblot the total, soluble and insoluble protein of 
the induced plasmid is shown. The induced total protein control was included. The positions of 
molecular weight standards (kDa) are shown on the right. Arrows indicate the positions of bands of 
interest.  
 
Immunoblotting with anti-His antibodies confirms the correct transcription of KIF5A820-
1032, KIF5A800-951 and KIF5A820-951 with immunoreactive bands present in all total, 
soluble and insoluble fractions. Overall a lower concentration of KIF5A820-1032 is present 
in the soluble extract when compared to both the total and insoluble fractions, 
resulting in a soluble:insoluble ratio of 32 %. Whereas higher concentrations of 
KIF5A800-951 and KIF5A820-951 are present in the soluble extract when compared to both 
the total and insoluble fractions, giving a soluble:insoluble ratio of 54 % and 57 % 
respectively. In the total and insoluble fractions of KIF5A820-1032 the presence of a 
higher molecular weight band was seen at ~ 55 kDa. In the total, soluble and insoluble 
fractions of KIF5A800-951 and KIF5A820-951 the presence of several higher molecular 
weight bands were seen at weights in the range of 36-98 kDa for KIF5A800-951 and ~ 36 
kDa for KIF5A820-951. These higher molecular weight bands are most likely aggregated 
KIF5A820-951. Anti-His antibodies also recognised several major immunoreactive bands 
lower than the predicted molecular weight of KIF5A820-1032, KIF5A800-951 and KIF5A820-951. 
These lower molecular weight bands may be the result of proteolytic degradation 
occurring at the C-terminus of KIF5A820-1032, KIF5A800-951 and KIF5A820-951. This is because 
KIF5A820-1032, KIF5A800-951 and KIF5A820-951 are N-terminally His-tagged and the lower 
molecular weight band can be visualised after immunoblotting with anti-His 
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antibodies. Previous work in Section 3.2.4 and Section 4.2.2 has shown that KIF5A800-
1032 constructs are prone to proteolytic degradation at the C-terminus. As mentioned 
earlier, Seeger and Rice (2010) also showed that the degradation of the C-terminal 
amino acids 945-963 of KIF5B occurs over time in bacterially expressed constructs. 
However, the KIF5A800-951 and KIF5A820-951 constructs were designed specifically in an 
attempt to prevent this proteolytic degradation from occurring. Thus, it is quite likely 
that KIF5A and KIF5B do not share the same proteolytic cleavage sites.       
Solubility was deemed sufficient after expression using conditions previously optimized 
for the expression of pET151TOPOKIF5A800-1032 (Section 4.2.2). Thus, standard growth 
and solubilisation conditions for all three constructs were established. These were the 
induction of 250 ml cultures with 1 mM IPTG for 4 h at 18°C. Protein was solubilised in 
40 ml re-suspension buffer (50 mM TRIS-HCl [pH 8.0], 400 mM NaCL, 10 % w/v 
glycerol, 5 mM β-ME, protease inhibitors) 20 µg/ml lyzozyme for 30 min and sonicated 
on ice with 6 bursts of 10 sec with 10 sec rest intervals. A summary of the overall 
cloning, expression and optimization of expression is shown in Table 4.2. 
Protein 
Generation 
of 
construct 
Correct 
expression 
in E.coli 
Visual analysis of the 
soluble fraction using 
Coomassie Blue staining 
% Solubilisation 
KIF5A820-1032   Clear band in the soluble fraction 
32 % 
KIF5A800-951   Clear band in the soluble fraction  
54 % 
KIF5A820-951   Clear band in the soluble fraction 57 % 
Table 4.2 Summary of the overall cloning, expression and solubilisation optimisation for 
pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951. 
 
In order to investigate if expressed KIF5A820-1032, KIF5A800-951 and KIF5A820-951 can be 
purified via affinity chromatography experiments using Ni2+ affinity resin were carried 
out. Soluble protein extract (20 ml) of transformed pETDUETKIF5A820-1032, 
pETDUETKIF5A800-951 or pETDUETKIF5A820-951 bacterial cultures of 250 ml induced with 1 
mM IPTG for 4 h at 18°C were incubated with the Ni2+ affinity resin for 1 h, washed to 
remove non-specifically bound protein and eluted with 250 mM imidazole (Section 
2.2.4.1). Soluble, unbound, washed and eluted fractions were analysed by SDS-PAGE 
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using Coomassie blue staining. The results of the affinity purification of KIF5A820-1032, 
KIF5A800-951 and KIF5A820-951 are shown in Figure 4.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Purification of KIF5A820-1032, KIF5A800-951 and KIF5A820-951 under native conditions using Ni
2+
 
affinity resin. 
BL21 E.coli cells were transformed with pETDUETKIF5A820-1032, pETDUETKIF5A800-951 or pETDUETKIF5A820-
951 and the cell homogenates were prepared after 250 ml cultures supplemented with 1 % w/v glucose 
were induced with 1 mM IPTG for 4 h at 18°C. Soluble cell homogenate was incubated with Ni
2+ 
affinity 
resin for 1 h and washed and eluted from the resin as 1 ml fractions. KIF5A820-1032 and KIF5A820-951 are 
representative of n = 1 purification experiments, whereas KIF5A820-951 is representative of n = 4 
purification experiments. The positions of molecular weight standards (kDa) are shown on the right. 
Arrows indicate the positions of bands of interest.  
A = Coomassie Blue stained KIF5A820-1032 purification. B = Coomassie Blue stained KIF5A800-951 purification. 
C = Coomassie Blue stained KIF5A820-951 purification. 
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Affinity chromatography experiments show the presence of KIF5A820-1032, KIF5A800-951 
and KIF5A820-951 in the soluble fraction indicating correct expression and solubilisation. 
Analysis of KIF5A820-1032 purification does not include the supernatant sample which 
makes it difficult to assess how efficiently KIF5A820-1032 binds the Ni
2+ affinity resin. 
KIF5A800-951 shows a visible decrease in protein in the supernatant compared to the 
soluble sample indicating that KIF5A800-951 is efficiently binding the Ni
2+ affinity resin. 
There is no visible decrease in KIF5A820-951 in the supernatant compared to the soluble 
sample indicating that KIF5A820-951 is not efficiently binding the Ni
2+ affinity resin. 
KIF5A820-1032 is not visible in any of the eluted fractions after Coomassie Blue staining. 
Whereas a high yield of KIF5A820-951 is visible in the eluted fractions after Coomassie 
Blue staining. KIF5A820-951 purification also shows the presence of several 
contaminating background proteins in the elution fractions, albeit at a very low 
concentration in comparison to KIF5A820-951. The purification of KIF5A820-951 indicates 
two major bands being eluted from the resin. The lower molecular weight band is most 
likely the product of proteolytic degradation, as noted previously in Figure 4.10, after 
expression in BL21 E.coli cells. KIF5A820-951 shows poor overall elution from Ni
2+ affinity 
resin with very high concentrations of contaminating proteins detected in all elution 
fractions. In summary, KIF5A820-1032 and KIF5A820-951 showed poor purification when 
using Ni2+ affinity resin, with the proteins either not being eluted from the resin or a 
high concentration of contaminating background proteins also being eluted. Whereas 
KIF5A800-951 displayed a high yield of relatively pure protein after affinity 
chromatography experiments and is a good candidate for further analysis. 
Due to the aggregation of KIF5A800-1032 seen in Figure 4.8 the aggregation state of 
affinity chromatography purified KIF5A800-951 was tested. Purified KIF5A800-951 was 
centrifuged at 100,000 x g for 20 min and the resulting pellet and soluble protein 
sample analysed. The results are shown in Figure 4.12. 
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High speed centrifugation has demonstrated that the majority of the affinity 
chromatography purified KIF5A800-1032 is soluble and hence is an ideal candidate to 
carry out further structural studies. A summary of the overall cloning, expression, 
optimization of expression, yield after purification and aggregation state testing of all 
single KIF5A cargo binding domain proteins is shown in Table 4.3. 
Protein 
Generation 
of 
construct 
Correct 
expression 
in E.coli 
cells? 
Visual 
analysis of 
the soluble 
fraction  
% 
Solubilisation 
Sufficient 
yield after 
purification? 
Aggregation 
testing 
KIF5A800-1032 
(S-tag)   
Clear band in 
the soluble 
fraction 
35 %   
KIF5A800-1032 
(His-tag)   
Clear band in 
the soluble 
fraction  
4 %   
KIF5A820-1032 
(His-tag)   
Clear band in 
the soluble 
fraction 
32 %   
KIF5A800-951 
(His-tag)   
Clear band in 
the soluble 
fraction  
54 %   
KIF5A820-951 
(His-tag)   
Clear band in 
the soluble 
fraction  
57 %   
Table 4.3 Summary of the overall cloning, expression, solubilisation optimisation, purification and 
aggregation testing for KIF5A800-1032, His-tagged KIF5A800-1032, KIF5A820-1032, KIF5A800-951 and KIF5A820-951. 
 
In an attempt to further purify as well as assess the native state of KIF5A800-951 an 
additional step of size exclusion chromatography was carried out (Section 2.2.4.5). In 
this case a Superpose™ 6 column was used and can separate proteins from 5–5,000 
Figure 4.12 Assessment of the aggregation state 
of KIF5A800-951. 
Bacterial protein samples were centrifuged at 
100,000 x g for 20 min at 4˚C and the resulting 
protein pellet and soluble supernatant analysed 
via SDS-PAGE using Coomassie Blue staining.  
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kDa in size. Prior to loading onto the Superose 6 column KIF5A800-951 protein was buffer 
exchanged to remove glycerol and concentrated on a Vivaspin 10 kDa molecular 
weight cut off column to a concentration of ~ 2 mg/ml (Section 2.2.4.3). The resulting 
KIF5A800-951 was found to remain soluble after buffer exchange and protein 
concentration (data not shown). The results of the size exclusion chromatography are 
shown in Figure 4.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 Size exclusion chromatography analysis of affinity chromatography purified KIF5A800-951.  
Affinity chromatography purified KIF5A800-951 was eluted from the Superose 6 column as 0.5 ml fractions. 
Results are representative of n = 2 size exclusion experiments. In all Coomassie Blue stained gels and 
immunoblots elution volumes 13 – 17 ml are shown. The positions of molecular weight standards (kDa) 
are shown on the right. Arrows indicate the positions of bands of interest.  
A = Molecular weight standards used to calibrate the Superose 6 column and the resulting elution 
profile. B = Coomassie Blue stained KIF5A800-951 elution fractions. C = Immunoblot of KIF5A800-951 elution 
fractions probed with anti-His antibodies. 
 
A 
B C 
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The results from the size exclusion chromatography experiments indicate a good 
separation of molecular weight standards. KIF5A800-951 was detected in immunoblot 
lanes corresponding to elution volumes 15–16.5 ml. The majority of KIF5A800-951 is seen 
in elution volume 15.5 ml in both Coomassie Blue stained gels and immunoblots. 
Calibration of the protein standards indicate that the eluted KIF5A800-951 is in the range 
of 66 – 158 kDa. Immunoblotting also indicates two lower molecular weight bands of 
approximately 16 kDa and 6 kDa in size as seen previously in Figure 4.10. Although size 
exclusion chromatography has has yielded some limited information regarding the 
native state of KIF5A800-951, the yield is seen to decrease after separation and is hence 
not an ideal method to further purify KIF5A800-951. 
In order to assess if KIF5A800-951 can bind microtubules in a similar manner to KIF5B 822-
944 (Seeger and Rice, 2010) a microtubule binding assay was performed (Section 
2.2.4.6.1). Previous work in the same study has indicated that the interaction of KIF5B 
with the microtubule is largely electrostatic and can be influenced by the strength of 
the ionic buffer. Therefore, prior to the microtubule binding assay KIF5A800-951 was 
buffer exchanged using a Vivispin 10 kDa molecular weight cut off column to lower the 
NaCl concentration from 400 mM to 150 mM. The resulting KIF5A800-951 was found to 
remain soluble after buffer exchange and to not aggregate (data not shown). 
Approximately 1.8 µM of stable and polymerised microtubules were incubated with 
varying concentrations of KIF5A800-951 and the resulting soluble and pellet fractions 
analysed after high speed centrifugation via SDS-PAGE and Coomassie Blue staining. 
The results of the microtubule binding assay are shown in Figure 4.14.    
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Figure 4.14 Microtubule binding assay showing the association of microtubules with KIF5A800-951. 
Varying concentrations of affinity chromatography purified KIF5A800-951 was incubated with 
approximately 1.8 µM of stable and polymerised microtubules for 15 min at room temperature. The 
samples were subsequently centrifuged for 15 min at 392,000 x g to separate into pellet and soluble 
fractions. S = supernatant or unbound KIF5A800-951 and P = pellet or bound KIF5A800-951. Control 1 = 
microtubule only sample and Control 2 = KIF5A800-951 only sample. The positions of molecular weight 
standards (kDa) are shown on the right. The arrow indicates the position of KIF5A800-951.  
 
 
 
The results from the Coomassie Blue stained gel of the microtubule binding assay 
indicates the presence of tubulin at approximately 50 kDa in all sample lanes except 
for control two. The majority of tubulin is seen in the pellet fraction indicating the 
successful polymerisation of tubulin subunits into microtubules. The results also 
indicate that the majority of KIF5A800-951 incubated at a concentration of 0.34–1.6 μM 
are found in the protein pellet, indicating that KIF5A800-951 is binding to the 
microtubules. Samples incubated with 2.4 μM and 4.1 μM of KIF5A800-951 also show the 
presence of KIF5A800-951 in the pellet indicating a positive interaction with 
microtubules. Although the majority of KIF5A800-951 in the 2.4 μM and 4.1 μM 
microtubule incubated samples are seen in the soluble fraction. This is most likely due 
to the saturation of binding domains available on the polymerised microtubules. As the 
incubated concentration of KIF5A800-951 increases the amount of tubulin noted in the 
soluble sample decreases. This could be due to a “bundling effect” where soluble 
tubulin is pelleted in the sample despite not specifically binding KIF5A800-951. Overall 
the results from the microtubule binding assay have indicated that KIF5A800-951 can 
interact with polymerised microtubules in vitro.      
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4.3 DISCUSSION 
The structure and function of the motor domain of kinesin-1 has been well studied, 
with a high resolution crystal structure of the motor domain having been elucidated 
(Kull et al., 1996; Kozielski et al., 1997; Section 1.2.1). However structural information 
regarding the cargo binding domain of kinesin-1, vital for transportation of cargo, is 
relatively unknown. Attempts to gain a high yield of purified KIF5A cargo binding 
domain in association with its in vitro binding partner TRAK2 for structural studies 
were unsuccessful (see work in Chapter 3). Therefore the aim of this chapter was to 
generate a high yield of the purified cargo binding domain of KIF5A as a singly 
expressed protein.  
In this chapter it has been demonstrated that a functional KIF5A cargo binding domain 
protein with a high yield after affinity chromatography can be generated in bacterial 
cells. Initially five constructs, pETDUETKIF5A800-1032, pET151TOPOKIF5A800-1032, 
pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and pETDUETKIF5A820-951, were generated 
and the successful expression of protein in a bacterial system were verified. The 
analysis of S-tagged KIF5A800-1032 showed poor yield of purified protein after affinity 
chromatography using S-protein affinity resin. This result coupled with the poor yield 
of purified TRAK2100-380/KIF5A800-1032 seen in Section 4.2.1, also using S-protein affinity 
resin, indicates that the S-tag is being obscured from the resin via the tertiary folding 
of KIF5A800-1032. Subsequently, the generation of a construct to re-locate and change 
the affinity tag from an S-tag present on the C-terminus to a His-tag present on the N-
terminus of KIF5A800-1032 resulted in an increased yield of protein after affinity 
chromatography purification experiments. However, the His-tagged KIF5A800-1032 was 
unstable and the majority of His-tagged KIF5A800-1032 aggregated after purification. The 
analysis of KIF5A820-1032 and KIF5A820-951 showed high solubility after protein expression 
but poor yield after purification via affinity chromatography. Whereas KIF5A800-951 
resulted in high solubility after expression, gave a high yield after affinity 
chromatography purification and remained stable. Therefore KIF5A800-951 is an ideal 
candidate for further structural studies.   
The analysis of KIF5A800-951 using size exclusion chromatography gave some insight into 
the native state of the purified protein. Results indicated that the majority of KIF5A800-
951 elutes from the column in the region of 66–158 kDa. The predicted molecular 
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weight of KIF5A800-951 is 18.8 kDa and hence the size exclusion chromatography data 
implies the affinity purified KIF5A800-951 is not a single monomeric subunit. KIF5A800-951 
could instead be possibly interacting with more than one other KIF5A800-951 molecule. 
Dimerisation of native kinesin-1 normally involves interaction of the two heavy chains 
via the stalks coiled-coil domain (Jiang et al., 1997; Hackney et al., 2009). However this 
region is not present in KIF5A800-951 and so cannot explain the interaction of KIF5A800-951 
molecules after expression in bacterial cells. One alternative interpretation may be the 
presence of the two cysteine residues present at amino acids 847 and 943 of KIF5A800-
951. These cysteine residues may be forming disulfide bonds resulting in the cross 
linking of more than one KIF5A800-951 molecule. This cross linking of cysteine residues is 
unlikely to be occurring after solubilisation of KIF5A800-951 due to the presence of the 
reducing agent β-ME in the solubilisation buffer. Disulfide bonds may be being 
introduced after purification via affinity chromatography due to the high concentration 
of KIF5A800-951 without the presence of a reducing agent in the elution buffer. It is also 
worth noting that estimating the size of KIF5A800-951 using size exclusion 
chromatography relies on the assumption that the protein is globular. Recent work by 
Seeger et al. (2012) has indicated that the cargo binding domain of kinesin proteins are 
highly disordered. More specifically this work demonstrated that KIF5B 822-963 and 
KIF5B 860-963 are highly disordered. However, using microtubule binding assays it was 
also shown that KIF5B 822-963 and KIF5B 860-963 remain functional (Seeger et al., 
2012). Thus, it is difficult to know if KIF5A800-951 is acting as a globular protein to allow 
an accurate assessment of its native state after purification. The results from the size 
exclusion chromatography experiments indicated that the yield of KIF5A800-951 
decreased after separation by molecular weight using size exclusion chromatography. 
Overall, although size exclusion chromatography gave some insight into the native 
state of the affinity chromatography purified KIF5A800-951, due to the loss of protein 
yield it was deemed unsuitable to act as an additional purification step. 
The work in this chapter has not managed to fulfil the long term aim, stated in Section 
4.1.1, of gaining a solved crystal structure of the cargo binding domain of KIF5A. 
However, what this chapter has done is make significant steps forward to help achieve 
this goal. Work presented here has demonstrated that soluble KIF5A800-951 is able to be 
expressed in a bacterial expression system and is also able to be purified to mg 
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quantities after affinity chromatography purification. The affinity purified KIF5A800-951 is 
also stable and does not aggregate after buffer exchange experiments. Although the 
yield of KIF5A800-951 is high there is the presence of His-tagged protein with a lower 
molecular weight. If future experiments to generate a crystal structure of KIF5A800-951 
are to succeed then the protein sample will need to be purified further. A homogenous 
sample i.e. no proteolytically cleaved species, must be present in order to create 
conditions to form crystals for structural analysis. This work to gain a crystal structure 
of the cargo binding domain of kinesin-1 still remains an important target to achieve. A 
solved tertiary structure of the cargo binding domain of KIF5A could lead to a better 
understanding of how kinesin-1 can interact with such a variety of cargo and adaptor 
proteins, as well as a better understanding of the mechanisms behind their regulation. 
However, as discussed earlier, the recent work by Seeger et al. (2012) has suggested 
that the cargo binding domain of KIF5B is highly disordered. This work suggests that 
gaining a protein of the kinesin-1 cargo binding domain that can crystallise is unlikely 
due to their unstructured nature. Hence an alternative method such as protein nuclear 
magnetic resonance (NMR) spectroscopy could be employed. Due to the small size of 
KIF5A800-951 NMR spectroscopy may be used to help determine the structure of the 
kinesin-1 cargo binding domain.  
As discussed in Section 1.4 previous studies have shown that the cargo binding domain 
of kinesin-1 is capable of binding to the motor domain (Cai et al., 2007; Hackney et al., 
2009; Wong et al., 2009). The binding of the cargo binding to the motor domain is 
thought to act as a mechanism for self-inhibition and could act as way to prevent the 
unnecessary movement of kinesin-1 without any cargo. Seeger and Rice, (2010) has 
also demonstrated the ability of KIF5B 892-914 to bind directly to microtubules. KIF5B 
892-914 includes the final few turns of the predicted coiled-coil domain finishing just 
before the conserved QIAK region known to be important for binding of the cargo 
binding to the motor domain. KIF5B 892–914 and the equivalent region of KIF5A share 
a 70 % amino acid sequence identity. This high amino acid identity alludes to the 
possibility that KIF5A may also bind microtubules using a similar sequence domain. In 
this chapter KIF5A800-951 was shown, via a microtubule binding assay, to co-sediment 
with microtubules. This result demonstrates that, like KIF5B, the cargo binding domain 
of KIF5A can interact with microtubules in vitro. This also indicates that the regulation 
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of movement of KIF5A in vivo may be mediated by the interaction of the cargo binding 
domain to the microtubules. Dietrich et al. (2008) has further demonstrated that the 
KIF5B cargo binding domain can bind both the motor domain and microtubules 
simultaneously. This is interesting as it alludes to the possibility that the cargo binding 
domain of kinesin-1 can prevent movement by binding directly the microtubule as well 
as the nucleotide pocket of the motor domain. The work presented in this chapter as 
well as the work referenced above gives a strong network of evidence to indicate that 
kinesin-1 will dissociate from the cargo that is being transported and remain bound to 
the microtubules.  
 
4.3.1 Overall conclusions 
 The bacterial expression constructs pETDUETKIF5A800-1032, 
pET151TOPOKIF5A800-1032, pETDUETKIF5A820-1032, pETDUETKIF5A800-951 and 
pETDUETKIF5A820-951 were successfully generated.  
 The expression of each tagged KIF5A cargo binding domain with the correct 
predicted size was verified by immunoblotting. Further, optimal growth and 
solubilisation conditions were established for each construct. 
 His-tagged KIF5A800-1032 and KIF5A800-951 cargo binding domain constructs could 
be purified. However, the highest yield and the least aggregation were found 
for KIF5A800-951. Thus, KIF5A800-951 is a good candidate for further structural 
analyses.  
 Similar to KIF5B, KIF5A800-951 was found to associate with microtubules in vitro. 
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CHAPTER 5 
 
 
THE ASSOCIATION BETWEEN THE TRAK AND 
KINESIN-1 FAMILIES; AN INVESTIGATION USING A 
CO-IMMUNOPRECIPITATION STRATEGY 
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5.1 RATIONALE  
As discussed in the Introduction the KHC of kinesin-1 has been shown to bind several 
kinesin adaptor proteins including Syntabulin, GRIP-1, UNC76, Milton, SNAP23, 
SNAP25, FEZ1, TRAK1 and TRAK2 (Section 1.2.4). How and where on the KHC the 
binding occurs for each of these is as yet poorly understood. Only on the adaptor 
proteins UNC-76, GRIP-1, SNAP23, SNAP25, Milton, TRAK1 and TRAK2 have 
experiments been carried out in an attempt to map their site of binding to kinesin-1. 
What is not known is if the interaction between kinesin-1 and the many adaptor 
proteins known to bind kinesin-1 share conserved binding patterns or in fact have 
separate methods of association. The C-terminal tail domain of Drosophila UNC-76 has 
been shown via yeast two-hybrid and co-purification assays to bind amino acids 850-
975 of Drosophila KHC (Gindhart et al., 2003). GRIP1 will bind to amino acids 807-934 
to the KHC of KIF5A, KIF5B and KIF5C (Setou et al., 2002). Previous experiments to 
identify the binding domain of kinesin-1 to the TRAK/Milton family of adaptor proteins 
utilised KIF5C as a model kinesin. Initially KIF5C was divided into two main regions. 
These regions were amino acids 1-335 and 336-957. KIF5C 1-335 corresponded to the 
motor domain and KIF5C 336-957 included the non-motor domain. KIF5C 336-953 was 
shown using yeast two-hybrid interaction assays, co-immunoprecipitation experiments 
and FRET studies to interact with TRAK2. Whereas yeast two-hybrid interaction assays 
and co-immunoprecipitation experiments using KIF5C 1-335 showed no interaction 
with TRAK2 (Smith et al., 2006). FRET experiments utilising TRAK1 have also concluded 
that the non-motor domain of KIF5C is responsible for correct interaction (Brickley et 
al., 2011). Further work divided the KIF5C non-motor domain into three regions; these 
were amino acids 336-542, 593-804 and 827-957. Again using yeast two-hybrid 
interaction assays and co-immunoprecipitation experiments it was shown that amino 
acids 827-957 of KIF5 interact with TRAK2 while 336-542 and 593-804 do not. 
Conversely the amino acids 124-283 of TRAK2 but not TRAK1 were found to associate 
with the cargo binding domain of KIF5C, amino acids 827-957 (Brickley et al., 2005).  
The cargo binding domains of the kinesin-1 family share an overall ~ 86 % amino acid 
identity. KIF5A possesses an additional distal 71 C-terminal amino acids compared to 
KIF5B and KIF5C as shown in Figure 5.1. In the brain, TRAK2 associates predominantly 
with the kinesin-1, KIF5A (Brickley et al., 2005). In this chapter experiments have been 
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designed to refine further the TRAK1 and TRAK2 binding site within the cargo domain 
of KIF5A and KIF5C. Initially a series of KIF5A C-terminal truncations were generated to 
confirm that, as for KIF5C, it is the cargo binding domain that binds to TRAK2.  
 
 
Figure 5.1 Comparison of human KIF5A, KIF5B and KIF5C kinesin-1 sub-types.  
Structures of KIF5A, KIF5B and KIF5C showing the amino acid numbers of the motor, stalk and cargo 
binding domains.  
 
 
In order to assess the binding relationship between kinesin-1 and the TRAK/Milton 
protein family, recombinant tagged clones of kinesin-1 and TRAK1 and TRAK2 need to 
be co-expressed in a mammalian cell line. HEK 293 cells are widely used for co-
immunoprecipitation experiments because they are simple to culture and transfect. 
Although HEK 293 cells endogenously express KIF5B there is no endogenous 
expression of KIF5A, KIF5C or the TRAK/Milton family of proteins (Brickley et al., 2005). 
Hence the HEK 293 mammalian cell line makes it ideal to assess these proteins of 
interest in isolation.  
 
5.1.1 Aims of this chapter 
I. Ascertain if KIF5A can co-immunoprecipitate with TRAK2 after co-expression in 
HEK 293 cells. 
II. Using truncated KIF5A constructs refine the binding site within TRAK1 and 
TRAK2 via co-immunoprecipitation in HEK 293 cells. 
III. Using truncated KIF5C constructs refine the binding site within TRAK1 and 
TRAK2 via co-immunoprecipitation in HEK 293 cells. 
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5.2 RESULTS 
The aim of this chapter was to refine the region of amino acids on kinesin-1 that bind 
to the TRAK family of proteins. In order to do this, tagged recombinant clones of TRAK1 
or TRAK2 and either wild-type and mutated KIF5A or KIF5C were co-expressed in HEK 
293 cells and their respective association determined by co-immunoprecipitation. A 
schematic representation of the co-immunoprecipitation experiments are shown in 
Figure 5.2. 
 
 
 
 
 
Figure 5.2 A schematic representation of the co-immunoprecipitation experiments. 
 
Initially, wild-type and mutated KIF5A and KIF5C recombinant constructs for expression 
in mammalian cells were generated following PCR amplification from pBSKIF5A 
(human) and pN-EYFP-KIF5C (human). KIF5A PCR products were sub-cloned in frame 
using the restriction sites EcoRI/BamHI into pcDNA4HisMax (pcDNA). KIF5C PCR 
products were sub-cloned in frame using the restriction sites EcoRI/NotI into pcDNA. 
Recombinant KIF5A and KIF5C have an N-terminal His-tag. pCMVTRAK2 was generated 
as in Smith et al. (2006). Recombinant TRAK2 (rat) has a C-terminal Flag-tag. 
pCMVTRAK1 was generated as in Brickley et al. (2005). Recombinant TRAK1 (human) 
has an N-terminal c-Myc-tag. All recombinant clones were verified via DNA sequencing 
(Section 2.2.2.13). Figure 5.3 shows schematics of the recombinant clones after 
expression in HEK 293 cells. 
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Figure 5.3 Schematic representations of recombinant tagged KIF5A, KIF5C, TRAK1 and TRAK2. 
 
HEK 293 cells were co-transfected with TRAK1 or TRAK2 and either wild-type or 
mutated KIF5A or KIF5C, cell homogenates were prepared, Triton X-100 solubilised and 
the resulting soluble fraction used for co-immunoprecipitation experiments (Section 
2.2.5.8). Co-immunoprecipitation experiments involving TRAK1 were carried out using 
anti-c-Myc antibodies. Co-immunoprecipitation experiments involving TRAK2 were 
carried out using anti-Flag antibodies. Both TRAK1 and TRAK2 co-immunoprecipitation 
experiments were carried out simultaneously with non-immune antibodies as a 
negative control. The resulting immune and non-immune pellets were dissolved in 20 
µl 3 x SDS-PAGE sample buffer and 5 µl 1 M DTT and divided into 90 % and 10 % 
aliquots. The 10 % samples of the immune and non-immune pellets were analysed 
using the precipitating antibody i.e. anti-c-Myc or anti-Flag for detection of TRAK1 or 
TRAK2 respectively. The 90 % samples were analysed using anti-His antibodies for 
detection of KIF5A or KIF5C.  
 
5.2.1 Does TRAK2 associate with the cargo binding domain of KIF5A? 
To determine if TRAK2 associates with the cargo binding domain of KIF5A three 
recombinant KIF5A clones were generated. These were pcDNAKIF5A, pcDNAKIF5A1-825 
and pcDNAKIF5A1-961. pcDNAKIF5A encodes full length KIF5A which is a positive 
control, pcDNAKIF5A1-825 was engineered to delete the KIF5A cargo binding domain 
and pcDNAKIF5A1-961 to remove the extra C-terminal 71 amino acids not found in KIF5B 
and KIF5C (Figure 5.1).  
Initially experiments were carried out to show that the recombinant proteins were 
expressed in mammalian cell lines. Thus, HEK 293 cells were transfected with 
pCMVTRAK2, pcDNAKIF5A, pcDNAKIF5A1-825 or pcDNAKIF5A1-961, cell homogenates 
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were prepared (Section 2.2.5.7) and analysed by immunoblotting using either anti-Flag 
or anti-His antibodies as appropriate (Section 2.2.3.5). Representative immunoblots 
are shown in Figure 5.4. Each KIF5A construct was successfully expressed in HEK 293 
cells as demonstrated by immunoreactive bands corresponding to their predicted 
sizes, i.e. KIF5A = 126.5 ± 2 kDa (n = 21), KIF5A1-825 = 99.5 ± 1.3 kDa (n = 11) and KIF5A1-
961 = 115.8 ± 1.3 kDa (n = 13). For the TRAK2 construct, anti-Flag antibodies recognised 
two major immunoreactive bands, i.e. 120.4 ± 1.7 kDa (n = 20) and 115.1 ± 1.3 kDa (n = 
20). The major band of ~ 120 kDa corresponds to the predicted molecular weight of 
TRAK2. Previous experiments to over-express the same TRAK2-Flag construct in HEK 
293 cells also resulted in the detection of a lower molecular weight immunoreactive 
species (Brickley et al., 2005). The lower molecular weight band is most likely a product 
of proteolytic degradation. It is unlikely that this lower molecular weight band is 
caused by non-specific antibody reactivity since it is not detected in the non-
transfected cell samples. It could also be theorised that the proteolytic degradation is 
occurring at the N-terminus of the TRAK2 protein. This is because the TRAK2 is C-
terminally Flag tagged and the lower molecular weight band can be visualised after 
immunoblotting with anti-Flag antibodies. Another possible cause of the lower 
molecular weight band seen could be that the TRAK2 proteins are differentially post-
translationally modified.  
 
 
 
 
 
 
 
Figure 5.4 Demonstration of the expression of TRAK2, KIF5A, KIF5A1-825 and KIF5A1-961 in HEK 293 cells. 
HEK 293 cells were transfected with pCMVTRAK2, pcDNAKIF5A, pcDNAKIF5A1-825 or pcDNAKIF5A1-961. Cell 
homogenates were prepared 48 h post-transfection and detergent solubilised. In all immunoblots lane 1 
= transfected cell homogenate and lane 2 = non-transfected cell homogenate. The positions of 
molecular mass standards (kDa) are shown on the right. Arrows indicate the positions of 
immunoreactive bands. 
A = Immunoblot probed with anti-Flag antibodies. B, C, D = Immunoblot probed with anti-His antibodies. 
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To ascertain if the cargo binding domain of KIF5A binds to TRAK2, co-
immunoprecipitation assays were carried out. HEK 293 cells were co-transfected with 
pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or pcDNAKIF5A1-961. 
Representative immunoblots from co-immunoprecipitation experiments (Section 
2.2.5.8) are shown in Figure 5.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Association of TRAK2 with KIF5A, KIF5A1-825 and KIF5A1-961: demonstration by co-
immunoprecipitation. 
HEK 293 cells were co-transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or 
pcDNAKIF5A1-961. Cell homogenates were prepared 48 h post-transfection, detergent solubilised and co-
immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. In all 
immunoblots lane 1 = transfected HEK 293 cell homogenate, lane 2 = non-immune pellet and lane 3 = 
anti-Flag pellet. Immunoblots are representative of at least n = 3 co-immunoprecipitations from at least 
n = 3 independent transfections. The positions of molecular mass standards (kDa) are shown on the 
right. Arrows indicate the position of immunoreactive bands. 
A, B, C = 10 % of the immune and non-immune pellets probed with anti-Flag antibodies. D, E, F = 90 % of 
the immune and non-immune pellets probed with anti-His antibodies. 
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TRAK2 was present in all immune pellets but not in the non-immune pellets. This is 
expected and demonstrates that the immunoprecipitation of the TRAK2 protein was 
successful. KIF5A and KIF5A1-961 were present in the immune pellet but not the non-
immune pellet. This shows that KIF5A and KIF5A1-961 co-immunoprecipitate with TRAK2 
following co-expression in HEK 293 cells. No signal was detected for KIF5A1-825 in 
immune pellets. This indicates that KIF5A1-825 does not co-immunoprecipitate with 
TRAK2 when co-expressed in HEK 293 cells.  
To demonstrate that KIF5A, KIF5A1-825 and KIF5A1-961 recombinant proteins were 
expressed to a similar level when co-expressed with TRAK2, quantitative 
immunoblotting was performed (Section 2.2.3.5). Band densitometry of the solubilised 
fractions from co-expression experiments were expressed as a percentage of the full 
length KIF5A. Histograms summarising the relative expression of TRAK2, KIF5A, KIF5A1-
825 and KIF5A1-961 are shown in Figure 5.6. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Histograms showing the expression levels of TRAK2 and KIF5A, KIF5A1-825 and KIF5A1-961 
following co-expression. 
HEK 293 cells were co-transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or 
pcDNAKIF5A1-961. Cell homogenates were prepared 48 h post-transfection, detergent solubilised and 
each was analysed by immunoblotting with the appropriate antibodies. The ratio of immunoreactivity of 
the soluble input was taken and expressed as a percentage of the control which is 100 %. The graph 
shows the means ± S.E.M for at least n = 3 experiments from at least n = 3 independent co-
transfections. Statistical significance was measured using a student’s t-test.   
A = Immunoreactivity of TRAK2 wild type: TRAK2 truncation after co-expression with KIF5A.  
B = Immunoreactivity of KIF5A wild type: KIF5A truncation after co-expression with TRAK2.  
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No significant change in the expression level of TRAK2 was noted when co-expressed 
with KIF5A, KIF5A1-825 or KIF5A1-961. Also no significant change in the expression level of 
KIF5A1-825 or KIF5A1-961 recombinant proteins were seen when co-expressed together 
with TRAK2 compared to the full length KIF5A.  
The immunoblots from co-immunoprecipitation experiments (Figure 5.4) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK2 with KIF5A, KIF5A1-825 and KIF5A1-961. Band 
densitometry of immune pellet bands compared to that of the input from co-
immunoprecipitations were taken and expressed as a percentage of the full length 
KIF5A control (100 %). Representative histograms are shown in Figure 5.7.  
 
 
 
 
 
 
 
 
Figure 5.7 Histograms showing the association of TRAK2 with KIF5A, KIF5A1-825 and KIF5A1-961 following 
co-immunoprecipitation. 
HEK 293 cells were co-transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or 
pcDNAKIF5A1-961. Cell homogenates were prepared 48 h post-transfection, detergent solubilised and co-
immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. The ratio of 
immunoreactivity of the immune pellet: soluble input was taken and expressed as a percentage of the 
control which is 100 %. The graph shows the means ± S.E.M for at least n = 3 co-immunoprecipitations 
from at least n = 3 independent transfections. The statistical significance was measured using a 
student’s t-test where *P < 0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 pellet: TRAK2 soluble input. B = Immunoreactivity of KIF5A pellet: KIF5A 
soluble input.  
 
Quantitative immunoblot analysis confirmed the findings demonstrated in Figure 5.4, 
i.e. KIF5A1-825 does not co-immunoprecipitate with TRAK2 to a statistical significance of 
P < 0.001. In contrast, KIF5A1-961 has a ~ 50 % increase in interaction with TRAK2 with 
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respect to TRAK2/KIF5A (n = 6 independent co-immunoprecipitations from n = 6 
independent transfections).  
 
5.2.2 Refinement of the TRAK2 binding site within the KIF5A cargo binding domain 
Experiments carried out in Section 5.2.1 demonstrated that KIF5A co-
immunoprecipitates with TRAK2 via the KIF5A cargo binding domain. To investigate the 
specific residues in the cargo binding domain responsible for binding to TRAK2 further 
truncations were generated. These truncations exploited amino acid regions showing 
the highest degree of difference and similarity between the three kinesin-1 subtypes. 
These KIF5A truncations were pcDNAKIF5A1-942, pcDNAKIF5A1-909, pcDNAKIF5A1-885, 
pcDNAKIF5A1-877 and pcDNAKIF5A1-861. KIF5A1-942, KIF5A1-909, KIF5A1-885 and KIF5A1-877 
were chosen to exploit the amino acids of KIF5A that are different when compared to 
KIF5B and KIF5C. KIF5A1-861 was chosen to remove some of the positively charged 
amino acids present between KIF5A 825-877 that may be responsible for protein-
protein interactions. The amino acid locations of the KIF5A truncations are shown in 
Figure 5.8. 
 
 
 
 
 
 
 
 
Figure 5.8 Alignment of the kinesin-1 cargo binding domains.  
An alignment of the cargo binding domain amino acid sequences of KIF5A, KIF5B and KIF5C showing the 
choice of truncated amino acids. The amino acids identical between KIF5A, KIF5B and KIF5C sub-types 
are highlighted in black while those in grey are similar. Red stars indicate previously truncated KIF5A 
constructs. Green stars indicate newly truncated KIF5A constructs. 
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Initial experiments were carried out to show that the recombinant proteins were 
expressed in mammalian cell lines. Thus, HEK 293 cells were transfected with 
pcDNAKIF5A1-942, pcDNAKIF5A1-909, pcDNAKIF5A1-885, pcDNAKIF5A1-877 and 
pcDNAKIF5A1-861, cell homogenates were prepared (Section 2.2.5.7) and analysed by 
immunoblotting using anti-His antibodies (Section 2.2.3.5). Representative 
immunoblots are shown in Figure 5.9. Each KIF5A construct was successfully expressed 
in HEK 293 cells as demonstrated by immunoreactive bands corresponding to their 
predicted sizes, i.e. KIF5A1-942 = 117.4 ± 1.8 kDa (n = 7), KIF5A1-909 = 114.7 ± 2 kDa (n = 
7), KIF5A1-885 = 107.1 ± 4.6 kDa (n = 5), KIF5A1-877 = 105.9 ± 2.8 kDa (n = 8) and KIF5A1-861 
= 107.8 ± 4.6 kDa (n = 3).  
 
 
 
 
 
 
 
Figure 5.9 Demonstration of the expression of KIF5A1-942, KIF5A1-909, KIF5A1-885, KIF5A1-877 and KIF5A1-861 
in HEK 293 cells. 
HEK 293 cells were transfected with pcDNAKIF5A1-942, pcDNAKIF5A1-909, pcDNAKIF5A1-885, pcDNAKIF5A1-
877 or pcDNAKIF5A1-861. Cell homogenates were prepared 48 h post-transfection and detergent 
solubilised. In all immunoblots lane 1 = transfected soluble sample and lane 2 = non-transfected HEK 
293 cells. The positions of molecular mass standards (kDa) are shown on the right. Arrows indicate the 
position of immunoreactive bands. 
A, B, C, D, E = Immunoblot probed with anti-His antibodies. 
 
 
To refine the TRAK2 binding site within the KIF5A cargo binding domain co-
immunoprecipitation assays were carried out. HEK 293 cells were co-transfected with 
pCMVTRAK2 and either pcDNAKIF5A1-942, pcDNAKIF5A1-909, pcDNAKIF5A1-885, 
pcDNAKIF5A1-877 or pcDNAKIF5A1-861. Full length KIF5A is known to co-
immunoprecipitate with TRAK2 and KIF5A1-825 does not co-immunoprecipitate with 
TRAK2 (Section 5.2.1). Hence, pcDNAKIF5A and pcDNAKIF5A1-825 were each co-
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transfected with pCMVTRAK2 to act as positive and negative controls. Representative 
immunoblots from co-immunoprecipitation experiments (Section 2.2.5.8) are shown in 
Figure 5.10. 
 
Figure 5.10 Association of TRAK2 with KIF5A, KIF5A1-942 KIF5A1-909, KIF5A1-885, KIF5A1-877 KIF5A1-861 and 
KIF5A1-825: demonstration by co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-942, 
pcDNAKIF5A1-909, pcDNAKIF5A1-885, pcDNAKIF5A1-877, pcDNAKIF5A1-861 or pcDNAKIF5A1-825. Cell 
homogenates were prepared 48 h post-transfection, detergent solubilised and co-immunoprecipitations 
carried out using either anti-Flag antibodies or non-immune Ig. In all immunoblots lane 1 = transfected 
soluble HEK 293 cell homogenate, lane 2 = non-immune pellet and lane 3 = anti-Flag pellet. 
Immunoblots are representative of at least n = 3 co-immunoprecipitations from n = 3 independent 
transfections. The positions of molecular mass standards (kDa) are shown on the right. Arrows indicate 
the position of immunoreactive bands. 
A, B, C, D, E, F, G = 10 % of the immune and non-immune pellets probed with anti-Flag antibodies.  
H, I, J, K, L, M, N = 90 % of the immune and non-immune pellets probed with anti-His antibodies. 
 
TRAK2 was present in all immune pellets but not in the non-immune pellets. This is 
expected and demonstrates that the immunoprecipitation of the TRAK2 protein was 
successful. KIF5A, KIF5A1-942, KIF5A1-909, KIF5A1-885 and KIF5A1-877 were present in the 
immune pellet but not the non-immune pellet. This shows that KIF5A, KIF5A1-942, 
KIF5A1-909, KIF5A1-885 and KIF5A1-877 co-immunoprecipitate with TRAK2 following co-
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expression in HEK 293 cells. No signal was detected for KIF5A1-861 and KIF5A1-825 in 
immune pellets. This indicates that KIF5A1-861 and KIF5A1-825 do not co-
immunoprecipitate with TRAK2 when co-expressed in HEK 293 cells. Thus, the critical 
amino acids for TRAK2 binding are 861-961 of KIF5A. 
To demonstrate that KIF5A, KIF5A1-942, KIF5A1-909, KIF5A1-885, KIF5A1-877, KIF5A1-861 and 
KIF5A1-825 recombinant proteins were expressed to a similar level when co-expressed 
with TRAK2, quantitative immunoblotting was performed (Section 2.2.3.5.3). Band 
densitometry of the solubilised fractions from co-expression experiments were 
expressed as a percentage of the full length KIF5A. Histograms summarising the 
relative expression of TRAK2, KIF5A, KIF5A1-942, KIF5A1-909, KIF5A1-885, KIF5A1-877, KIF5A1-
861 and KIF5A1-825 are shown in Figure 5.11. 
 
 
 
 
 
 
 
 
 
Figure 5.11 Histograms showing the expression levels of TRAK2 and KIF5A, KIF5A1-942, KIF5A1-909, 
KIF5A1-885, KIF5A1-877, KIF5A1-861 and KIF5A1-825 following co-expression. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-942, 
pcDNAKIF5A1-909, pcDNAKIF5A1-885, pcDNAKIF5A1-877, pcDNAKIF5A1-861 or pcDNAKIF5A1-825. Cell 
homogenates were prepared 48 h post-transfection, detergent solubilised and each was analysed by 
immunoblotting with the appropriate antibody as shown above. The ratio of immunoreactivity of the 
soluble input was taken and expressed as a percentage of the control which is 100 %. The graph shows 
the means ± S.E.M for at least n = 3 experiments from at least n = 3 independent co-transfections. 
Statistical significance was measured using a student’s t-test where *P < 0.05.   
A = Immunoreactivity of TRAK2 wild type: TRAK2 truncation after co-expression with KIF5A.  
B = Immunoreactivity of KIF5A wild type: KIF5A truncation after co-expression with TRAK2.  
 
No significant change in the expression level of KIF5A1-942, KIF5A1-909, KIF5A1-885, KIF5A1-
877, KIF5A1-861 and KIF5A1-825 recombinant proteins when co-expressed together with 
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TRAK2 were seen when compared to the full length KIF5A. Also no significant change in 
the expression level of TRAK2 was noted when co-expressed with KIF5A, KIF5A1-942, 
KIF5A1-909, KIF5A1-877, KIF5A1-861 and KIF5A1-825. However, the relative expression of 
TRAK2 when co-expressed with KIF5A1-885 was found to be significantly lower (P < 
0.05).  
The immunoblots from co-immunoprecipitation experiments (Figure 5.9) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK2 with KIF5A, KIF5A1-942, KIF5A1-909, KIF5A1-885, KIF5A1-877, 
KIF5A1-861 and KIF5A1-825. Band densitometry of immune pellet bands compared to that 
of the input from co-immunoprecipitations were taken and expressed as a percentage 
of the full length KIF5A control (100 %). Representative histograms are shown in Figure 
5.12.  
 
  
 
 
 
 
 
 
 
 
Figure 5.12 Histograms showing the association of TRAK2 with KIF5A, KIF5A1-942, KIF5A1-909, KIF5A1-885, 
KIF5A1-877, KIF5A1-861 and KIF5A1-825 following co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-942, 
pcDNAKIF5A1-909, pcDNAKIF5A1-885, pcDNAKIF5A1-877, pcDNAKIF5A1-861 and pcDNAKIF5A1-825. Cell 
homogenates were prepared 48 h post-transfection, detergent solubilised and co-immunoprecipitations 
carried out using either anti-Flag antibodies or non-immune Ig. The ratio of immunoreactivity of the 
immune pellet: soluble input was taken and expressed as a percentage of the control which is 100 %. 
The graph shows the means ± S.E.M for at least n = 3 co-immunoprecipitations from at least n = 3 
independent transfections. The statistical significance was measured using a student’s t-test where *P < 
0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 pellet: TRAK2 soluble input. B = Immunoreactivity of KIF5A pellet: KIF5A 
soluble input.  
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Quantitative band analysis shows a significant decrease in the co-immunoprecipitation 
of the truncated KIF5A recombinant proteins with that of TRAK2. KIF5A1-942, KIF5A1-909, 
KIF5A1-885 all appear to show a ~ 50 % decrease in co-immunoprecipitation with TRAK2. 
KIF5A1-877 shows a ~ 90 % decrease in co-immunoprecipitation with TRAK2. KIF5A1-861 
does not co-immunoprecipitate with TRAK2 after co-expression in HEK 293 cells. 
Truncation of the eight amino acid sequence from KIF5A1-885 to create KIF5A1-877 has 
also revealed a significant reduction in co-immunoprecipitation with TRAK2 of ~ 30 %. 
KIF5A1-861 and KIF5A1-825 both demonstrate no ability to co-immunoprecipitate with 
TRAK2. This group of co-immunoprecipitation experiments has revealed three possible 
sites within the KIF5A cargo binding domain as being important for association with 
TRAK2. The first identified site was located between KIF5A 942-961, the second site 
between KIF5A 877-885 and the third between KIF5A 861-877. All three amino acid 
binding regions are highlighted in Figure 5.13. 
 
   KIF5A 825  SQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAKEG 
 
   KIF5A 886  AMKDKRRYQQEVDRIKEAVRYKSSGKRGHSAQIAKPVRPGHYPASSPTNPYGTRSPECISY 
 
   KIF5A 947  TNSLFQNYQNLYLQATPSSTSDMYFANSCTSSGATSSGGPLASYQKANMDNGNATDINDNR 
 
   KIF5A 1008 SDLPCGYEAEDQAKLFPLHQETAAS 
Figure 5.13 Amino acid regions responsible for the association of KIF5A with TRAK2.  
The first identified site is located between amino acids 942-961 and is highlighted in purple. The second 
identified site is located between amino acids 877-885 and is highlighted in red. The third identified site 
is located between amino acids 861-877 and is highlighted in blue. 
 
5.2.3 Further refinement of amino acids 877-885 of KIF5A by truncation 
Section 5.2.2 showed that an eight amino acid sequence between KIF5A 877-885 is 
responsible for ~ 30 % of KIF5A’s ability to co-immunoprecipitate with TRAK2. Hence, 
the role of these eight amino acids was investigated. This was carried out by further 
truncating the amino acid region of interest resulting in three new recombinant clones, 
pcDNAKIF5A1-883, pcDNAKIF5A1-881 and pcDNAKIF5A1-879.  
As for previous recombinant KIF5A proteins, initial experiments were carried out to 
show that the recombinant proteins were expressed in mammalian cell lines. Thus, 
HEK 293 cells were transfected with pcDNAKIF5A1-883, pcDNAKIF5A1-881 and 
pcDNAKIF5A1-879, cell homogenates were prepared (Section 2.2.5.7) and analysed by 
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immunoblotting using anti-His antibodies. Representative immunoblots are shown in 
Figure 5.14. Each KIF5A construct was successfully expressed in HEK 293 cells as 
demonstrated by immunoreactive bands corresponding to their predicted sizes, i.e. 
KIF5A1-883 = 105.7 kDa ± 3.4 (n = 6), KIF5A1-881 = 101 kDa ± 1.6 (n = 3) and KIF5A1-879 = 
107.3 kDa ± 2.2 (n = 7).  
 
 
 
 
 
 
 
 
Figure 5.14 Demonstration of the expression of KIF5A1-883, KIF5A1-881 and KIF5A1-879 in HEK 293 cells. 
HEK 293 cells were transfected with pcDNAKIF5A1-883, pcDNAKIF5A1-881 or pcDNAKIF5A1-879. Cell 
homogenates were prepared 48 h post-transfection and detergent solubilised. In all immunoblots lane 1 
= transfected cell homogenate and lane 2 = non-transfected cell homogenate. The positions of 
molecular mass standards (kDa) are shown on the right. Arrows indicate the position of immunoreactive 
bands. 
A, B, C = Immunoblot probed with anti-His antibodies. 
 
 
To further refine the amino acids 877-885 of KIF5A, co-immunoprecipitation assays 
were carried out. HEK 293 cells were co-transfected with pCMVTRAK2 and either 
pcDNAKIF5A1-883, pcDNAKIF5A1-881 or pcDNAKIF5A1-879. pcDNAKIF5A and pcDNAKIF5A1-
825 were each co-transfected with pCMVTRAK2 to act as positive and negative controls. 
Representative immunoblots from co-immunoprecipitation experiments (Section 
2.2.5.8) are shown in Figure 5.15. 
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Figure 5.15 Demonstration by immunoprecipitation the association of TRAK2 with KIF5A, KIF5A1-883, 
KIF5A1-881, KIF5A1-879 and KIF5A1-825 following their co-expression in HEK 293 cells. 
HEK 293 cells were transfected with pCMVTRAK2 and either KIF5A, KIF5A1-883, KIF5A1-881, KIF5A1-879 and 
KIF5A1-825. Cell homogenates were prepared 48 h post-transfection, detergent solubilised and co-
immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. In all 
immunoblots lane 1 = transfected soluble HEK 293 cell homogenate, lane 2 = non-immune pellet and 
lane 3 = anti-Flag pellet. Immunoblots are representative of at least n = 3 co-immunoprecipitations from 
n = 3 independent transfections. The positions of molecular mass standards (kDa) are shown on the 
right. Arrows indicate the position of immunoreactive bands. 
A, B, C, D, E = 10 % of the immune and non-immune pellets probed with anti-Flag antibodies. F, G, H, I, J 
= 90 % of the immune and non-immune pellets probed with anti-His antibodies. 
 
TRAK2 was present in all immune pellets but not in the non-immune pellets. This was 
expected and demonstrates that the immunoprecipitation of the TRAK2 protein was 
successful. KIF5A, KIF5A1-883, KIF5A1-881 and KIF5A1-879 were all found to be present in 
the immune pellet but not in the non-immune pellet. This indicates that KIF5A, KIF5A1-
883, KIF5A1-881 and KIF5A1-879 co-immunoprecipitate with TRAK2 following their co-
expression in HEK 293 cells. No signal was detected for KIF5A1-825 in immune pellets. 
This indicates that KIF5A1-825 does not co-immunoprecipitate with TRAK2 when co-
expressed in HEK 293 cells.  
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To demonstrate that KIF5A, KIF5A1-883, KIF5A1-881, KIF5A1-879 and KIF5A1-825 recombinant 
proteins were expressed to a similar level when co-expressed with TRAK2, quantitative 
immunoblotting was performed (Section 2.2.3.5). Band densitometry of the solubilised 
fractions from co-expression experiments were expressed as a percentage of the full 
length KIF5A. Histograms summarising the relative expression of TRAK2, KIF5A, KIF5A1-
883, KIF5A1-881, KIF5A1-879 and KIF5A1-825 are shown in Figure 5.16. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Histograms showing the expression levels of TRAK2 and KIF5A, KIF5A1-883, KIF5A1-881, 
KIF5A1-879 and KIF5A1-825 following co-expression. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-883, 
pcDNAKIF5A1-881, pcDNAKIF5A1-879 or pcDNAKIF5A1-825. Cell homogenates were prepared 48 h post-
transfection, detergent solubilised and analysed by immunoblotting with the appropriate antibody. The 
ratio of immunoreactivity of the soluble input was taken and expressed as a percentage of the control 
which is 100 %. The graph shows the means ± S.E.M for at least n = 3 experiments from at least n = 3 
independent co-transfections. Statistical significance was measured using a student’s t-test where *P < 
0.05.   
A = Immunoreactivity of TRAK2 wild type: TRAK2 truncation after co-expression with KIF5A.  
B = Immunoreactivity of KIF5A wild type: KIF5A truncation after co-expression with TRAK2.  
 
No significant change in the expression level of TRAK2 was noted when co-expressed 
with KIF5A, KIF5A1-879 and KIF5A1-825. However, the relative expression of TRAK2 when 
co-expressed with both KIF5A1-883 and KIF5A1-881 is significantly lower. Also no 
significant change in the expression level of KIF5A1-883, KIF5A1-881, KIF5A1-879 and KIF5A1-
825 recombinant proteins when co-expressed together with TRAK2 were seen when 
compared to the full length KIF5A.  
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The immunoblots from co-immunoprecipitation experiments (Figure 5.15) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK2 with KIF5A1-883, KIF5A1-881, KIF5A1-879 and KIF5A1-825. 
Band densitometry of immune pellet bands compared to that of the input from co-
immunoprecipitations were taken and expressed as a percentage of the full length 
KIF5A control (100 %). Representative histograms are shown in Figure 5.17.  
 
  
 
 
 
 
 
 
 
Figure 5.17 Histograms showing the association of TRAK2 with KIF5A, KIF5A1-883, KIF5A1-881, KIF5A1-879 
and KIF5A1-825 following co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-883, 
pcDNAKIF5A1-881, pcDNAKIF5A1-879 or pcDNAKIF5A1-825. Cell homogenates were prepared 48 h post-
transfection, detergent solubilised and co-immunoprecipitations carried out using either anti-Flag 
antibodies or non-immune Ig. The ratio of immunoreactivity of the immune pellet: soluble input was 
taken and expressed as a percentage of the control which is 100 %. The graph shows the means ± S.E.M 
for at least n = 3 co-immunoprecipitations from at least n = 3 independent transfections. Statistical 
significance was measured using a student’s t-test where *P < 0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 pellet: TRAK2 soluble input. B = Immunoreactivity of KIF5A pellet: KIF5A 
soluble input.  
 
Quantitative band analysis shows a significant decrease of co-immunoprecipitation of 
the truncated KIF5A recombinant proteins with that of TRAK2. KIF5A1-883, KIF5A1-881, 
KIF5A1-885 all appear to show a ~ 30-60 % decrease in co-immunoprecipitation with 
TRAK2.  
 
 
 
A B 
TRAK2 KIF5A 
184 
 
- 250
- 98
- 64
- 50
1 2
KIF5AΔ877-883
Antibody = His
5.2.4 Further refinement of amino acids 877-883 of KIF5A by deletion 
Results in Section 5.2.3 demonstrated that truncating the eight amino acid sequence 
877-885 of KIF5A to yield KIF5A1-883, KIF5A1-881 and KIF5A1-879 had resulted in no further 
refinement of the TRAK2 binding site. Therefore, this region of amino acids was 
deleted from full length KIF5A protein to assess the impact this deletion has upon co-
immunoprecipitation of KIF5A with TRAK2. Due to the truncated constructs 
pcDNAKIF5A1-883 and pcDNAKIF5A1-885 showing a similar level of interaction with TRAK2 
after co-immunoprecipitation experiments, only the amino acids 877-883 of KIF5A 
were deleted from the full length KIF5A protein. The recombinant construct 
pcDNAKIF5AΔ877-883 was achieved by overlap extension PCR (Section 2.2.2.14) allowing 
the deletion of the nucleotide sequence encoding these six amino acids.  
Initial experiments were carried out to show that the recombinant protein was 
expressed in a mammalian cell line. Thus, HEK 293 cells were transfected with 
pcDNAKIF5AΔ877-883, cell homogenates were prepared (Section 2.2.5.7) and analysed by 
immunoblotting using anti-His antibodies (Section 2.2.3.5). The representative 
immunoblot is shown in Figure 5.18. The KIF5AΔ877-883 construct was successfully 
expressed in HEK 293 cells as demonstrated by an immunoreactive band 
corresponding to the predicted size, i.e. KIF5AΔ877-883 = 122.9 kDa ± 9 (n =5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To assess the impact of deleting amino acids 877-883 from the full length KIF5A 
protein, co-immunoprecipitation assays were carried out. HEK 293 cells were co-
transfected with pCMVTRAK2 and pcDNAKIF5AΔ877-883. pcDNAKIF5A and pcDNAKIF5A1-
825 were each co-transfected with pCMVTRAK2 to act as positive and negative controls. 
Figure 5.18 Demonstration of the expression of KIF5AΔ877-883 
in HEK 293 cells. 
HEK 293 cells were transfected with KIF5AΔ877-883. Cell 
homogenates were prepared 48 h post-transfection and 
detergent solubilised. In the immunoblot lane 1 = 
transfected cell homogenate and lane 2 = non-transfected 
cell homogenate. The positions of molecular mass standards 
(kDa) are shown on the right. The arrow indicates the 
position of the immunoreactive band. Immunoblot probed 
with anti-His antibodies. 
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Representative immunoblots from co-immunoprecipitation experiments (Section 
2.2.5.8) are shown in Figure 5.19. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 Demonstration by immunoprecipitation the association of TRAK2 with KIF5A, KIF5A1-825 
and KIF5AΔ877-883 following their co-expression in HEK 293 cells. 
HEK 293 cells were transfected with pCMVTRAK2 and either KIF5A, KIF5A1-825 or KIF5AΔ877-883. Cell 
homogenates were prepared 48 h post-transfection, detergent solubilised and co-immunoprecipitations 
carried out using either anti-Flag antibodies or non-immune Ig. In all immunoblots lane 1 = transfected 
soluble HEK 293 cell homogenate, lane 2 = non-immune pellet and lane 3 = anti-Flag pellet. 
Immunoblots are representative of at least n = 3 co-immunoprecipitations from n = 3 independent 
transfections. The positions of molecular mass standards (kDa) are shown on the right. Arrows indicate 
the position of immunoreactive bands. 
A, B, C = 10 % of the immune and non-immune pellets probed with anti-Flag antibodies. D, E, F = 90 % of 
the immune and non-immune pellets probed with anti-His antibodies. 
 
TRAK2 was present in all immune pellets but not in the non-immune pellets. This was 
expected and demonstrates that the immunoprecipitation of the TRAK2 protein was 
successful. KIF5A and KIF5AΔ877-883 were found to be present in the immune pellet but 
some protein, albeit at a low level, is visualised in the non-immune pellet and may be a 
result of incomplete washing of the immune pellet. This indicates that KIF5A and 
KIF5AΔ877-883 co-immunoprecipitates with TRAK2 following their co-expression in HEK 
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293 cells. No signal was detected for KIF5A1-825 in immune pellets. This indicates that as 
observed previously KIF5A1-825 does not co-immunoprecipitate with TRAK2 when co-
expressed in HEK 293 cells.  
To demonstrate that KIF5A, KIF5A1-825 and KIF5AΔ877-883 recombinant proteins were 
expressed to a similar level when co-expressed with TRAK2, quantitative 
immunoblotting was performed (Section 2.2.3.5). Band densitometry of the solubilised 
fractions from co-expression experiments were expressed as a percentage of the full 
length KIF5A. Histograms summarising the relative expression of TRAK2, KIF5A, KIF5A1-
825 and KIF5AΔ877-883 are shown in Figure 5.20. 
 
 
 
 
 
 
 
 
Figure 5.20 Histograms showing the expression levels of TRAK2 and KIF5A, KIF5A1-825 and KIF5AΔ877-883 
following co-expression. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or pcDNA 
KIF5AΔ877-883. Cell homogenates were prepared 48 h post-transfection and detergent solubilised and 
each was analysed by immunoblotting with the appropriate antibody as shown above. The ratio of 
immunoreactivity of the soluble input was taken and expressed as a percentage of the control which is 
100 %. The graph shows the means ± S.E.M for at least n = 3 experiments from at least n = 3 
independent co-transfections. Statistical significance was measured using a student’s t-test. 
A = Immunoreactivity of TRAK2 wild type: TRAK2 truncation after co-expression with KIF5A.  
B = Immunoreactivity of KIF5A wild type: KIF5A truncation after co-expression with TRAK2.  
 
No significant change in the expression level of TRAK2 was noted when co-expressed 
with KIF5A, KIF5A1-825 and KIF5AΔ877-883. Also no significant change in the expression 
level of KIF5A1-825 and KIF5AΔ877-883 recombinant proteins when co-expressed together 
with TRAK2 were seen when compared to the full length KIF5A.  
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The immunoblots from co-immunoprecipitation experiments (Figure 5.19) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK2 with KIF5A1-825 and KIF5AΔ877-883. Band densitometry of 
immune pellet bands compared to that of the input from co-immunoprecipitations 
were taken and expressed as a percentage of the full length KIF5A control (100 %). 
Representative histograms are shown in Figure 5.21.  
   
 
 
 
 
 
 
Figure 5.21 Histograms showing the association of TRAK2 with KIF5A, KIF5A1-825 and KIF5AΔ877-883  
following co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5A, pcDNAKIF5A1-825 or pcDNA 
KIF5AΔ877-883. Cell homogenates were prepared 48 h post-transfection, detergent solubilised and co-
immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. The ratio of 
immunoreactivity of the immune pellet: soluble input was taken and expressed as a percentage of the 
control which is 100 %. The graph shows the means ± S.E.M for at least n = 3 co-immunoprecipitations 
from at least n = 3 independent transfections. The statistical significance was measured using a 
student’s t-test where *P < 0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 pellet: TRAK2 soluble input. B = Immunoreactivity of KIF5A pellet: KIF5A 
soluble input.  
 
Quantitative band analysis shows a significant decrease of co-immunoprecipitation of 
the truncated KIF5A recombinant proteins with that of TRAK2. KIF5AΔ877-883 shows a 
significant decrease of ~ 30 % in co-immunoprecipitation with TRAK2 after co-
expression in HEK 293 cells.  
 
5.2.5 Does KIF5C associate with TRAK2 using the same amino acid motif as KIF5A? 
Section 5.2.2 has shown that there is a step wise reduction in the co-
immunoprecipitation of truncated KIF5A with TRAK2 in HEK 293 cells. As discussed 
previously the work undertaken to demonstrate that kinesin-1 associates with TRAK2 
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via the cargo binding domain had been carried out using the KIF5C sub-type (Smith et 
al., 2006). To see if both the KIF5A and KIF5C sub-types share critical amino acid 
residues needed for TRAK2 binding, the KIF5C clones pcDNAKIF5A1-889 and 
pcDNAKIF5C1-881 were created. These clones contained a stop codon at identical 
locations to the flanking region of the eight amino acid region on KIF5A. This region has 
been shown in Section 5.2.2 to be responsible for approximately 30 % of the ability of 
KIF5A to co-immunoprecipitate with TRAK2. A positive and negative control, 
pcDNAKIF5C and pcDNAKIF5C1-828, were also cloned.  
HEK 293 cells were transfected with pcDNAKIF5C, pcDNAKIF5C1-889, pcDNAKIF5C1-881 
and pcDNAKIF5C1-828 and soluble cell homogenates prepared (Section 2.2.5.7). The 
resulting soluble cell h mogenates were analysed by immunoblotting using anti-His 
antibodies. Representative immunoblots showing the expression of KIF5C, KIF5C1-889, 
KIF5C1-881 and KIF5C1-828 are shown in Figure 5.22. Each protein was successfully 
expressed in HEK 293 as demonstrated by immunoreactive bands corresponding to the 
predicted size. The molecular weight of KIF5C is = 120.4 ± 6.8 kDa (n = 5), KIF5C1-889 = 
114.4 ± 5.2 kDa (n = 5), KIF5C1-881 = 113.5 ± 4.4 kDa (n = 5) and KIF5C1-828 = 104.9 ± 4.3 
kDa (n = 3). 
 
 
 
 
 
 
 
 
Figure 5.22 Demonstration of the expression of KIF5C, KIF5C1-889, KIF5C1-881 and KIF5C1-828 in HEK 293 
cells. 
HEK 293 cells were transfected with pcDNAKIF5C, pcDNAKIF5C1-889, pcDNAKIF5C1-881 or pcDNAKIF5C1-828. 
Cell homogenates were prepared 48 h post-transfection and detergent solubilised. In all immunoblots 
lane 1 = transfected soluble sample and lane 2 = non-transfected HEK 293 cells. The positions of 
molecular mass standards (kDa) are shown on the right. Arrows indicate the position of immunoreactive 
bands. 
A, B, C, D = Immunoblots probed with anti-His antibodies. 
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HEK 293 cells were co-transfected with pCMVTRAK2 and either pcDNAKIF5C, 
pcDNAKIF5C1-889, pcDNAKIF5C1-881 or pcDNAKIF5C1-828. Representative immunoblots 
from co-immunoprecipitation experiments (Section 2.2.5.8) are shown in Figure 5.23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Association of TRAK2 with KIF5C, KIF5C1-889, KIF5C1-881 and KIF5C1-828: demonstration by co-
immunoprecipitation. 
HEK 293 cells were co-transfected with pCMVTRAK2 and either pcDNAKIF5C, pcDNAKIF5C1-889, 
pcDNAKIF5C1-881 or pcDNAKIF5C1-828. Cell homogenates were prepared 48 h post-transfection, detergent 
solubilised and immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. In 
all immunoblots lane 1 = transfected HEK 293 cell homogenate, lane 2 = non-immune pellet and lane 3 = 
anti-Flag pellet. Immunoblots are representative of at least n = 3 co-immunoprecipitations from at least 
n = 3 independent transfections. The positions of molecular mass standards (kDa) are shown on the 
right. Arrows indicate the position of immunoreactive bands. 
A, B, C, D = 10 % of the immune and non-immune pellets probed with anti-Flag antibodies. E, F, G, H = 
90 % of the immune and non-immune pellets probed with anti-His antibodies.  
 
 
TRAK2 was present in all immune pellets but not in the non-immune pellets. This is 
expected and demonstrates that the immunoprecipitation of the TRAK2 protein was 
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successful. KIF5C, KIF5C1-889 and KIF5C1-881 were present in the immune pellet but not 
the non-immune pellet. This shows that KIF5C, KIF5C1-889 and KIF5C1-881 co-
immunoprecipitate with TRAK2 following co-expression in HEK 293 cells. No signal was 
detected for KIF5C1-828 in immune pellets. This indicates that KIF5C1-828 does not co-
immunoprecipitate with TRAK2 when co-expressed in HEK 293 cells.  
To demonstrate that KIF5C, KIF5C1-889, KIF5C1-881 and KIF5C1-828 recombinant proteins 
were expressed to a similar level when co-expressed with TRAK2, quantitative 
immunoblotting was performed (Section 2.2.3.5.3). Band densitometry of the 
solubilised fractions from co-expression experiments were expressed as a percentage 
of the full length KIF5C. Histograms summarising the relative expression of TRAK2, 
KIF5C, KIF5C1-889, KIF5C1-881 and KIF5C1-828 are shown in Figure 5.24. 
 
  
 
 
 
 
 
 
Figure 5.24 Histograms showing the expression levels of TRAK2 and KIF5C, KIF5C1-889, KIF5C1-881 and 
KIF5C1-828 following co-expression. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5C, pcDNAKIF5C1-889, 
pcDNAKIF5C1-881 or pcDNAKIF5C1-828. Cell homogenates were prepared 48 h post-transfection, detergent 
solubilised and each was analysed by immunoblotting with the appropriate antibodies. The ratio of 
immunoreactivity of the soluble input was taken and expressed as a percentage of the control which is 
100 %. The graph shows the means ± S.E.M for at least n = 3 experiments from at least n = 3 
independent co-transfections. Statistical significance was measured using a student’s t-test where *P < 
0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 wild type: TRAK2 truncation after co-expression with KIF5C.  
B = Immunoreactivity of KIF5C wild type: KIF5C truncation after co-expression with TRAK2.  
 
 
No significant change in the expression level of TRAK2 was noted when co-expressed 
with KIF5C1-889. However, the relative expression of TRAK2 when co-expressed with 
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KIF5C1-881 and KIF5C1-828 was found to be significantly higher. No significant change in 
the expression level of KIF5C1-828 recombinant proteins was seen when compared to 
the full length KIF5C after co-expression together with TRAK2. However, KIF5C1-889 and 
KIF5C1-881 were found to be significantly higher after co-expression with TRAK2 when 
compared to full length KIF5C. This difference in expression levels seen between 
TRAK2 and KIF5C1-889 and KIF5C1-881 is most likely due to differences in transfection 
efficiencies.    
The immunoblots from co-immunoprecipitation experiments (Figure 5.23) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK2 with KIF5C, KIF5C1-889, KIF5C1-881 and KIF5C1-828. Band 
densitometry of immune pellet bands compared to that of the input from co-
immunoprecipitations were taken and expressed as a percentage of the full length 
KIF5C control (100 %). Representative histograms are shown in Figure 5.25.  
 
 
  
 
 
 
 
 
 
 
 
Figure 5.25 Histograms showing the association of TRAK2 with KIF5C, KIF5C1-889, KIF5C1-881 and KIF5A1-
828 following co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK2 and either pcDNAKIF5C, pcDNAKIF5C1-889, 
pcDNAKIF5C1-881 or pcDNAKIF5A1-828. Cell homogenates were prepared 48 h post-transfection, detergent 
solubilised and co-immunoprecipitations carried out using either anti-Flag antibodies or non-immune Ig. 
The ratio of immunoreactivity of the immune pellet: soluble input was taken and expressed as a 
percentage of the control which is 100 %. The graph shows the means ± S.E.M for at least n = 3 co-
immunoprecipitations from at least n = 3 independent transfections. The statistical significance was 
measured using a student’s t-test where *P < 0.05 and ***P < 0.001.   
A = Immunoreactivity of TRAK2 pellet: TRAK2 soluble input. B = Immunoreactivity of KIF5C pellet: KIF5C 
soluble input.  
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Quantitative band analysis shows a significant decrease in co-immunoprecipitation of 
the truncated KIF5C1-889, KIF5C1-881 and KIF5C1-828 recombinant proteins with that of 
TRAK2 after co-expression in HEK 293 cells. KIF5C1-889 shows a ~ 70 % decrease in co-
immunoprecipitation with TRAK2 when compared to KIF5C. KIF5C1-881 shows a 
decrease of ~ 95 % in co-immunoprecipitation with TRAK2. KIF5C1-828 shows no co-
immunoprecipitation with TRAK2. This result confirms that the cargo binding domain 
of KIF5C is needed for correct co-immunoprecipitation with TRAK2. Overall the series 
of KIF5C truncations revealed a similar binding profile as found for KIF5A. This is a 
three mode method of association; the first site was identified between amino acids 
KIF5C 889-957, the second between amino acids KIF5C 881-889 and the third between 
amino acids KIF5C 828-881. 
 
5.2.6 Does TRAK1 associate with KIF5A in a similar manner to TRAK2? 
As discussed in the introduction the TRAK family consists of two family members 
sharing an amino acid identity of 44 %. Currently all of the experiments in this chapter 
have focused around the more studied rat TRAK2 protein. All three kinesin-1 sub-types 
have demonstrated the ability to co-immunoprecipitate with both TRAK1 and TRAK2 in 
HEK 293 cells (Brickley et al., 2005). It is therefore interesting to assess if there are any 
differences in binding of the kinesin-1 family between TRAK1 and TRAK2. There is a 93 
% amino acid identity between rat and human TRAK1. Due to the high amino acid 
sequence identity between human TRAK1 and rat TRAK1, the human TRAK1 clone was 
chosen to study the interaction between TRAK1 and KIF5A. Investigating the 
interaction between human TRAK1 and human KIF5A will also bear more physiological 
resemblance to the in vivo interaction in human neuronal cells. Recombinant clones 
KIF5A, KIF5A1-961, KIF5A1-879, KIF5A1-877 and KIF5A1-825 were selected to assess the 
interaction with TRAK1. These clones were used because previous work in this chapter 
has shown these truncations to be the most critical for interaction with TRAK2.   
Initial experiments were carried out to show that recombinant TRAK1 could be 
expressed in a mammalian cell line. Thus, HEK 293 cells were transfected with 
pCMVTRAK1, cell homogenates were prepared (Section 2.2.5.7) and analysed by 
immunoblotting using anti-c-myc antibodies (Section 2.2.3.5). The representative 
immunoblot is shown in Figure 5.26. The TRAK1 construct was successfully expressed 
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in HEK 293 cells as demonstrated by an immunoreactive band corresponding to the 
predicted size, i.e. TRAK1 = 124.5 ± 2.2 kDa (n = 18). 
 
 
 
 
 
 
 
 
To ascertain if the KIF5A truncated constructs bind to TRAK1 in a similar method to 
TRAK2, co-immunoprecipitation experiments were carried out. HEK 293 cells were co-
transfected with pCMVTRAK1 and either pcDNAKIF5A1-961, pcDNAKIF5A1-879, 
pcDNAKIF5A1-877 or pcDNAKIF5A1-825. Representative immunoblots from co-
immunoprecipitation experiments (Section 2.2.5.8) are shown in Figure 5.27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Demonstration of the expression of TRAK1 in 
HEK 293 cells. 
HEK 293 cells were transfected with pCMVTRAK1. Cell 
homogenates were prepared 48 h post-transfection and 
detergent solubilised. In all immunoblots lane 1 = 
transfected soluble sample and lane 2 = non-transfected 
HEK 293 cells. The positions of molecular mass standards 
(kDa) are shown on the right. The arrow indicates the 
position of the immunoreactive band. Immunoblot probed 
with anti-c-myc antibodies. 
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Figure 5.27 Association of TRAK1 with KIF5A, KIF5A1-961, KIF5A1-879, KIF5A1-877 and KIF5A1-825: 
demonstration by co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK1 and either pcDNAKIF5A, pcDNAKIF5A1-961, 
pcDNAKIF5A1-879, pcDNAKIF5A1-877 or pcDNAKIF5A1-825. Cell homogenates were prepared 48 h post-
transfection, detergent solubilised and immunoprecipitations carried out using either anti–c-Myc 
antibodies or non-immune Ig. In all immunoblots lane 1 = transfected HEK 293 cell homogenate, lane 2 
= non-immune pellet and lane 3 = anti-c-myc pellet. Immunoblots are representative of at least n = 3 co-
immunoprecipitations from n = 3 independent transfections. The positions of molecular mass standards 
(kDa) are shown on the right. Arrows indicate the position of immunoreactive bands. 
A, B, C, D, E = 10 % of the immune and non-immune pellets probed with anti-c-myc antibodies.  
F, G, H, I, J = 90 % of the immune and non-immune pellets probed with anti-His antibodies.  
 
 
 
TRAK1 was present in all immune pellets but not in the non-immune pellets. This is 
expected and demonstrates that the immunoprecipitation of the TRAK1 protein was 
successful. KIF5A, KIF5A1-961, KIF5A1-879, KIF5A1-877 and KIF5A1-825 were present in the 
immune pellet but not the non-immune pellet. This shows that KIF5A, KIF5A1-961, 
KIF5A1-879, KIF5A1-877 and KIF5A1-825 co-immunoprecipitate with TRAK2 following co-
expression in HEK 293 cells.  
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To demonstrate that KIF5A, KIF5A1-961, KIF5A1-877, KIF5A1-879 and KIF5A1-825 recombinant 
proteins were expressed to a similar level when co-expressed with TRAK1, quantitative 
immunoblotting was performed (Section 2.2.3.5). Band densitometry of the solubilised 
fractions from co-expression experiments were expressed as a percentage of the full 
length KIF5A. Histograms summarising the relative expression of TRAK1, KIF5A, KIF5A1-
961, KIF5A1-877, KIF5A1-879 and KIF5A1-825 are shown in Figure 5.28. 
 
  
 
 
 
 
 
 
 
Figure 5.28 Histograms showing the expression levels of TRAK1 and KIF5A, KIF5A1-961, KIF5A1-879, 
KIF5A1-877 and KIF5A1-825 following co-expression. 
HEK 293 cells were transfected with pCMVTRAK1 and either pcDNAKIF5A, pcDNAKIF5A1-961, 
pcDNAKIF5A1-877, pcDNAKIF5A1-879 or pcDNAKIF5A1-825. Cell homogenates were prepared 48 h post-
transfection, detergent solubilised and each was analysed by immunoblotting with the appropriate 
antibodies. The ratio of immunoreactivity of the soluble input was taken and expressed as a percentage 
of the control which is 100 %. The graph shows the means ± S.E.M for at least n = 3 experiments from at 
least n = 3 independent co-transfections. Statistical significance was measured using a student’s t-test 
where *P < 0.05.   
A = Immunoreactivity of TRAK1 wild type: TRAK1 truncation after co-expression with KIF5A.  
B = Immunoreactivity of KIF5A wild type: KIF5A truncation after co-expression with TRAK1.  
 
 
No significant change in the expression level of TRAK1 was noted when co-expressed 
with KIF5A1-961, KIF5A1-877 and KIF5A1-825. However, the relative expression of TRAK1 
when co-expressed with KIF5A1-879 was found to be significantly higher. Also no 
significant change in the expression level of KIF5A1-961, KIF5A1-879, KIF5A1-877 and KIF5A1-
825 recombinant proteins were seen when compared to the full length KIF5A after co-
expression with TRAK1.  
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The immunoblots from co-immunoprecipitation experiments (Figure 5.27) were 
quantified to determine if there was a difference in the efficiency of co-
immunoprecipitation of TRAK1 with KIF5A, KIF5A1-961, KIF5A1-877, KIF5A1-879 and KIF5A1-
825. Band densitometry of immune pellet bands compared to that of the input from co-
immunoprecipitations were taken and expressed as a percentage of the full length 
KIF5A control (100 %). Representative histograms are shown in Figure 5.29.  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.29 Histograms showing the association of TRAK1 with KIF5A, KIF5A1-961, KIF5A1-879, KIF5A1-877 
and KIF5A1-825 following co-immunoprecipitation. 
HEK 293 cells were transfected with pCMVTRAK1 and either pcDNAKIF5A, pcDNAKIF5A1-961, 
pcDNAKIF5A1-879, pcDNAKIF5A1-877 and pcDNAKIF5A1-825. Cell homogenates were prepared 48 h post-
transfection, detergent solubilised and co-immunoprecipitations carried out using either anti-Flag 
antibodies or non-immune Ig. The ratio of immunoreactivity of the immune pellet: soluble input was 
taken and expressed as a percentage of the control which is 100 %. Graph shows the average values 
obtained (± S.E.M). Statistical significance was measured using a student’s t-test where **P < 0.01.   
A = Immunoreactivity of TRAK1 pellet: TRAK1 soluble input. B = Immunoreactivity of KIF5A pellet: KIF5A 
soluble input.  
 
Quantitative band analysis shows no significant change in the co-immunoprecipitation 
of the truncated KIF5A1-961, KIF5A1-879 and KIF5A1-877 recombinant proteins with that of 
TRAK1 after co-expression in HEK 293 cells. KIF5A1-828 shows a ~ 85 % decrease in co-
immunoprecipitation with TRAK1 when compared to full length KIF5A. Interestingly 
the enhancement of KIF5A1-961 co-immnoprecipitation of approximately 50 % with 
TRAK2 seen in Figure 5.7 was not seen when KIF5A1-961 was co-immunoprecipitated 
with TRAK1. These results imply that TRAK1/KIF5A appears to show a different pattern 
of binding when compared to TRAK2/KIF5A (Figure 5.7). This indicates the main region 
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responsible for 85 % co-immunoprecipitation with TRAK1 is amino acids 825-877 of 
KIF5A. A summary of all the KIF5A and KIF5C truncated constructs are shown in Figure 
5.30. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.30 Comparison of human KIF5A, KIF5B and KIF5C kinesin-1 sub-types. 
An alignment of the cargo binding domain amino acid sequences of KIF5A, KIF5B and KIF5C. The amino 
acids identical between KIF5A, KIF5B and KIF5C sub-types are highlighted in black while those in grey are 
similar. Green stars show the position of KIF5A truncations. Blue stars show the position of KIF5C 
truncations. The green box shows the KIF5A amino acid sequence that was deleted. 
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5.3 DISCUSSION 
Kinesin-1 is responsible for transporting many cargoes throughout the cell. It is by 
mapping the amino acids responsible for the binding to its wide variety of associated 
protein partners that a better understanding of how kinesin-1 physically interacts in a 
cellular environment can be gained. Previous work has demonstrated the ability of all 
the kinesin-1 family members to associate with TRAK2. More specifically in the case of 
the KIF5C sub-type it has been shown that the C-terminal tail known as the cargo 
binding domain interacts with TRAK2 (Smith et al., 2006). In this chapter it has been 
demonstrated that KIF5A also co-immunoprecipitates with TRAK2 after co-expression 
in HEK 293 cells. It has also been established that deletion of the KIF5A cargo binding 
domain results in the loss of co-immunoprecipitation with TRAK2. This result suggests 
that TRAK2 binds to KIF5A via the cargo binding domain. Deletion of the distal 71 
amino acid KIF5A C-terminal tail results in a ~ 50 % increase in co-immunoprecipitation 
between KIF5A/TRAK2. This indicates that this region may play a regulatory role in 
terms of the efficacy of binding between KIF5A and TRAK2. It is also possible to 
speculate that these extra 71 amino acids may also have a role in KIF5A specific cargo 
transport.  
A series of C-terminal KIF5A truncations revealed three possible sites within the KIF5A 
cargo binding domain as being important for co-immunoprecipitation with TRAK2. The 
first identified site was located between KIF5A 942-961 and is responsible for ~ 45 % of 
the total ability to co-immunoprecipitation with TRAK2. The second site was 
between KIF5A 877-885 and is responsible for ~ 30 % of the total co-
immunoprecipitation with TRAK2. The third site was between KIF5A 861-877 and is 
responsible for ~ 10 % of the total co-immunoprecipitation with TRAK2.  
Additional analysis of the eight amino acid sequence KIF5A 877-885 by truncation or 
deletion did not refine the second site further. The eight amino acid region of KIF5A 
877-885 consists of ALKEAKEG. When these eight amino acids are further truncated 
and co-expressed with TRAK2 no change in co-immunoprecipitation was revealed. This 
indicates that the two amino acids alanine and leucine are responsible for the ~ 30 % 
decrease in co-immunoprecipitation with TRAK2. This result in itself is perhaps a 
surprise due to the characteristics of the amino acids present in this motif. Both 
alanine and leucine are neutral non-polar amino acids and are rarely associated to be 
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necessary for protein-protein interactions. It is more likely the case that the deletion of 
these two alanine and leucine amino acids may alter the tertiary structure in turn 
inhibiting other important amino acids needed for binding.  
A series of KIF5C truncations revealed a similar binding profile as found for KIF5A. This 
is a three mode method of association; the first site was identified between amino 
acids KIF5C 889-957, the second between amino acids KIF5C 881-889 and the third 
between amino acids KIF5C 828-881. This is not a surprising result when the 83 % 
amino acid identity between KIF5A and KIF5C at the cargo binding domain is taken into 
consideration, indicating a high probability of a shared mechanism of association with 
TRAK2. This also confirms the importance of the eight amino acid motif for efficient co-
immunoprecipitation with the TRAK2 protein. This motif is highly conserved between 
KIF5A, KIF5B and KIF5C with only the very C-terminal end amino acid of the eight 
sequence motif differing between the three sub-types (Figure 5.30). Although the 
amino acid sequence identity is high between KIF5A and KIF5C, in the cargo binding 
domain there are subtle differences in amino acid composition. These subtle 
differences could allude to changes in specificities towards the kinesin-1’s binding 
partners, as well as alternative functions within the cell. It is known that the kinesin-1 
family members show marked differences in tissue distribution, with KIF5B present in 
nearly all tissue types and KIF5A and KIF5C found to be predominantly neuron specific 
(Kanai et al., 2000). It is this difference in tissue specificity that could indicate roles for 
KIF5A and KIF5C and their binding partners that are specific only to neuronal cells. 
Work in this chapter regarding the binding of TRAK1 to KIF5A has appeared to show a 
different pattern of association when compared to the binding of TRAK2 to KIF5A. The 
same KIF5A truncations that show a step-wise decrease in the ability to co-
immunoprecitate with TRAK2 in HEK 293 cells showed no reduction in the ability to co-
immunoprecipitate with TRAK1. The amino acids 825-877 of KIF5A have been shown to 
be responsible for 85 % of the ability of KIF5A to co-immunoprecipitate with TRAK1 
whereas the same region is only responsible for 10 % of the overall ability of KIF5A to 
co-immunoprecipitate with TRAK2. Both TRAK1 and TRAK2 share an overall amino acid 
identity of 44 %. Despite the low amino acid identity between the two TRAK proteins, 
previous research has demonstrated very similar roles for TRAK1 and TRAK2 within the 
cell. TRAK1 and TRAK2 will associate with kinesin-1 in vivo and in vitro (Brickley et al., 
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2005). Furthermore, TRAK1 and TRAK2 have also demonstrated the ability to co-
immunoprecipitate with both Miro1 and Miro2, atypical Rho GTPases present on the 
outer membrane of the mitochondria, after co-expression in HEK 293 cells (Fransson et 
al., 2006). The work presented in Section 5.2.5 is not the first evidence to suggest that 
TRAK1 and TRAK2 may in fact associate with kinesin-1 via different modes of 
association. Previous experiments using yeast two-hybrid interaction assays and co-
immunoprecipitations showed that amino acids 124-283 of TRAK2 are responsible for 
association with KIF5C, but this was shown to not be the case for amino acids 124-283 
of TRAK1 (Brickley et al., 2005). In cultured rat hippocampal neurons TRAK1 shRNAi has 
been shown to prevent mitochondrial movement, whereas TRAK2 shRNAi did not 
(Brickley and Stephenson, 2011). The role of the TRAK family has been highlighted by 
the number of differing cargoes known to bind either TRAK1 or TRAK2. As discussed in 
the introduction these cargoes include the K+ channel Kir2.1 and GABAα receptor β2 
subunit that are both known to bind TRAK2 (Beck et al., 2002; Grishin et al., 2006; 
Section 1.3.2). This may allude to differing roles for TRAK1 and TRAK2 within the cell as 
well the use of differing mechanisms to regulate the TRAK/kinesin-1 formation of 
trafficking complexes. 
If TRAK1 and TRAK2 are to bind the kinesin-1 proteins using an independent 
mechanism as the data in this chapter suggests; will one TRAK protein have 
preferential binding to one sub-type of kinesin-1 compared to another? Macaskill et al. 
(2009a) put forward evidence suggesting that Miro proteins bind kinesin-1 
independently of the TRAK family. This suggests that there is the possibility of two 
distinct methods of Miro-mediated mitochondrial transport within neurons; either 
where Miro proteins bind directly to the kinesin-1 protein, or where the association is 
mediated by either TRAK1 or TRAK2. This theory is given further weight when it was 
shown that only approximately 50 % of mitochondria co-distribute with TRAK2 in 
cultured neurons of which only 35 % of the mitochondrial population is mobile 
(MacAskill et al., 2009; Brickley and Stephenson 2011). Under conditions of low ATP it 
is feasible to think that both TRAK1 and TRAK2 could be called into action by the cell in 
an attempt to increase mitochondrial distribution. This increase in mitochondrial 
distribution would allow the neuronal cell to maintain the high levels of ATP needed    
to ensure correct cellular function in locations such as the axonal processes.  
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Although the work in this chapter extends the understanding of the molecular 
interaction between kinesin-1 and the TRAK/Milton family of proteins it leaves many 
questions unanswered. For example kinesin-1 has always been known for its ability to 
transport cargo through the cellular environment, but what is less known is how this 
cargo transport is regulated. It has not been until relatively recently that studies into 
how this occurs have taken place. As explained in the introduction kinesin-1 is capable 
of self-regulating movement along the microtubules using the conserved QIAK motif 
found in the cargo binding domain (Hackney and Stock, 2000; Section 1.4). How this 
QIAK motif links in with the binding of adaptor proteins and cargo to the cargo binding 
domain has yet to be determined, but none the less asks interesting questions as to 
how the kinesin-1 molecule can bind cargo complexes, transport them along 
microtubules, stop/regulate transport to where the cargo needs to be delivered and 
then restart this whole process again.    
 
5.3.1 Overall conclusions 
 Similarly to KIF5C, KIF5A co-immunoprecipitates with TRAK2 after co-expression 
in HEK 293 cells. 
 Deletion of the KIF5A cargo binding domain results in the loss of co-
immunoprecipitation with TRAK2. This suggests that TRAK2 binds to KIF5A via the 
cargo binding domain.  
 Deletion of the distal 71 amino acid KIF5A C-terminal tail results in an increased co-
immunoprecipitation of KIF5A with TRAK2. This demonstrates that this region may 
play a regulatory role in terms of the efficacy of binding between KIF5A and TRAK2.  
 A series of C-terminal KIF5A truncations revealed three possible sites within 
the KIF5A cargo binding domain as being important for association with TRAK2. The 
first identified site was located between KIF5A 942-961, the second site 
between KIF5A 877-885 and the third between KIF5A 861-877. 
 Additional analysis of the eight amino acid sequence KIF5A 877-885 by deletion or 
truncation did not refine the second site further.  
 A series of KIF5C truncations revealed a similar binding profile as found for KIF5A. 
This is a three mode method of association; the first site was identified between 
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amino acids KIF5C 889-957, the second between amino acids KIF5C 881-889 and 
the third between amino acids KIF5C 828-881. 
 Binding of TRAK1 to KIF5A showed a different pattern of association when 
compared to the binding of TRAK2 to KIF5A.  
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CHAPTER 6 
 
GENERAL CONCLUSIONS AND  
FUTURE DIRECTIONS 
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6.0 GENERAL CONCLUSIONS 
Kinesins are motor proteins that have roles in cell division as well as the transport of 
various organelles and protein complex cargoes within cells. The TRAK/Milton family of 
proteins are known to bind to the cargo binding domain of kinesin-1 forming a link 
between the motor protein and their cargoes. The main aim of this thesis was to 
understand the biochemical interaction of the kinesin-1/TRAK trafficking complex. This 
was important considering the vital role the kinesin-1/TRAK complex plays in the 
transport as well as the regulation of numerous cargoes, including mitochondria, 
throughout neuronal cells. 
Previous attempts to understand further the structure of the cargo binding domain of 
kinesin-1 have been largely unsuccessful and a crystal structure of the cargo binding 
domain of kinesin-1 has yet to be determined. To determine the structure of the cargo 
binding domain of the kinesin-1 sub-type, KIF5A, large amounts of pure and stable 
protein are required. This is best achieved using expression of epitope tagged 
recombinant proteins in bacterial systems. In this thesis attempts were made to create 
a KIF5A cargo binding domain protein that could be utilised for structural analysis. Due 
to the known binding of TRAK2 with the kinesin-1 family it was hypothesized that 
TRAKs may stabilize the KIF5A cargo binding domain. Hence, the DNA encoding the 
KIF5A cargo binding domain, KIF5A800-1032, and the DNA encoding the kinesin 
interacting domain of TRAK2, TRAK2100-380, were cloned into a bicistronic expression 
vector to result in epitope-tagged contsructs. The expression of both proteins was 
characterized with respect to yield and solubilisation efficiency. TRAK2100-380 
expression and solubilisation was found to be stabilised by the presence of the co-
expresing KIF5A800-1032, contrary to the hypothesis. Affinity chromatography of soluble 
protein extracts found that KIF5A800-1032 and TRAK2100-380 did co-purify indicating that 
they can still associate in vitro. However, the yield was insufficient for further 
structural characterisation.  
Due to the poor yield of co-expressed TRAK2100-380/KIF5A800-1032 and in order to 
determine the structure of the cargo binding domain of KIF5A, several C-terminal 
constructs which varied in size and epitope tag location were generated. The bacterial 
growth and solubilisation conditions were optimized to maximize the yield of the 
various KIF5A cargo domain recombinant proteins. Each recombinant KIF5A cargo 
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binding domain protein was purified using an appropriate affinity chromatography 
resin and conditions were established to optimize the purity, yield, stability and 
aggregation state. One construct, KIF5A800-951, was isolated to a sufficient yield and did 
not aggregate. Therefore, KIF5A800-951 is a good candidate for further structural 
analysis. However it is worth noting that, as discussed in Section 4.3, a bioinformatics 
survey has revealed a high magnitude of disorder in the cargo binding domain of KIF5B 
(Seeger et al., 2012). Seeger et al. (2012) demonstrated that overall the KIF5B protein 
is predicted to be ~ 18 % disordered compared to ~ 72 % disorder in the cargo binding 
domain. This result indicates that the kinesin-1 cargo binding domain may not remain 
stable and hence may be more difficult to form a crystal needed for structural studies. 
It is logical to think that a certain degree of disorder/flexibility is required in order for 
certain domains of kinesin-1, such as the motor and stalk domain, to function 
correctly. For example the motor domain will regularly allow changes in the nucletode 
binding region as well as the stalk domain changing conformation to allow for self-
regulation. However, why the cargo binding domain needs to remain in such an 
unstructured comformation is unknown. It could be hypothesised that in part a 
disordered cargo binding domain is due to constant changes caused by post-
translational modifications such as phosphorylation or O-GlcNacylation. It is known 
that the enzyme OGT forms part of the kinesin-1/TRAK/Miro complex (Brickley et al., 
2011), which could have an effect upon the cargo/kinesin complex and in turn the 
conformation of kinesin-1. As for KIF5B (Seeger and Rice, 2010), KIF5A800-951 was found 
to co-sediment with microtubules in vitro. This result indicates that the cargo binding 
domain of KIF5A may be essential for the inactivation cargo transport within neuronal 
cells.   
Previous work has demonstrated that TRAK2124-283 is responsible to binding to KIF5C827-
957 (Brickley et al., 2005; Smith et al., 2006; Brickley et al., 2011). In order to refine 
further the TRAK2 binding site within the cargo binding domain of KIF5A a series of 
nine rationally designed C-terminal truncations of KIF5A were generated. These 
constructs were co-expressed with TRAK2 in HEK 293 cells and their binding was 
determined by co-immunoprecipitation assays followed by quantitative 
immunoblotting. Results indicated that the deletion of the distal 75 C-terminal amino 
acids of KIF5A enhanced the co-immunoprecipitation of TRAK2 with KIF5A. Further 
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truncations also resulted in a reduction of KIF5A immunoreactivity in immune pellets 
implying a decrease in co-immunoprecipitation with KIF5A. This decrease in co-
immunoprecipitation revealed three possible TRAK2 binding sites within the cargo 
binding domain of KIF5A. Amino acid truncations of KIF5C also revealed a three mode 
method of association with TRAK2 after co-immunoprecipitation from HEK 293 cells. 
However binding of TRAK1 to KIF5A showed a different pattern of association when 
compared to the binding of TRAK2 to KIF5A. This work could be the beginning of a 
larger effort to fully characterize the many known adaptor and cargo protein binding 
sites on kinesin-1. Due to the vast array of binding proteins it is feasible to think that 
there may be an overlap in these binding regions. Do some adaptor proteins or cargo 
compete for binding to kinesin-1? Previous work by Glater et al. (2006) has 
demonstrated that Milton competes with the KLCs for binding to the same KHC 
domain. Experiments using Drosophila over-expressing myc-KLC demonstrated that 
the co-immunoprecipitation of myc-KLC with anti-myc antibodies resulted in the 
presence of KHC, whereas Milton did not co-immunopreciptate with myc-KLC. 
However, co-immunoprecipitation experiments utilising antibodies directed to KHC 
successfully co-immunoprecipitated both myc-KLC and Milton. Thus, these results 
indicate that the KHC of kinesin-1 may form separate complexes with either Milton or 
with KLC (Glater et al., 2006). Hence, a better idea of where the interacting proteins of 
kinesin-1 bind coupled with a more detailed structural analysis may give a better 
picture of the overall binding mechanisms and regulation behind kinesin-1 transport.    
 
6.1 FUTURE DIRECTIONS 
The results in both Chapter 3 and Chapter 4 have demonstrated that the exact design 
of each KIF5A cargo binding domain construct can have profound effects on the 
properties of each protein and the way they behave after expression in a bacterial 
system. So one possible future direction would be to screen a larger variety of 
constructs in differing combinations in order to see if a co-complex of TRAK2/KIF5A 
that is sufficiently soluble, able to be purified and stable after purification can be 
achieved. 
Work in Chapter 4 has shown that it is possible to express a soluble KIF5A cargo 
binding domain protein that can be purified to a high yield and remains stable. 
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However, work still remains to be carried out in order to create a protein sample 
suitable for X-ray crystallographic studies. Hence it is necessary to further purify the 
KIF5A800-951 protein sample. This could be achieved using a different purification system 
such as ion exchange chromatography. Seeger et al. (2012) has demonstrated that the 
cargo binding domain of kinesin-1 is disordered hence leading to the possibility that a 
crystal may be difficult to obtain. As mentioned in Section 4.3 protein NMR 
spectroscopy could be also be utilised as an alternative method to learn more about 
the structure of the cargo binding domain of KIF5A. It would also be interesting to 
assess further the smaller molecular weight species of the KIF5A cargo binding domain 
noted after affinity tag purification. Mass spectrometry analysis of the lower molecular 
weight KIF5A protein could allow the possible region of proteolytic cleavage to be 
identified.  
As demonstrated in Chapter 5 the deletion of the 75 C-terminal amino acids of KIF5A, 
that are not present in either KIF5B or KIF5C, have been shown to increase the co-
immunoprecipitation of TRAK2 after co-expression in HEK 293 cells. This result 
indicates that these 75 amino acids may hinder the binding of TRAK2 to KIF5A. 
Therefore it would be interesting to the transfection of a deleted 75 C-terminal tail 
KIF5A construct in primary neuronal cells could increase the number of mitochondria 
that are motile. This could be achieved, as in Brickley and Stephenson (2011), by using 
live cell time lapse imaging of stained neuronal cells. In addition, exactly what role 
these extra 75 amino acids play in the binding of the cargo binding domain of KIF5A to 
adaptor protein/cargo is unclear. It would therefore be interesting to ascertain if these 
extra amino acids has a role in KIF5A specific cargo binding. This could be assessed by 
using a yeast two-hybrid system utilising the 75 amino acid C-terminal domain of KIF5A 
as bait to screen a brain cDNA library to see if any positive interactors are discovered.  
Results in Chapter 4 have demonstrated that, like KIF5B, the cargo binding domain of 
KIF5A can interact with microtubules in vitro (Seeger and Rice, 2010). Work by Dietrich 
et al. (2008) has also indicated that the cargo binding domain of KIF5B can bind both 
the motor domain and the microtubule simultaneously. Therefore it is interesting to 
see if this is similar for KIF5A. A simple pull-down assay utilising the motor domain of 
KIF5A and KIF5A800-951 would help to confirm this possible interaction. A microtubule 
binding assay using KIF5A800-851 and a KIF5A motor domain that has been mutated to 
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remove its binding specificity to the microtubule (i.e. amino acids R280S of KIF5A 
(Ebbing et al., 2008)) could also give insight into the apparent three part binding of the 
microtubule/motor/C-terminal tail of KIF5A complex. In addition, the complex of 
KIF5A800-951 binding to microtubules could be assessed using cryo-electron microscopy, 
either with or without the presence of the motor domain. This could give some insight 
into the crucial binding complex. 
Work in Chapter 5 as well as the previous studies summarised in Section 1.2.4 has only 
started to uncover the number of kinesin-1 cargo binding domain interactors. 
However, the way in which they coordinate and the extent of the overlap of their 
specific binding sites is still largely unknown. What causes a kinesin-1 protein to 
preferentially bind an adaptor/cargo protein over another? The affinity of these 
separate interactions could be individually measured by surface plasma resonance. In 
this experimental system the KIF5A800-951 protein could be immobilized on the surface 
of a sensor chip, and the interacting proteins, such as GRIP1, TRAK/Milton or RanBP2 
(see Section 1.2.4) introduced. The affinity of each interaction could then be measured 
using a BIACORE X-100 system. This could give data regarding the binding affinity of 
the proteins, as well as information about the kinetics and the strength of the 
interactions. 
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pETDUET1
5.4 kb
Ori
f1 ori 
Ampicillin resistance
pETDUETKIF5A800-1032
6.1 kb
Ori
FseI
MunI
f1 ori 
Ampicillin resistance
pETDUETTRAK2100-380
6.2 kb
Ori
EcoRI
HindIII
f1 ori 
Ampicillin resistance
pETDUETTRAK2100-380 /
KIF5A800-1032
6.9 kb
Ori
EcoRI
HindIII
FseI
MunI
f1 ori 
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3.1 The vector maps for pETDUET1, pETTRAK2100-380, pETKIF5A800-1032 and pETTRAK2100-
380/KIF5A800-1032.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in E.coli cells is induced by that of a T7 polymerase, in 
turn controlled by a lac operon. A. Shows the vector map for pETDUET1. B. Shows the vector map for 
pETTRAK2100-280. This clone used the restriction sites EcoRI/HindIII to insert TRAK2100-380 into MCS1. C. 
Shows the vector map for pETKIF5A800-1032. This clone used the restriction sites FseI/MunI to insert 
KIF5A800-1032 into MCS2. D. Shows the vector map for pETTRAK2100-380/KIF5A800-1032. This clone used the 
restriction sites EcoRI/HindIII to insert TRAK2100-380 into MCS1 and the restriction sites FseI/MunI to 
insert KIF5A800-1032 into MCS2. 
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pETKIF5A800-951
5.9 kb
Ori
BamHI
EcoRI
f1 ori 
Ampicillin resistance
pETKIF5A820-951
5.8 kb
Ori
BamHI
EcoRI
f1 ori 
Ampicillin resistance
pETKIF5A820-1032
5.1 kb
Ori
BamHI
EcoRI
f1 ori 
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.1 The vector maps for pETKIF5A800-951, pETKIF5A820-951 and pETKIF5A820-1032.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in E.coli cells is induced by that of a T7 polymerase, in 
turn controlled by a lac operon. A. Shows the vector map for pETKIF5A100-280. This clone used the 
restriction sites BamHI/EcoRI to insert KIF5A800-951 into MCS1. B. Shows the vector map for pETKIF5A820-
951. This clone used the restriction sites BamHI/EcoRI to insert KIF5A820-951 into MCS1. C. Shows the 
vector map for pETKIF5A820-1032. This clone used the restriction sites BamHI/EcoRI to insert KIF5A820-1032 
into MCS1. 
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pET151TOPO
5.8 kb
MCS
la
cI
Ampicillin resistance
pET151TOPO
KIF5A800-1032
6.5 kb
MCS
la
cI
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4.2 The vector maps for pET151D-TOPO and pET151D-TOPOKIF5A800-1032.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in E.coli cells is induced by that of a T7 polymerase, in 
turn controlled by a lac operon. A. Shows the vector map for pET151D-TOPO. B. Shows the vector map 
for pET151D-TOPOKIF5A800-1032. This clone used the blunt ended PCR product to insert KIF5A800-1032 into 
the MCS.  
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pcDNAKIF5A
8.4 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-961
8.2 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-942
8.1 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-885
8.0 kb
BamHI EcoRI
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.1 The vector maps for pcDNAKIF5A, pcDNAKIF5A1-961, pcDNAKIF5A1-942 and pcDNAKIF5A1-
885.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in mammalian cells is induced by that of a Pcmv 
promoter. A. Shows the vector map for pcDNAKIF5A. This clone used the restriction sites BamHI/EcoRI 
to insert KIF5A into the MCS. B. Shows the vector map for pcDNAKIF5A1-961. This clone used the 
restriction sites BamHI/EcoRI to insert KIF5A1-961 into the MCS. C. Shows the vector map for 
pcDNAKIF5A1-942. This clone used the restriction sites BamHI/EcoRI to insert KIF5A1-942 into the MCS. D. 
Shows the vector map for pcDNAKIF5A1-885. This clone used the restriction sites BamHI/EcoRI to insert 
KIF5A1-885 into the MCS. 
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pcDNAKIF5A1-883
8.0 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-881
7.9 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-879
7.9 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-877
7.9 kb
BamHI EcoRI
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.2 The vector maps for pcDNAKIF5A1-883, pcDNAKIF5A1-881, pcDNAKIF5A1-879 and 
pcDNAKIF5A1-879.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in mammalian cells is induced by that of a Pcmv 
promoter. A. Shows the vector map for pcDNAKIF5A1-883. This clone used the restriction sites 
BamHI/EcoRI to insert KIF5A1-883 into the MCS. B. Shows the vector map for pcDNAKIF5A1-881. This clone 
used the restriction sites BamHI/EcoRI to insert KIF5A1-881 into the MCS. C. Shows the vector map for 
pcDNAKIF5A1-879. This clone used the restriction sites BamHI/EcoRI to insert KIF5A1-879 into the MCS. D. 
Shows the vector map for pcDNAKIF5A1-877. This clone used the restriction sites BamHI/EcoRI to insert 
KIF5A1-877 into the MCS. 
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pcDNAKIF5A1-861
7.9 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5A1-825
7.8 kb
BamHI EcoRI
Ampicillin resistance
pcDNAKIF5AΔ877-883
8.4 kb
BamHI EcoRI
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.3 The vector maps for pcDNAKIF5A1-861, pcDNAKIF5A1-825 and pcDNAKIF5AΔ877-883.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in mammalian cells is induced by that of a Pcmv 
promoter. A. Shows the vector map for pcDNAKIF5A1-861. This clone used the restriction sites 
BamHI/EcoRI to insert KIF5A1-861 into the MCS. B. Shows the vector map for pcDNAKIF5A1-825. This clone 
used the restriction sites BamHI/EcoRI to insert KIF5A1-825 into the MCS. C. Shows the vector map for 
pcDNAKIF5AΔ877-883. This clone used the restriction sites BamHI/EcoRI to insert KIF5AΔ877-883 into the MCS.  
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pcDNAKIF5C
8.2 kb
EcoRI NotI
Ampicillin resistance
pcDNAKIF5C1-889
8.1 kb
EcoRI NotI
Ampicillin resistance
pcDNAKIF5C1-881
8.0 kb
EcoRI NotI
Ampicillin resistance
pcDNAKIF5C1-828
7.9 kb
EcoRI NotI
Ampicillin resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5.4 The vector maps for pcDNAKIF5C, pcDNAKIF5C1-889, pcDNAKIF5C1-881 and pcDNAKIF5A1-
828.  
To facilitate replication in E.coli cells, the cloning vector has an ampicillin resistance marker, and an 
origin of replication. The transcription of protein in mammalian cells is induced by that of a Pcmv 
promoter. A. Shows the vector map for pcDNAKIF5C. This clone used the restriction sites EcoRI/NotI to 
insert KIF5C into the MCS. B. Shows the vector map for pcDNAKIF5A1-889. This clone used the restriction 
sites EcoRI/NotI to insert KIF5A1-889 into the MCS. C. Shows the vector map for pcDNAKIF5C1-881. This 
clone used the restriction sites EcoRI/NotI to insert KIF5C1-881 into the MCS. D. Shows the vector map for 
pcDNAKIF5C1-828. This clone used the restriction sites EcoRI/NotI to insert KIF5C1-828 into the MCS. 
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